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Foreword 
This thesis dissertation is the result of four years of research at the Pharmacokinetics 
and Biopharmaceutical Analysis Laboratory and at the Cell Line Development and 
Molecular Biotechnology Laboratory - Animal Cell Technology Unit of Instituto de 
Tecnologia Química e Biológica – Universidade Nova de Lisboa and Instituto de 
Biologia Experimental e Tecnológica (Oeiras, Portugal) under the supervision of Dr. 
Ana Luísa Simplício and co-supervision of Dr. Ana Sofia Coroadinha. 
The work presented herein intended to contribute to the improvement of 
Carboxylesterases (CESs) knowledge through the development of new analytical 
methodologies as well as new production processes enabling enzymatic analysis and 
characterisation. Moreover, this thesis also contributes with an improved in vitro 
Caco-2 cell model showing higher levels of human carboxylesterase 2 (hCES2) 
expression and activity. 
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Abstract 
The first barrier oral drugs and prodrugs encounter prior to reaching an organism’s 
systemic circulation is the gastrointestinal (GI) tract, specifically the intestine, which is 
the primary section for absorption. Therefore, it is fundamental to understand the 
permeability of the therapeutic agent as well as its potential metabolism by human 
enterocytes, since biotransformation may result in the inactivation of the therapeutic 
agent or, to the contrary, in the formation of more therapeutically active metabolites. 
Carboxylesterases (CESs), phase I metabolising enzymes, are important in the 
metabolism of several drugs and prodrugs with amide, ester, or thioester functional 
groups. After cytochrome (CYP) P450s and UDP-glucuronosyltransferases (UGTs), CESs 
are the most relevant enzymes for the metabolism of therapeutic agents.  
Carboxylesterase 2 (hCES2) is the main CES expressed in the human intestine and is an 
increasingly important enzyme in anti-cancer combined therapies for the treatment 
of different pathologies such as colon adenocarcinoma and malignant glioma, due to 
its potential to improve the anti-cancer effect of certain therapeutic compounds. 
Notwithstanding, it is down regulated in the most used intestinal model for 
permeability, the human colon adenocarcinoma derived Caco-2 cell line. On the 
contrary, carboxylesterase 1 (hCES1), the main CES expressed in the human liver, is 
highly expressed in Caco-2 cells, unlike what is known to occur in the intestine.  
The main goal of the work presented in this thesis was to increase the fundamental 
knowledge of hCES2 and to improve the in vitro to in vivo relevance of Caco-2 cells, by 
increasing the expressed hCES2 levels. 
To study and characterize hCES2 activity, as well as to differentiate its activity from 
other esterases in complex biological samples, proper tools had to be developed, as 
described in Section 2. Through the usage of both a specific CES2 and a general CES 
inhibitor, loperamide and BNPP, respectively, a fast, simple, and repeatable capillary 
electrophoresis method requiring low sample volumes was successfully developed 
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and is applicable even when substrates and products absorb at the same wavelength. 
The developed methodology was applied to a variety of samples and proved to be 
suitable for the quantitation of hCES2-specific activity in mixtures of expressed and 
purified CES1 and hCES2 enzymes. Moreover, the developed method showed that 
transiently transfected HEK-293T cells had 15-fold higher hCES2-specific activity than 
non-transfected cells. This method also showed effectiveness in distinguishing CES2-
specific activity in different mammalian sera containing a variety of esterases. The 
developed methodology should be applicable to a wider variety of samples with 
esterase activity, as well as for the analysis of the activities of other esterases, once 
appropriate substrates and inhibitors are used.  
Using the appropriate tools to study hCES2, a method enabling the production and 
purification of this enzyme was developed. This successfully strategy, described in 
Section 3, resulted in the first recombinant human hCES2 enzyme produced using 
human HEK-293T cells in suspension. The utilized strategy demonstrated that the 
addition of an in-frame, C-terminally localized 10x histidine tag, was sufficient to 
promote hCES2 secretion. This avoided the need of additional N-terminal signal 
sequences or the modification or deletion of the Endoplasmic Reticulum (ER) 
retention sequence, which are the traditional strategies. Moreover, using both 
standard and in-house developed biochemical and analytical techniques, new 
fundamental features were unravelled, such as the presence of oligomeric active and 
inactive forms of hCES2, which was previously reported as existing only in a 
monomeric 60 kDa form, leading the way to possible new discoveries concerning 
hCES2 properties. Different oligomeric forms had previously been reported for hCES1; 
the present work suggests this might be a common feature for CESs.  
Equipped with a deeper knowledge about hCES2, Caco-2 cells were overexpressed 
with hCES2. This cell line, mimicking human enterocytes, fails in the accurate 
absorption prediction of ester-containing drugs and prodrugs especially of those 
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metabolised by hCES2. Section 4 describes the successful genetic engineering of this 
cell line resulting in a population with increased hCES2 mRNA, protein expression, and 
activity levels. No changes in cell differentiation and polarization ability were detected 
in comparison with the parental cell line, as the overexpressing population retained 
the capacity to express similar levels of alkaline phosphatase. A hCES2-expressing 
Caco-2 cell line was generated through clonal selection and its stability during 
passaging and differentiation, was evaluated. An obvious decay of enzyme expression 
was observed at higher passage numbers, confirming a previously reported hurdle to 
Caco-2 manipulation. New clues to understand and overcome this limitation of the 
Caco-2 model are provided. Upon complete validation with reference compounds, 
the newly developed cell line has the potential to become a useful tool for coupling 
the study of intestinal absorption with intestinal metabolism, especially when it 
involves the hydrolysis of ester-containing drugs and prodrugs. 
Overall, the work developed in this thesis, opened new paths to unravel more 
mysteries of hCES2 and Caco-2 cells. 
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Resumo 
Fármacos e pró-fármacos administrados por via oral encontram no trato 
gastrointestinal, em especial no intestino delgado, região primordial de absorção, a 
primeira barreira antes de alcançarem o sistema circulatório. Torna-se, desta forma, 
fundamental, compreender as propriedades dos agentes terapêuticos em termos de 
permeabilidade, bem como a possível susceptibilidade a serem metabolizados nos 
enterócitos humanos, uma vez que a sua bio-transformação pode conduzir à 
inativação, ou, pelo contrário, à formação de metabolitos de maior ação terapêutica. 
Carboxilesterases (CESs) são enzimas metabólicas de fase I importantes no 
metabolismo de fármacos e pró-fármacos contendo grupos químicos funcionais 
específicos tais como amidas, ésteres ou tio-ésteres. Carboxilesterases são, depois 
das citocromo (CYP) P450 e das UDP-glucoronosil-transferases (UGTs), as enzimas de 
maior relevância para o metabolismo de agentes terapêuticos.  
A carboxilesterase 2 (hCES2) é a principal CES expressa no intestino humano, sendo 
uma enzima de importância crescente em terapias anti-cancerígenas combinadas 
para o tratamento de diversas patologias tais como o adenocarcinoma do colon ou o 
glioma maligno, devido ao potencial que tem de aumentar o efeito anti-cancerígeno 
de certos compostos terapêuticos. Esta enzima encontra-se, contudo, regulada 
negativamente no modelo intestinal mais utilizado para a avaliação da 
permeabilidade intestinal, a linha celular Caco-2, derivada de um adenocarcinoma de 
colon humano. Pelo contrário, a carboxilesterase 1 (hCES1), a CES de maior expressão 
no fígado humano, é altamente expressa nas células Caco-2, de modo oposto ao que 
se sabe ocorrer no intestino humano. 
O principal objetivo do trabalho apresentado nesta tese foi o de aumentar o 
conhecimento fundamental da hCES2 bem como o de melhorar a relevância in vitro-in 
vivo das células Caco-2, através do aumento da expressão dos níveis de hCES2. As 
ferramentas apropriadas para o estudo e caracterização da atividade da hCES2, bem 
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como para a diferenciação da atividade desta de outras esterases presentes em 
amostras biológicas complexas, tiveram de ser desenvolvidas, tal como descrito na 
Secção 2. A utilização de um inibidor específico da CES2, a loperamida, e de um 
inibidor geral das CESs, o BNPP, possibilitou o desenvolvimento com sucesso de um 
método rápido, simples, repetível e necessitando de pequenas quantidades de 
amostra, para análise em eletroforese capilar, com aplicabilidade mesmo em 
situações nas quais substratos e produtos de reação absorvem no mesmo 
comprimento de onda. A metodologia assim desenvolvida foi aplicada em diversos 
tipos de amostras e provou ser adequada para a quantificação da atividade específica 
da hCES2, mesmo quando presente em misturas de enzimas expressas e purificadas, 
contendo CES1. Adicionalmente, o método desenvolvido possibilitou demonstrar que 
a atividade específica de hCES2 aumenta 15 vezes em células HEK-293T transfectadas 
de forma transiente em comparação com as mesmas células não transfectadas. Este 
método provou ainda ser eficaz para distinguir a atividade específica de CES2 
presente em diferentes soros de mamíferos, contendo diversas esterases. A 
metodologia desenvolvida poderá ser adicionalmente aplicada não só a uma maior 
variedade de amostras contendo atividade de esterases, bem como para a avaliação 
de atividades de outras esterases desde que sejam utilizados substratos e inibidores 
apropriados. 
Recorrendo às ferramentas apropriadas ao estudo da hCES2, foi desenvolvido um 
método de produção e purificação desta enzima. Esta estratégia, descrita na Secção 3, 
revelou-se bem-sucedida, tendo resultado na produção pela primeira vez de uma 
enzima hCES2 recombinante humana, em células de origem humana, a linha celular 
HEK-293T, crescidas em suspensão. A estratégia utilizada permitiu demonstrar que a 
adição, na mesma grelha de leitura, de uma cauda de 10x histidinas na região C-
terminal da hCES2, é suficiente para promover a secreção da proteína. Esta 
abordagem permitiu evitar recorrer às estratégias tradicionais tais como: adição de 
sequências sinal na região N-terminal; modificação ou delecção da sequência de 
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retenção no Retículo Endoplasmático (ER). Adicionalmente, através da utilização de 
técnicas analíticas e bioquímicas quer tradicionais quer desenvolvidas no laboratório, 
foi possível revelar novas propriedades fundamentais da hCES2 tais como a presença 
de formas oligoméricas ativas e inativas, desta proteína anteriormente descrita como 
existindo apenas na forma de monómero com 60 kDa, abrindo caminho a eventuais 
novas descobertas relativamente às suas propriedades. De facto, diferentes formas 
oligoméricas foram já descritas para a hCES1; o trabalho aqui apresentado sugere que 
esta possa ser uma característica comum a todas as CESs. 
Munidos de um conhecimento mais aprofundado sobre a hCES2, procedeu-se ao 
aumento de expressão desta enzima nas células Caco-2. Esta linha celular, que 
mimetiza os enterócitos humanos, apresenta limitações na previsão da absorção de 
fármacos e pró-fármacos contendo grupos éster, especialmente daqueles que são 
metabolizados pela hCES2. Na Secção 4 é descrita a modificação bem-sucedida desta 
linha celular, através de técnicas de engenharia genética, resultando no 
estabelecimento de uma população com níveis superiores de atividade de hCES2, 
reflectida também ao nível do mRNA e ao nível da expressão proteica. Comparando a 
linha celular Caco-2 com a nova população celular, não foram detectadas diferenças 
em termos da capacidade de diferenciação celular nem ao nível da capacidade de 
polarização das células, uma vez que na nova população, com níveis superiores de 
expressão de hCES2, foram detectados níveis semelhantes de expressão de fosfatase 
alcalina. Foi observado um decaimento óbvio na expressão enzimática de hCES2, a 
passagens mais elevadas, confirmando a dificuldade previamente reportada ao nível 
da manipulação da linha celular Caco-2. Neste trabalho são fornecidas novas 
indicações de como ultrapassar estas limitações. A nova linha celular desenvolvida 
tem o potencial de se tornar uma ferramenta importante na conjugação dos estudos 
de absorção e de metabolismo intestinais, especialmente úteis aquando da presença 
de hidrólise de fármacos e pró-fármacos contendo grupos éster.  
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De uma forma global, o trabalho desenvolvido nesta tese permitiu abrir novos 
caminhos na descoberta de mistérios adicionais da hCES2 e das células Caco-2. 
 
* Este texto foi escrito ao abrigo do novo acordo ortográfico. Nas palavras com grafias alternativas, a nova grafia foi 
preterida.  
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1.1 The fundamentals of carboxylesterases 
Carboxylesterases (CESs), generally regarded as hydrolytic enzymes, are involved in 
the conversion of ester containing compounds into their carboxylic acid and alcohol 
metabolites. The enzymatic mechanism, through which these enzymes act upon their 
substrates, has been previously reviewed (Satoh and Hosokawa 2006) and new 
insights continuously arise through classical enzymatic activity assays as well as more 
recent techniques such as X-ray crystallography (Redinbo and Potter 2005). 
Carboxylesterases have been traditionally classified with acetylcholinesterases 
(AcChE) and butirylcholinesterases (BuChE) as type-B esterases. These enzymes are 
inhibited by organophosphates, unlike type-C (such as acetylesterases) and type-A 
hydrolases (such as paraoxonase; Table 1.1). Type-A esterases hydrolyse these 
compounds, such as paraoxon, but type-C esterases do not interact with them 
(Aldridge 1993; Liederer and Borchardt 2006).  
Table 1.1 Esterases differentiation according with organophosphates hydrolisys/inhibition 
Esterase 
type 
Hydrolyse 
organophosphates? 
Are inhibited by 
organophosphates? 
A Yes No 
B No Yes 
C No No 
Aldridge 1993;Liederer and Borchardt 2006. 
After oxidative enzymes such as cytochrome (CYP) P450 enzymes and UDP-
glucuronosyltransferases (UGTs), esterases are the third major class of enzymes 
involved in the metabolic clearence of currently administered therapeutic drugs, 
(Williams et al. 2004; Liederer and Borchardt 2006). Esterases B are additionally 
classified as belonging to the α/β-hydrolase fold superfamily. α/β-Hydrolases have 
their secondary structure characterised by an α/β/α sandwich in which five to eight β-
sheets form a core connected by α helices (Hotelier et al. 2004). Type-B esterases are 
serine α/β-hydrolases in which a catalytic triad composed of serine, glutamate and 
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histidine aminoacids connected by hydrogen bonds is essential for their enzymatic 
activity (Liederer and Borchardt 2006). 
1.1.1 Carboxylesterases across species 
Carboxylesterases are ubiquitously present throughout all forms of life, from bacteria 
to man. Their enzymatic capability has been explored through diverse industrial 
applications such as organic chemical synthesis and agrochemical industry, being this 
a very active research field (Jeon et al. 2011). Special attention has been devoted to 
thermostable carboxylesterases isolated from different archea, due to their possible 
application as industrial biocatalysts (Angkawidjaja et al. 2012). Carboxylesterases 
role in the metabolism of xenobiotic compounds is well known. By acting as 
detoxifying agents, they have, for instance, been applied in environmental monitoring 
(Wheelock et al. 2006). Other functions, however, have been attributed to 
carboxylesterases. In fungi, best known as feruloyl esterases, they have been 
implicated in hemicellulose solubilisation (Tartar et al. 2009). In insects, their 
functions range from insecticide resistance and other detoxifying functions, to 
pheromone-degrading enzymes, the first being generally intracellular and the second, 
extracellular (Durand et al. 2012; Claudianos et al. 2006). In plants, they have been 
described as having important defensive functions without intrinsic catalytic activities 
(Akashi et al. 2005). In olive (Olea europaea) pollen, for instance, they have been 
identified and implicated in its germination (Rejón et al. 2012). 
Being so diverse and widely represented, carboxylesterase family 
classification is not a trivial task. It has been proposed to divide it into thirteen clades: 
eight exclusive plant carboxylesterases clades (I to VIII); clade C containing the fungi 
Aspergillus nidulans genes and clades A, B, D and E all containing representatives of 
microorganisms, other fungi and mammals (Akashi et al. 2005). Although a good 
effort, this classification has been based in only one hundred and two sequences. 
Thus, alternative classifications exist. For example, microbial carboxylesterases are 
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usually classified on the basis of conserved sequence motifs and biological properties, 
comprising eight families (I to VIII; Jeon et al. 2011). Insect carboxylesterases have 
been classified into three major classes, subdivided into thirteen clades (Claudianos et 
al. 2006). The ESTHER database has a comprehensive amount of available α/β-
hydrolases gene and protein information from all species. Useful links to other 
databases as well as other relevant information are also available (Renault et al. 
2005).  
1.1.2 Looking in more detail to carboxylesterases in mammals 
Mammalian carboxylesterases, the most studied, also have their own 
classification, into five groups (CES1 to CES5), mainly attending to sequence identity 
(Satoh and Hosokawa 2006). Due to recent advancements in whole genome 
sequencing, several new CESs genes have been unravelled in different species, such as 
opossum, a marsupial, and primates . Their comparison with the already known CESs 
has been performed (Holmes et al. 2008; Holmes et al. 2009; Williams et al. 2010). 
This diversity has converged to the proposal of a new nomenclature for mammalian 
carboxylesterases (Holmes et al. 2010). The newly proposed nomenclature was not 
followed in this thesis as it is restricted to few mammalian species, posing difficulties 
in its usage.  
Mammalian CESs are intra or extracellularly localised in diverse tissues. 
Intracellular CESs are usually found inside the endoplasmic reticulum (ER) having a 
specific retention sequence that interacts with the KDEL receptor (Satoh and 
Hosokawa 2006) as it happens with human carboxylesterases (hCESs; Satoh and 
Hosokawa 2006). Nonetheless, carboxylesterase 1 isoform 1 (CES1A1 or 
CES1_AB119997) has been reported to exist in hepatic cytosol (Tabata et al. 2004). 
Differences in the number, tissue distribution, substrate selectivity as well as 
sensitivity towards different inhibitors have been previously reported for different 
mammals (Williams et al. 2011). For example, mice and rats not only have more CESs 
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than humans, they also present several secreted forms in the plasma and different 
substrate specificity: the pranlukast drug was found to be hydrolysed in rats but not in 
humans (Fukami and Yokoi 2012).  
In terms of regulation, mammalian carboxylesterases share similarities with 
other xenobiotic-metabolising enzymes since they may be induced by similar agents. 
An example is their induction by chemicals such as phenobarbital, well known to 
induce CYP enzymes (Satoh and Hosokawa 1998). In the case of down-regulation, 
hCES1 and carboxylesterase 2 (hCES2) as well as CYP enzymes are suppressed by 
Interleukin-6 (Yang et al. 2007). Nonetheless, specific inhibitors for CESs have been 
reported, such as bis-p-nitrophenyl phosphate (BNPP) and benzyl (Yoon et al. 2004; 
Tsurkan et al. 2012). Due to their potential pharmacological application, the search 
for CESs specific inhibitors is, in fact, an active research field. 
Human CES1 has traditionally been the most studied hCES, being the only 
human form that has, so far, a fully known structure (Bencharit et al. 2003). However, 
increased attention has been devoted to hCES2 due, for example, to its role in the 
activation of the anti-cancer prodrug irinotecan (CPT-11) and its potential application 
in prodrug-activating gene therapies (Yano et al. 2008; Uchino et al. 2008). 
1.1.3 Human carboxylesterase 2 
Human CES2 is found in different tissues, especially in the liver, intestine, 
and kidney (Fukami and Yokoi 2012). It constitutes a good example of the 
aforementioned species variation of CESs. Through a BLAST-P (Altschul et al. 1997) 
search, the first fifty hits correspond exclusively to eighteen mammalian species 
(Table 1.2). The search was performed in ESTHER database against all protein 
sequences available (http://bioweb.ensam.inra.fr/ESTHER/general?what=index), 
using as query the amino acid sequence of hCES2, which is shown as the first entry of 
the table (see Appendice Table for the technical details concerning the search). The 
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sequence identities towards the used query, as well as additional information are 
provided. These include: protein accession numbers in ESTHER and UniProt 
databases; alternative protein entries (italicized); protein name and function 
information available at UniProt database; gene designation (italicized) when existing; 
GeneBank accession number; level of experimental evidence of protein existence; 
length of the full protein as well as the last four amino acids. The first non-mammalian 
hydrolase arising in the search is an uncharacterised protein from Anolis carolinensis, 
an American chameleon (class Reptilia), showing 50% amino acid sequence identity to 
hCES2, whereas hCES1 only appears later, with 46% identity towards the query (See 
Appendice Table).  
Genetic expression of hCES2 has been well documented, ranging from gene 
structure to the potential promoters involved in the transcription initiation in 
different human tissues (Wu et al. 2003). Moreover, 3 trancript variants of the gene 
(Schiel et al. 2007) as well as several single nucleotide polymorphisms (SNPs) have 
been documented (Wu et al. 2004; Kubo et al. 2005). Some of these, such as the 
IVS10-88 (interVening sequence, i.e., intron) SNP, were shown to decrease hCES2 
mRNA expression in colorectal tumours (Marsh et al. 2004). 
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Table 1.2 CES2 protein across different species  
UniProt protein 
(gene) 
UNIPROT  ID % # AA 
Last 4 
AA 
ESTHER  GeneBank  Function 
Homo sapiens (Human)             
Carboxylesterase 2 
(CES2) 
O00748 
(A8K367, 
Q4G0E9) 
100 559 HTEL human-2cxes Y09616.1 
Detoxification of xenobiotics and activation of ester 
and amide prodrugs. High catalytic efficiency for 
hydrolysis of cocaine, 4-MUBA, heroin and 6-
monoacetylmorphine (Pindel et al. 1997). 
Pan troglodytes (Chimpanzee)             
Uncharacterised 
protein 
H2QBA6 97 623 HTEL pantr-h2qba6 AACZ03102754.1 Hydrolase activity (evp: predicted). 
Gorilla gorilla (Lowland gorilla)           
Uncharacterised 
protein 
G3RPG8 
(G3QYW6, 
G3QYX2) 
95 623 HTEL gorgo-g3qyw6 - Hydrolase activity (evp: predicted). 
Pongo abelii (Sumatran orangutan)             
Uncharacterised 
protein (CES2) 
H2NR54 93 623 HTEL ponab-h2nr54 - Hydrolase activity (evp: predicted). 
Nomascus leucogenys (Northern white-cheeked gibbon)       
Uncharacterised 
protein (CES2) 
G1QVW2 91 606 HTEL nomle-g1qvw2 ADFV01013581.1 Hydrolase activity (evp: predicted). 
Papio hamadryas (Hamadryas baboon)           
Ces2 B5TZ26 90 561 HTEL papha-b5tz26 FJ147179.1 
Hydrolase activity (evp: transcript level; Holmes et al. 
2009). 
Macaca mulatta (Rhesus monkey)             
Uncharacterised 
protein 
F6UNJ2 88 543 HTEL macmu-f6unj2 - Hydrolase activity (evp: predicted). 
Putative 
uncharacterised 
protein 
G7NQ39 88 543 HTEL macmu-g7nq39 CM001272.1 Hydrolase activity (evp: predicted). 
Callithrix jacchus (White-tufted-ear marmoset)         
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Uncharacterised 
protein 
F6ZPL6 
(F6Z7R7) 
83 620 HTEL calja-f6zpl6 
ACFV01013743.1, 
ACFV01013744.1, 
ACFV01013745.1 
Hydrolase activity (evp: predicted). 
Ailuropoda melanoleuca (Giant panda)           
Uncharacterised 
protein (CES2) 
D2H9C9 
(G1MFN8) 
77 534 HTEL ailme-d2h9c9 
GL192596.1, 
ACTA01043044.1 
Hydrolase activity (evp: predicted; Li et al. 2010). 
Equus caballus (Horse)             
Uncharacterised 
protein (CES2) 
F7BJ10 77 579 HTEL horse-f7bj10 - Hydrolase activity (evp: predicted; Wade et al. 2009). 
Loxodonta africana (African bush elephant)           
Uncharacterised 
protein (CES2) 
G3TN98 76 554 HTEL loxaf-g3tn98 - Hydrolase activity (evp: predicted).  
Canis lupus familiaris (Dog)             
Uncharacterised 
protein (Ces2) 
F1P6W8 74 585 HTEL canfa-f1p6w8 - 
Hydrolase activity (evp: predicted; Lindblad-Toh et al. 
2005). 
Oryctolagus cuniculus (European rabbit)           
Uncharacterised 
protein 
G1TZV1 74 558 HTEL rabit-g1tzv1 AAGW02053044.1 Hydrolase activity (evp: predicted). 
Uncharacterised 
protein 
G1SJQ8 74 621 HTEL rabit-g1sjq8 AAGW02067905.1 Hydrolase activity (evp: predicted).  
Uncharacterised 
protein 
G1T6X7 74 558 HTEL rabit-g1t6x7 AAGW02053044.1 Hydrolase activity (evp: predicted).  
Uncharacterised 
protein 
G1TDR0 74 534 HTEL rabit-g1tdr0 AAGW02067906.1 Hydrolase activity (evp: predicted). 
Uncharacterised 
protein 
G1T7P3 73 532 HTEL rabit-g1t7p3 AAGW02053044.1 Hydrolase activity (evp: predicted). 
Uncharacterised 
protein 
G1T7Q5 73 561 HTEL rabit-g1t7q5 AAGW02053044.1 Hydrolase activity (evp: predicted). 
Uncharacterised 
protein 
G1SN51 72 561 HTEL rabit-g1sn51 
AAGW02067906.1 
AGW02067907.1 
Hydrolase activity (evp: predicted).  
Uncharacterised 
protein 
G1TMC5 72 556 HTEL rabit-g1tmc5 AAGW02053046.1 Hydrolase activity (evp: predicted). 
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Liver carboxylesterase 
2 (CES2) 
P14943 72 532 HTEL rabit-2cxes - 
Detoxification of xenobiotics and activation of ester 
and amide prodrugs (evp: protein level; Ozols 1989). 
Uncharacterised 
protein 
G1T6L1 71 528 HTEL rabit-g1t6l1 AAGW02053044.1 Hydrolase activity (evp: predicted). 
Rattus norvegicus (Brown rat)             
Ces2h (Ces2h) Q32Q55 73 558 HTEL ratno-q32q55 BC107806.1 
Carboxylesterase activity (evp: transcript level; Gibbs 
et al. 2004). 
LOC679149 protein Q4QR68 70 561 HTEL ratno-q4qr68 BC097486.1 Carboxylesterase activity (evp: transcript level). 
Carboxylesterase 5, 
isoform CRA_a (Ces2e) 
G3V7J5 70 557 HTEL ratno-phebest 
D50580.1, 
CH474006.1 
Hydrolase activity (evp: predicted; Gibbs et al. 2004). 
Ces2c (Ces2c) G3V9D8 70 561 HAEL ratno-pbcxe 
AB010635.1, 
CH473986.1 
Hydrolase activity (evp: predicted; Gibbs et al. 2004). 
Carboxylesterase 
(Ces2) 
O70177 69 561 HAEL ratno-sicxe AB010632 Carboxylesterase activity (evp: predicted). 
Ces2g (Ces2g) D3ZXQ0 67 560 HKEL ratno-d3zxq0 CH473972.1 
Carboxylesterase activity (evp: predicted; Gibbs et al. 
2004). 
Carboxylesterase 
(Protein Ces2a) 
Q8K3R0 66 558 HAEL ratno-LOC246252 
NM_144743, 
AY034877 
Carboxylesterase activity (evp: transcript level; Gibbs 
et al. 2004). 
Ces2i (Ces2i) D3ZE31 66 559 HAEL ratno-d3ze31 - 
Carboxylesterase activity (evp: predicted; Gibbs et al. 
2004). 
Cavia porcellus (Guinea pig)             
Uncharacterised 
protein (CES2) 
H0V5V8 73 568 HTEL cavpo-h0v5v8 - Carboxylesterase activity (evp: predicted). 
Bos taurus (Aurochs)         
 
    
Carboxylesterase 2 
(intestine, liver; CES2) 
Q3T0R6 
(F1MU22) 
72 553 HTEL bovin-q3t0r6 
BC102288.1, 
AAFC03046191.1 
Carboxylesterase activity (evp: transcript level). 
Heterocephalus glaber (Naked mole rat)           
Carboxylesterase 2 G5BZE3 72 553 HAEL hetga-g5bze3 JH172552.1 Hydrolase activity (evp: predicted; Kim et al. 2011). 
Carboxylesterase 2 G5BP68 70 570 AAQE hetga-g5bp68 JH171227.1 Hydrolase activity (evp: predicted; Kim et al. 2011). 
Carboxylesterase 2 G5BP66 69 562 HAEL hetga-g5bp66 JH171227.1 Hydrolase activity (evp: predicted; Kim et al. 2011). 
Mus musculus (House mouse)             
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Ces2h (Ces2h) F6Z9B9 72 558 HKEL mouse-Ces2h 
AC166833.4, 
XM_488149.1 
Carboxylesterase activity (evp: predicted; Church et 
al. 2009). 
Ces2c (Ces2c) Q91WG0 71 561 HREL mouse-Ces2c 
BC015290.1, 
AC166833.4 
Carboxylesterase activity (evp: transcript level; 
Furihata et al. 2003). 
Uncharacterised 
protein (Ces2d-ps) 
D3YWM6 71 558 HREL mouse-Ces2d-ps - 
Hydrolase activity (evp: predicted; Church et al. 
2009). 
Ces2b (Ces2b) Q6PDB7 71 556 HTEL mouse-Ces2b BC058815.1 
Carboxylesterase activity (evp: transcript level; Mural 
et al. 2002). 
Carboxylesterase 5 
(Protein Ces2e) 
Q8BK48 70 559 HkEL mouse-Ces2e 
XM_134366, 
BC022148 
Carboxylesterase activity (evp: transcript level). 
Ces2g (Ces2g) E9PV38 68 560 HKEL mouse-Ces2g 
BC027185.1, 
BC024548.1, 
BC026641.1 
Carboxylesterase activity (evp: predicted; Church et 
al. 2009). 
Putative 
uncharacterised 
protein (Ces2a; Ces6) 
Q3TMR2 
(E9Q3D0) 
67 525 HAEL mouse-Ces2a 
BC024491.1, 
BC024517.1, 
BC025537.1 
Carboxylesterase activity (evp: transcript level).  
Cricetulus griseus (Chinese hamster)            
Carboxylesterase 2 G3IIG3 71 511 HGEL crigr-g3iig3 JH003006.1 Hydrolase activity (evp: predicted; Xu et al. 2011). 
Liver carboxylesterase G3IIG1 70 561 HKEL crigr-g3iig1 JH003006.1 Hydrolase activity (evp: predicted; Xu et al. 2011). 
Liver carboxylesterase G3I767 70 535 HKEL crigr-g3i767.2 JH001411.1 Hydrolase activity (evp: predicted; Xu et al. 2011). 
Liver carboxylesterase G3I766 69 561 HQEL crigr-g3i766 JH001411.1 Hydrolase activity (evp: predicted; Xu et al. 2011). 
Liver carboxylesterase G3I769 67 545 HAEL crigr-g3i769: JH001411.1 Hydrolase activity (evp: predicted; Xu et al. 2011). 
Mesocricetus auratus (Golden hamster)           
Carboxylesterase O35533 70 559 HQEL mesau-cxest2 D50577 
Carboxylesterase activity (evp: trancript level; Sone et 
al. 1994) 
Liver carboxylesterase Q64419 66 561 HSEL mesau-cxest D28566.1 
Detoxification of xenobiotics and activation of ester 
and amide prodrugs. (evp: transcript level; Sone et al. 
1994). 
ID - identity; #AA – protein length (number of aminoacids); evp – evidence of protein existence (according with UniProt 5 levels – see Apendice). 
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1.2 The tools to study carboxylesterases 
The study of CESs, such as their quantification and differentiation from other 
enzymes, may be performed through different techniques targeting expression levels, 
from gene to protein expression, by generating specific primers and antibodies 
(Sanghani et al. 2003; Morgan et al. 1994). Recently, simultaneous detection and 
quantification of hCES1 and hCES2 proteins by liquid chromatography coupled with 
tandem mass spectrometry (LC-MS/MS) was also shown to be possible (Sato et al. 
2012). A direct correlation between protein levels and enzyme activity is not always 
possible for these enzymes. Reports of both inability (Ross et al. 2012) and ability of 
performing such correlations (Sato et al. 2012) may be found in the literature. 
Different tools to evaluate CESs activity exist and have been reviewed, such as 
spectrophotometry, high-performance liquid chromatography (HPLC), and in-gel 
activity assays (Ross and Crow 2007). 
Carboxylesterase-mediated hydrolysis has been thoroughly studied and it is 
clear that many substrates have recognittion among different CESs as well as with 
other esterases. For example, p-nitrophenyl acetate (p-NPA), a classical CESs 
substrate, is hydrolysed not only by the different CESs but also by cholinesterases 
(Satoh and Hosokawa 2006). Even pharmacologically relevant compounds known for 
their higher specificities towards CES2, such as aspirin (Tang et al. 2006), irinotecan 
(Humerickhouse et al. 2000), and cocaine (Hatfield et al. 2010) are also hydrolysed by 
BuChE (Li et al. 2005). 
Due to this promiscuity in substrate hydrolysis, it is very difficult to 
differentiate a single carboxylesterase activity in samples containing multiple CESs or 
other esterases by simple spectrophotometric assays. A classic example is the late 
demonstration of the absence of CES activity in healthy human plasma through an in-
gel activity assay with different substrates and inhibitors for CESs, cholinesterases, 
and other enzymes (Li et al. 2005). Using a similar approach by combining activity 
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detection in the presence of certain substrates and inhibitors with protein detection 
through Western blot, it was recently proposed to be possible to characterise an 
individual’s liver in terms of CES profile (Ross et al. 2012). 
A different perspective in CES analysis may arise upon looking to more 
physiological relevant conditions such as protein localisation and/or activity in whole-
living cells, instead of analysing purified enzymes, cell lysates, or tissue homogenates. 
The importance of addressing how enzymes behave in living cells, where complex 
networks of protein interactions occur, is detailed in Section 1.3.1. Recent advances in 
whole-living cell analysis have been made for cytoplasmic membrane anchored 
enzymes with the use of fluorescent probes (Ferruzza et al. 2012). Evaluating the 
activity of these types of enzymes is by far an easier task than to quantify the activity 
of ER localised enzymes, as it is the case of the majority of CESs. Nonetheless, recent 
advances have been made, such as the development of specific CES fluorescent 
probes (Wang et al. 2011) that have been applied to live imaging of whole-living cells 
(Hakamata et al. 2011). 
The development of simple, fast, and reliable tools enabling the 
differentiation and quantification of different CESs expression and activity is thus a 
very active research field, where some controversial questions still remain. To 
develop and improve the methodologies, as well as to test new substrates and 
inhibitors that will also improve already existing methodologies, purified CES enzymes 
are needed, as they constitute an easier step towards the analysis of more complex 
samples, such as cell extracts and tissue homogenates. Insights into the latest 
advances in recombinant CES manufacturing are given in Section 3. 
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1.3 From drug metabolising enzymes to intestinal permeability models  
1.3.1 The importance of seeing both sides - The irinotecan pathway in a human 
organism as a case study 
Notwithstanding the importance of studying purified or recombinant enzymes, it is 
crucial to understand their behaviour in the most physiologically relevant level, 
meaning the environment where native enzymes exist. This may mean that studies 
involving cells and/or organisms may have to be performed. An example involves the 
metabolism of the chemotherapeutic drug irinotecan. As mentioned above, hCES2 
hydrolyses irinotecan into its active metabolite, SN-38. The enzymatic reaction has 
been characterised with purified enzyme (Humerickhouse et al. 2000), resulting in the 
determination of important kinetic parameters. Nonetheless, the pathway of 
intravenous-delivered (IV) irinotecan transport and metabolism in the organism is 
complex involving the interplay of a complex network of proteins (Figure 1.1) in 
different cellular compartments. Phase I metabolising enzymes, including CES and 
CYP3A family members, as well as Phase II enzymes, such as UGTs and the interplay 
with drug efflux pumps from the ABC family. Both CESs and BuChEs are able to 
hydrolyse irinotecan, with CESs being more efficient to convert to SN-38. Human CES2 
was shown to be one hundred-fold more efficient than hCES1, and hCES3 the least 
efficient (Humerickhouse et al. 2000). Due to the differences in the hCES1 and hCES2 
expression in the liver and intestine, hCES2 accounts for the majority of irinotecan 
activation in the intestine and kidney while hCES1 has an important function in the 
activation of this pro-drug in the liver (Hatfield et al. 2011). 
Irinotecan is inactivated through oxidation by CYP3A4/5 into aminopentane 
carboxylic acid (APC), M4, and primary amine metabolite (NPC; Santos et al. 2000; 
Innocenti et al. 2009). SN-38 is inactivated by UGT Phase II enzymes, namely 
UGT1A1/6/7/9/10 (de Jong et al. 2007). 
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Figure 1.1 Transport and metabolism networks: irinotecan pathway and the role of hCES2. Irinotecan, 
IV administered, is metabolised into its active metabolite, SN-38, in liver cells by Phase I enzymes hCES1 
and hCES2, and may be secreted throughout the ABCC1 active transporter. Irinotecan may also be 
oxidised into its inactive metabolites, APC, NPC and M4 by CYP3A enzymes. SN-38 may be further 
inactivated, through glucoronidation (SN-38G) by Phase II enzymes (UGT1A1, UGTA6, UGTA9, UGTA10) 
being ultimately eliminated from the organism through bile and urine. Secretion of irinotecan, SN-38 and 
SN-38G from the cell occurs through active transport (ABCC1, ABCB1, ABCC2 and ABCG2, members of ABC 
family of drug efflux proteins). Irinotecan is also metabolised in intestinal cells. SN-38 toxicity may include 
neutropenia and diarrhoea. Adapted and reprinted with permission from Macmillan Publishers Ltd: 
Nature Reviews Cancer (Scripture and Figg 2006), copyright (2006) and PharmGKB and Stanford 
University (Thorn et al. 2003), copyright to PharmGKB (2012). 
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Active transport of irinotecan, SN-38, and SN-38G to the extracellular space is 
facilitated by a few members from the ATP-binding cassette (ABC) family. Irinotecan is 
transported by ABCC1, ABCB1, and ABCC2; SN-38G is transported by ABCC2, and 
ABCG2; all of these may be involved in pumping SN-38 (Kweekel et al. 2008). 
The chemotherapeutic action of irinotecan is achieved through the binding of 
SN-38 to topoisomerase I (TOPO-1) during cell division, more specifically, during DNA 
replication. This complex, formed by SN-38 and TOPO-1, becomes blocked leading to 
the destruction of the DNA when the replication machinery clashes with it (Marsh and 
Hoskins 2010). Delayed-type diarrhoea and neutropenia, a decrease in neutrophils 
increasing the risk of infection (Ammann et al. 2012), are the most common toxic 
effects of irinotecan and their severity, reaching life-threatening cases, has been 
linked to some polymorphisms in certain genes, such as UGT1A1*28 (Marsh and 
Hoskins 2010; Innocenti et al. 2009; de Jong et al. 2007). 
Other examples of the interaction between different metabolic enzymes and 
efflux transporters have also been studied, such as the case of the interplay between 
P-glycoprotein (P-gp), multidrug resistance-associated protein 2 (Mrp2), CYP3A, and 
CES2 in the oral availability of vinorelbine, a pharmaceutical indicated for the 
treatment of some types of lung and breast cancer. Looking to these interactions in 
living cells or organisms may be crucial to better understand the reasons behind inter-
individual variability in oral dosing (Lagas et al. 2012).  
1.3.2 Intestinal permeability and metabolism overview 
Oral delivery is still the most common way of dosing drugs to the patients (Buckley et 
al. 2012). Every drug undergoes a series of transformations inside the organism that 
depends not only on the type of drug but also on the individual, due to the genetic 
variability found in humans. Overall, this path is refered to as the ADME (absorption, 
distribution, metabolism, and excretion) profile of a drug and involves many organs, 
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such as intestine, liver, and kidney, where different transformations may occur. It may 
be categorised in different stages, from Phase I-III. Phase I involves the modification 
of the compounds which may occur through oxidation or hydrolysis, for example. In 
Phase II, conjugation enzymes usually increase the hydrophilicity of the metabolised 
compound through the addition of a hydrophilic molecule, such as glucoronic acid, 
sulphate, or glutathione, to facilitate its elimination. Phase III involves the elimination 
of the compounds through active transporters (Huynh et al. 2009). Tissue distribution 
of these proteins has been previously reported (Nishimura and Naito 2006). Being the 
primary site for xenobiotic absorption and with an important function in drug 
metabolism (Shen et al. 1997), a special focus is devoted to the small intestine in the 
following sections. 
1.3.2.1 Architecture and function of intestinal epithelium 
The intestinal epithelium is found in two, the small and large intestine, of the four 
segments composing the gastrointestinal tract (GI). In the large intestine, the 
intestinal epithelium has a flat shape, punctuated with invaginations.  In the small 
intestine, it is composed of projections, the villi, and invaginations, the crypts of 
Lieberkühn (Figure 1.2). This different morphology is related with different functions 
of both segments, where the small intestine is mainly responsible for absorption and 
re-absorption of water is mainly performed by the large intestine. (Rizk and Barker 
2012; Dubreuil 2012; Vereecke et al. 2011). The intestinal epithelium protects the 
internal environment of the organ acting as a selective barrier, due to the tight 
junctions established between adjacent cells that also contribute to the integrity of 
the epithelial layer.  
There are different types of junctions characterised by their localisation and 
by the types of proteins involved. From apical to basolateral, one finds tight junctions 
followed by adheren junctions. These compose the apical junctions, involved in and 
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regulating the paracellular permeability, a type of transport occurring between cells. 
Gap junctions and desmosomes are the more basolateral types of junctions (Elamin et 
al. 2012; Ashida et al. 2011; Gumbiner 1996).  
Figure 1.2 Intestinal epithelium architecture and renewal. Intestinal epithelial cells differentiate as they 
migrate along the crypt-villus axis. Stem cells, housed at the crypt, give rise to the transient amplifying 
(TA) cells, which move forward originating the different intestinal epithelial cells. Fully differentiated cells 
reaching the tip of the villi enter programed cell death (apoptosis) being liberated into the lumen. Paneth 
cells are the exception cells migrating downwards. Adapted and reprinted with permission from Wiley 
Periodicals, Inc.: Wiley Interdisciplinary Reviews: Systems Biology and Medicine (Rizk and Barker 2012), 
copyright (2012). 
Mammalian intestinal epithelia are composed of different differentiated cell 
types: enterocytes (or absorptive cells), enteroendocrine, goblet, Paneth, Tuft, and M 
cells. All of these originate from transient amplifying cells (TA) which in turn derive 
from the stem cells housed at the base of the crypt. These cells differentiate along 
their migration path across the crypt-villus axis with a rapid renewal of 2-5 days. The 
exceptions are the Paneth and M cells which migrate towards the base of the crypt 
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(Dubreuil 2012; Vereecke et al. 2011; Nicoletti 2000). The majority of intestinal 
epithelium is composed of enterocytes, polarised cells specialised in absorption, 
bearing microvilli at their apical surface, also called the brush border membrane. 
Goblet cells are responsible for mucus production and are found both in small and 
large intestinal epithelia. Paneth cells are specialised in the production of 
antimicrobial factors being exclusive to the small intestine (Vereecke et al. 2011; 
Simon-Assmann et al. 2007). Enteroendocrine, Tuft, and M cells are less represented 
cell populations. The first are responsible for the secretion of diverse hormones thus 
contributing to the overall homeostasis of the epithelium. The functional significance 
of Tuft cells remains uncertain (Rizk and Barker 2012). M cells, present in both small 
and large intestinal epithelia, have defensive roles, being a route for the entry and 
contact between antigens (such as those from bacteria and virus) and the intestinal 
immune system (Nicoletti 2000). M cells have also been shown to be able to derive 
from differentiated absorptive enterocytes. In a curious experimental approach, fully 
differentiated enterocyte-like Caco-2 cells cultured in the presence of primary 
lymphocytes were converted into cells having M cell characteristics (Kernéis et al. 
1997). 
1.3.2.2 Enterocytes – permeability and metabolism 
Until reaching the systemic circulation, orally delivered therapeutics must cross the 
intestinal epithelium followed by the liver, through the hepatic portal vein. The 
exceptions, those not reaching the liver, are absorbed but directly enter the lymphatic 
system or are absorbed in the distal rectum (Shen et al. 1997). Oral bioavailability 
(Foral) corresponds to the fraction of dose that is absorbed (Fa) and not metabolised, 
crosses the intestinal epithelia to the hepatic portal vein (Fg) and not metabolised in 
the liver (Fh). Thus, the fraction of the administered drug that effectively reaches its 
site of action corresponds to the product of these three variables, a process also 
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known as first-pass biotransformation, where several metabolic enzymes and 
transporters are invovled (Thelen and Dressman 2009). 
The players involved in transport and metabolism in enterocytes have been 
extensively studied through several techniques. Different layers of expression and 
function, from genomics to metabolomics and transportomics have been thoroughly 
evaluated under various physiological conditions including inflammation (Stegmann 
et al. 2006; Fleet 2007; Béaslas et al. 2008; Romero-Calvo et al. 2011). Orally delivered 
xenobiotics, such as nutrients and drugs, have various routes to cross the intestinal 
epithelium (Figure 1.3). 
Figure 1.3 Intestinal absorption routes. Xenobiotic compounds may cross the intestinal epithelium 
through (1, 2, 3, 5, 6 and 7) or in between enterocytes (4). 1. Transcellular passive transport. 2. Active 
transport. 3. Facilitated passive diffusion. 4. Paracellular passive transport. 5. Efflux active transport. 6. 
Metabolic reaction. 7. Endocytosis. Reprinted with permission from Springer (Springer, Part of Springer 
Science+Business Media): The AAPS Journal (Balimane et al. 2006), copyright (2012). 
Intestinal absorption may occur through the intestinal cells or between cells 
and may involve the interplay of both transport proteins as well as metabolic 
enzymes. Passive absorption most commonly occurs through the cells, known as 
transcellular transport, where compounds are able to cross the cell membrane due to 
an adequate lipophylicity. Transport across channel proteins without energy 
expenses, known as facilitated diffusion or passive carrier-mediated absorption 
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(uniport), is another possibility. Absorption can also occur between cells, known as 
paracellular transport, where compounds transverse the junctions between cells.  
Drugs and other compounds may also be transported through the cells by 
endocytosis and active primary transport, utilising ATP, or active secondary transport, 
such as coupled carrier-mediated transport (symport or antiport). Efflux transporters 
are examples of active primary transporters and counter the apical to basolateral 
transport by the active transport of compounds towards the lumen of the intestine. 
They are members of the ABC family such as the breast cancer resistance protein 
(BCRP), P-gp and multidrug resistance-associated protein (MRP). Some Phase I 
metabolic enzymes, such as those from CYP and CES families, may metabolise the 
transported compound thus interfering with its absorption rate (Balimane et al. 2006; 
Buckley et al. 2012; Alberts et al. 2002). An example is the interplay between CYP3A 
metabolic enzymes and P-gp transport, where several drugs are substrates of both 
proteins (Christians et al. 2005; van Waterschoot and Schinkel 2011).  
The liver is the organ traditionally regarded as the primary site of drug 
metabolism. Nonetheless, the importance of intestinal metabolism should not be 
overlooked. It has been demonstrated that the majority of the metabolic enzymes 
found in liver cells are also present in the enterocytes. The enzymes found in small 
intestine have been extensively reviewed and include Phase I (CYP enzymes, with 
CYP3A4 being the most abundant; esterases; epoxide hydrolase; alcohol 
dehydrogenase) and Phase II (UGTs, sulfonotransferases, acetyl transferases, and 
glutathione S-transferases) metabolic enzymes (Bonnefille et al. 2011; Thelen and 
Dressman 2009; Lin et al. 1999; Shen et al. 1997). 
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1.4 Tools to study intestinal permeability and metabolism 
Several tools are available to evaluate intestinal permeability of drugs. Ranging from 
in vivo, in situ, ex vivo, in silico, and in vitro assays, they have been extensively 
reviewed in the literature (Cheng et al. 2008; Buckley et al. 2012; Volpe 2010; Geerts 
et al. 2011). The suitability of any given experimental model may be evaluated 
according to the accuracy of the in vitro-in vivo correlation (IVIVC) (Volpe 2010). No 
perfect model exists and the choice of which model(s) to use must rely on the 
knowledge of their main advantages and limitations. Several authors have proposed 
different strategies and outcomes on how to perform this choice (Fagerholm 2007; 
Christensen et al. 2012). Under the scope of this thesis, a brief overview of the 
possible approaches is performed with a special emphasis on in vitro models and 
Caco-2 cells. 
1.4.1 In vivo 
The usage of experimental or laboratory animal models constitutes the only whole 
living organism approach possible, besides the clinical studies performed with 
humans. Rat, dog, monkey, sheep, mouse, and pig are some of the most commonly 
used animals (Harrison et al. 2004; Fagerholm 2007; Cheng et al. 2008). 
In addition to the regulatory, ethical and economic constraints inherent to 
the use of animals (please refer to Section 1.4.6) another severe limitation arises from 
the demonstrated species differences that may affect the accuracy of the IVIVC (Crow 
et al. 2007; Williams et al. 2011). In fact, species differences may impact more than 
the extrapolation of absorption data to humans. An unfortunately notorious example 
is thalidomide, a mild sleeping pill that reduced morning sickness and was 
commercialized in the mid 1960’s. It caused the birth of several thousand impaired 
children although no defects had been previously noticed in rat newborns. It was later 
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discovered to impair the correct development of rabbit foetuses (Harrison et al. 
2004). 
1.4.2 In situ 
In the perfusion in situ technique, usually, a segment of the intestine of a numbed 
animal is perfused with a drug solution containing a predetermined concentration. By 
measuring the amount of drug that leaves the segment in the original or metabolised 
form, one may indirectly determine absorption. Different techniques were developed 
such as open, semi open, or closed perfusion (Lennernäs 1998; Volpe 2010). 
Perfusion models constitute the best approximation to the anatomy found 
in the living organ but require the usage of animals, their manipulation through 
anaesthesia and surgery, thus being an invasive, time consuming, and low throughput 
technique (Volpe 2010; Harrison et al. 2004). Resorting to animals, it shares the 
limitations of in vivo assays, mentioned above, using animal experimental models. 
1.4.3 Ex vivo 
In explant cultures, portions of the GI tissues are removed and cultured according to 
different methods and culture techniques (Randall et al. 2011). Two examples are the 
everted gut sac model and the diffusion chamber. In the first, a portion of everted 
intestine is filled, tied up and placed in a chamber containing the drug solution. The 
permeation of the drug is determined by measuring how much appears inside the sac. 
Different animals have been used for the application of this technique, with rat being 
the most common (Volpe 2010; Alam et al. 2012). In the diffusion chamber method, a 
portion of excised tissue is opened and cultured as a single layer in the interface of 
two chambers. The absorption rate is determined by measuring the amount of drug, 
placed in the apical chamber, found in the basolateral chamber (Volpe 2010). 
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Human or non-human animal tissue diffusion models maintain some of the 
characteristics encountered in the gut, such as the maintenance of the mucus layer. 
Nonetheless, several limitations may occur in this system such as the limited viability 
of the tissue and the stirring conditions. Underestimation of drug transport may occur 
due to the insufficient removal of the muscularis mucosa, the inner most layer of the 
mucosa (composed of the epithelium, lamina propria, and muscularis mucosa) and 
the region of the intestine that faces the lumen (Volpe 2010; Randall et al. 2011; Alam 
et al. 2012). 
1.4.4 In silico 
Computer software to perform physiologically-based pharmacokinetic (PBPK) 
modelling has been suggested as one of the best possibilities towards animal 
reduction for predicting drug ADME profiles (Harrison et al. 2004). Different 
predictive models exist and their potential have been previously reviewed (van de 
Waterbeemd and Gifford 2003; Theil et al. 2003). Commercially available software 
including SimCYP® Population-based ADME simulator and GastroPlus™ are examples 
of the existing possibilities to perform PBPK modelling that are already being used by 
pharmaceutical companies, such as Roche (Heikkinen et al. 2012). 
There is an increased acceptance of these types of studies due to their 
associated advantages: the costs are inexpensive compared to in vivo studies; they 
have been reported to provide qualitatively accurate predictions, despite the need for 
improved quantitative accuracy (Jacob et al. 2009); and they allow time savings 
(Heikkinen et al. 2012). Relying on available parameters, obtained through  both in 
vivo and in vitro experimentation, a general disadvantage is the quality of the existing 
data used to perform the modelling studies (Harrison et al. 2004; Fagerholm 2007). 
Another disadvantage of this approach has been the lack of validated prediction of 
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intestinal metabolism but different researchers are working towards improving it 
(Heikkinen et al. 2012).  
1.4.5 In vitro 
1.4.5.1 Non-cellular models 
Non-cellular models constitute simple, automatable, and highthroughput adaptable 
systems. They are usually less expensive and faster than cellular in vitro models, due 
to the avoidance of the culturing times, allowing larger pH ranges and drug 
concentrations. They are, however, unsuited for active transport studies and lipophilic 
compounds usually face membrane retention problems. Examples of these systems 
are the parallel artificial membrane permeability assay (PAMPA) and the phospholipid 
vesicle-based permeation assay (PVPA). The first is obtained through the coating of a 
hydrophobic filter, in 96-well plates, with an organic solution containing 
lecithin/phospholipids. PVPA is composed of a layer of liposomes in a porous filter 
where the pores are also filed with liposomes. These have been reported as the most 
effective systems for passive absorption studies through the transcellular route. 
Higher accuracy has been attributed to the PVPA method due to the avoidance of 
organic solvents and an apparent negligible unstirred water layer (Balimane et al. 
2006; Volpe 2010; Buckley et al. 2012).  
1.4.5.2 Cellular models 
Cellular models exist for the study of intestinal absorption and have been recently 
reviewed (Buckley et al. 2012; Sarmento et al. 2012). Primary cultures of enterocytes 
may be obtained through the differentiation of intestinal embryonic epithelial cells or 
isolated from adult human intestine. The first human villus-like primary culture of 
differentiated enterocytes (PCDE), able to survive for ten to twelve days in culture, 
was reported in 1998 (Perreault and Beaulieu 1998). Several limitations have impaired 
the routine use of normal human enterocyte primary cell lines, such as their limited 
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survival time, highly differentiated state, bacterial contamination, overgrowth of 
other cells from the tissue including mesenchymal cells, and very complex protocols 
for cell culturing (Simon-Assmann et al. 2007; Chougule et al. 2012). Advances in this 
field have been recently reported, in terms of improvements on reproducibility and 
less complex isolation methods (Chougule et al. 2012). The application of these new 
advances in absorption studies is yet to be performed.  
The most common cell culture models are immortalized intestinal epithelial 
cell lines from human or non-human animal origins (Simon-Assmann et al. 2007; 
Beaulieu and Ménard 2012; Chougule et al. 2012). Other cell culture models are non-
transformed intestinal epithelial cells, such as the rat small intestine epithelia (IEC) 
cell line, able to differentiate when co-cultured with foetal intestinal mesenchyme 
(Simon-Assmann et al. 2007). Animal or human derived cellular models enable the 
study of different types of permeability, such as passive diffusion (both transcellular 
and paracellular) and active transport including efflux mechanisms. A main advantage 
is the possibility to automate screens, thus constituting highthroughput techniques. 
Nonetheless, some of their pitfalls are the variability found between laboratories 
(inter-laboratory), the lack of expression of several transport proteins as well as a 
mucus layer, the nonspecific binding of compounds to the cells and to the devices 
used in cell culturing, and the poor predictability for those compounds crossing the 
cell by carrier-mediated transport or via the paracellular route (Balimane et al. 2006; 
Volpe 2010).  
Table 1.3 summarises the most common cell lines used for intestinal 
absorption studies, all of them able to form polarised epithelium–like cells.  
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Table 1.3 Advantages (+) and limitations (-) of immortalized intestinal epithelial cell lines  
Cell line Species / Tissue Characteristics 
Caco-2 
Human / Colon 
adenocarcinoma 
 + Human origin; spontaneous differentiation becoming 
enterocyte-like cells; domes formation in culture; expression of 
eflux transporters (e.g. P-gp, MRP2, BCRP). 
    
 - Tumour origin thus bearing mutations in several genes; inter-
laboratory variability; heterogeneous cell line; time-consuming 
(differentiation through a 21-days period); requires regular 
medium change; possibility of false negative results in drug 
permeability, due to lower expression of some carrier-mediated 
transporters and tighter junctions (paracellular transport), 
comparing with enterocytes; lack CYP3A4 expression to 
significant levels (high in enterocytes); low expression of hCES2 
and high expression of hCES1 (opposite of what is found in 
enterocytes).   
HT-29 
Human / Colon 
adenocarcinoma 
 + Human origin; differentiation becoming enterocyte-like cells 
under certain conditions (e.g. glucose-deprivation, glucose 
substitution by galactose, inosin or uridine as carbon source). 
Under certain culture conditions they differentiate into goblet 
cells, enabling drug absorption studies in the presence of a 
mucus layer. 
    
 - Tumour origin thus bearing mutations in several genes; lower 
expression of brush-border enzymes than enterocytes or Caco-
2 cells. 
MDCK Canine / Kidney 
 + Shorter culturing times (3 days); Good correlation with Caco-
2 cells in passive transcellularly transported compounds; 
Ameanable for cell transfections. 
    
 - Non-human origin; minimal metabolic activity (may be 
advantageous if metabolism is not a focus of the study); low 
expression of ABC transporters (may be advantageous; e.g., 
avoid P-gp efflux). 
2/4/A1 Rat / Foetal intestine 
 + More suitable for paracellular studies due to leakier 
monolayers formation. 
     - Non-human origin; temperature sensitive. 
LLC-PK1 Pig / Kidney  + Ameanable for cell transfections. 
  
 - Non-human origin; Low expression of certain drug 
transporters (may be advantageous). 
Balimane and Chong 2005; Balimane et al. 2006; Cheng et al. 2008; Irvine et al. 1999; Buckley et al. 2012; 
Sarmento et al. 2012; Simon-Assmann et al. 2007; Ungell 2004; Volpe et al. 2010. 
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Caco-2 cells, isolated from a colon adenocarcinoma (Fogh et al. 1977), were 
shown to spontaneously differentiate in culture (Pinto et al. 1983). Since their first 
characterisation studies (Ramond et al. 1985; Rousset 1986; Hidalgo et al. 1989), they 
have become the most well-established cell model for intestinal permeability in 
addition to their application in intestinal differentiation studies. Sub-clones of this cell 
line were selected with TC-7 being a more homogeneous Caco-2 cell line, leading to 
higher consistency in the obtained results, thus reducing their variability (Simon-
Assmann et al. 2007; Buckley et al. 2012). In Section 1.5, additional attention is 
devoted to Caco-2 cells. 
HT-29, isolated in 1964 by Fogh, was the first human colon carcinoma cell 
line established. Curiously, this cell line has the ability to differentiate into different 
cell types depending on the culture conditions: under glucose deprivation, it acquires 
enterocyte-like characteristics; in serum-free culture, half of the population acquires 
goblet cells characteristics; upon long-term culture in the presence of sodium 
butyrate the cells differentiate into goblet cells and the same happens in the presence 
of intermediate (10-6-10-5 mol.L-1) concentrations of the drug methotrexate (MTX); in 
the presence of high concentrations (10-4-10-3 mol.L-1) of MTX, only enterocyte-like 
cells are found; if low concentrations (10-7 mol.L-1) of this drug are present in the 
culture media, the population becomes half enterocyte-like and half globet-like. This 
plasticity has led to the isolation of different HT-29 sub-clones, such as the HT29-MTX 
mucous secreting cell line (Simon-Assmann et al. 2007).  
Mardin-Darby canine kidney (MDCK) cells and Lewis lung carcinoma-porcine 
kidney 1 (LLC-PK1) are cell lines commonly used to assess permeability of xenobiotics 
(Balimane and Chong 2005). MDCK cells were isolated in 1958 by Mardin and Darby 
and were immortalized through long-term in vitro culture (Bruyneel et al. 1990). LLC-
PK1 were isolated in 1976 and shown to be able to form dome-like structures (Hull et 
al. 1976). Special attention should be devoted to these cell lines as well as to the 
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2/4/A1, a rat foetal intestinal cell line conditionally immortalized with a temperature-
sensitive SV40 large T antigen (Tavelin et al. 1999), due to possible species differences 
(Balimane and Chong 2005). 2/4/A1 cell line has been proposed as representative for 
studying paracellular transport; however, differences in paracellular pore size 
distribution have been reported in comparison with what is found in enterocytes 
(Ungell 2004; Linnankoski et al. 2010).  
One of the critics of working with isolated single-cell cultures is the lack of 
physiological relevance due to the lack of interplay between cells that is found in vivo. 
As detailed in Section 1.3.2, the small intestine epithelium is composed of different 
cell types. Strategies to account for this diversity in vitro have been developed such as 
the co-culture of Caco-2 and HT-29, Caco-2 and Burkitt’s lymphoma-derived cell line 
(Raji), and even a triple co-culture system with these three cell lines (Sarmento et al. 
2012). Raji cells are a human B-cell reference line, isolated in 1964 from a patient 
suffering from lymphoma. Curiously, it is on the basis of the discovery and isolation of 
the Epstein-Barr virus (Pulvertaft 1964; Wu et al. 2004b; Karpova et al. 2005). As 
mentioned in Section 1.3.2, lymphocytes have the ability to convert Caco-2 into M 
cells. The co-culture of Caco-2 with Raji cells allows a better mimic of follicle-
associated epithelium, regions of the intestinal epithelium containing enterocytes, M, 
and goblet cells (des Rieux et al. 2007; Sarmento et al. 2012). Some other co-culture 
strategies trying to mimic the relationships between cells, even from different tissues 
in the organism, have already been reported such as the co-culture of enterocyte-like 
Caco-2 cells, with hepatocyte-like HepaRG cells (Rossi et al. 2012).  
1.4.6 The need for improved in vitro models 
As demonstrated in the previous sections, where the main limitations of the currently 
existing methods were presented, there are several scientific reasons pointing to the 
need to improve them to reduce the use of animal models. In fact, it was previously 
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stated that the extent of in vivo experimental animals’ usage is a consequence of both 
regulatory constraints and the limitations in currently available in vitro models 
(Schroeder et al. 2011).  
Achieving better in vitro tools to test drugs and other xenobiotics alleviates 
ethical and economic concerns. The ethical reasoning behind the need of adjusting 
the usage of animal models have led to the adoption by the European regulatory 
authorities of the 3R policy: Replace, Reduce, or Refine laboratory animal use when 
possible (Wells 2011; Schiffelers et al. 2012). This is included in the measures of the 
new European Directive 2010/63/EU that will be in effect on the 1st of January of 2013 
(Wells 2011). Aligned with the political regulations, the Scientific Advisory Committee 
of European Centre for the Validation of Alternative Methods (ECVAM) has 
contributed to the development, promotion, and adoption of new or improved 
alternatives to in vivo methods (Huynh et al. 2009). Although there is an increased 
pressure to minimise the usage of animal models, its prohibition in the drug 
development process is not envisioned in the near future (Schroeder et al. 2011). 
However, the Cosmetics industry is regulated by different legislation, and the usage of 
animals for testing final products has been prohibited in Europe since 2004. The 
banning is expected to be extended to cosmetic ingredients, at least for certain 
assays, in the near future, providing that new or improved in vitro testing are 
developed and validated (Schroeder et al. 2011).  
In economic terms, there is also the need to rethink and readjust the use of 
experimental animals in the process of drug discovery and development, for example. 
Latest estimations for the costs involved in the research and development (R&D) 
process of developing one marketable new molecular entity (NME) required investing 
US$ 1.78 billion to complete the process (Paul et al. 2010). In 2003, the estimations 
were US$ 403 million (DiMasi et al. 2003), and although differences between the 
estimation methods may be arguable, there is no doubt concerning the escalation of 
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the needed investment. These have been mainly attributed to the increase in the 
costs of clinical trials, as well as in costs involved in animal experimentation. Although 
clinical trials constitute the highest burden in the entire process, the costs attributed 
to animal testing are also a reason for concern (Dickson and Gagnon 2004). Therefore, 
improved in vitro models may decrease the investment in the development of new 
drugs.  
1.5 Caco-2 cell line 
Caco-2 cell line is one of the most used in vitro model for drug absorption prediction 
and is widely used by the pharmaceutical industry (Buckley et al. 2012) since it is 
accepted and recommended by the North-American regulatory authorities, the Food 
and Drug Administration (FDA), and the European authorities, the European 
Medicines Agency (EMA). Nonetheless, and as mentioned in the previous sections, 
this model has some limitations related with its intrinsic characteristics as well as the 
practiced cell culture methods.  
Caco-2 cells are known to be hypertetraploid (Pinto et al. 1983), having on 
average 89 (84-98) chromosomes. Spectral karyotyping revealed fourteen aberrant 
chromosomes in the Caco-2 karyotype (Melcher et al. 2002).  
Caco-2 cells are known to express both colonocyte and enterocyte 
phenotypes (Engle et al. 1998). Special attention has been devoted to the changes in 
gene expression occurring throughout the differentiation period. Using transcriptome 
analysis and comparing both enterocytes and colonocytes, it was shown that until 
reaching confluence, Caco-2 share mRNA profile similarities with both cell types, and 
thereafter becoming more and more similar to enterocytes (Anderle et al. 2003). 
Moreover, it was also found that upon differentiation, down-regulation of cell cycle, 
transcription and protein metabolism associated genes occured whereas the 
expression of cell adhesion, iron transport, and Phase II metabolism genes increased 
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(Bédrine-Ferran et al. 2004; Chopra et al. 2010). Changes in post-translational 
modification profiles, namely due to differences in glycosyltransferase expression, 
were also reported upon differentiation of the cells (Brockhausen et al. 1991) as well 
as in the metabolic profile of the cells, as evaluated through nuclear magnetic 
resonance (NMR; Lee et al. 2009). 
One of the main disadvantages with Caco-2 cells is the intra- and inter-
laboratory variability found in the results. The factors on the basis of this variability 
were previously studied (Zucco et al. 2005; Hayeshi et al. 2008; Prieto et al. 2010; 
Roth 2012). Table 1.4 shows some examples of each of these factors. So far, there is 
no standard operating procedure to work with these cells although several methods 
and conditions aiming to achieve the best culturing conditions were proposed 
(Hubatsch et al. 2007; Prieto et al. 2012; Natoli 2012). One may envision the best 
approach to be exploring the provided culturing methods throughout the literature, 
establish a protocol, and consistently reproduce it using a well characterised Caco-2 
cell line in a specific and characterised passage interval. The characterisation of the 
cells may be achieved through protein and mRNA analysis or the use of reference 
compounds during permeability experiments. Based upon this notion, it was 
demonstrated that independent of cell source and culturing conditions, Caco-2 is the 
in vitro cell model genetically closest to human enterocytes (Christensen et al. 2012). 
Recently, advances towards the achievement of more relevant physiological 
conditions were performed by showing that Caco-2 cells in 2-D cultures are able to 
differentiate in inserts containing only serum in the basolateral chamber (Ferruzza et 
al. 2012) and these cells are able to grow and differentiate in 3-D cultures (Elamin et 
al. 2012). 
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Table 1.4 Examples of different factors affecting Caco-2 variability 
Variability 
factor 
Examples 
Cell source 
Different cell banks provide Caco-2 cells from different depositers causing inter-
laboratory variability in the results even when using intra-laboratory standard 
culturing conditions (Hayeshi et al. 2008). 
 - DMSZ bank; cat.# ACC 169: deposited by Prof. A. Bacher, Technical University of 
Munich, Munich, Germany (http://www.dsmz.de/catalogues/catalogue-human-and-
animal-cell-lines.html). 
 - ECACC bank; cat.# 09042001: from ATCC, 1985; cat.# 86010202: deposited by Dr. J 
Clarke, AVRI, Pirbrigh (http://www.hpacultures.org.uk/collections/ecacc.jsp). 
 - ATCC bank; cat.# HTB-37™: deposited by J Fogh, 1977; cat.# CRL-2102™: deposited 
by MD Peterson and M Mooseker (http://www.lgcstandards-atcc.org/). 
Passage 
number 
 - Influences the expression of efflux proteins: MDR1 expression was lower in Caco-2 
cell above passage 45 in comparison with passage 30 (Siissalo et al. 2007). 
 - Influences different functional properties: TEER; cell proliferation rate, and 
multilayered areas increase at higher passages. Sucrose-isomaltose expression 
increases and alkaline phosphatase activity decreases also at higher passages 
(Sambuy et al. 2005). 
Seeding inocula 
during 
passaging 
 - Variable growth rates reported; should be adjusted to sub-culturing once a week 
(Zucco et al. 2005). 80% considered as a good confluence for sub-culturing but 
recent reports argue lowering to 50% to avoid heterogeneus growth conditions 
among the cells (Natoli et al. 2011). 
Seeding 
innocula for 
differentiation 
 - Wide range of reported seeding densities (10
3
 to 10
5
 cell.cm
-2
). Intermediate 
seeding densities (6 x 10
4
 cell.cm
-2
) reported as suitable for 21-day differentiation. 
Higher or lower densities reported as negatively influencing P-gp expression. Higher 
seeding densities may lead to multilayer formation (Sambuy et al. 2005). 
Medium 
 - Different medium reported from AMEM, DMEM to RPMI and different FBS 
percentages. Better performance was reported with DMEM using 10% FBS (Zucco et 
al. 2005). Usually additional supplementation with 1% NEAA is performed. 
 - Caco-2 originally from same source shown to have significant differences in drug 
metabolising enzymes when cultured in AMEM or DMEM (Roth et al. 2012). 
 - Hygromycin B antibiotic impacts cell adherence, monolayer integrity and cell 
morphology (Crespi et al. 1996; Rodolosse et al. 1998). 
Incubation 
conditions 
 - 37 °C is the standard temperature used; reported CO2 % varies from 5-10%; it 
should be adjusted to the concentration of sodium bicarbonate in the medium to 
achieve pH 7.4 according to Henderson-Hasselbach equation: pH = 6.1 + log (52 * 
mg/ml NaHCO3 / %CO2 -1) (Castilho et al. 2008). 
Filter support  
 - Filter material and pore size influence Caco-2: polycarbonate and pore diameter of 
0.4 μm reported as better for monolayer achievement (Hubatsch et al. 2007). Pore 
size has been reported as impacting dome formation (Ramond et al. 1985). 
Cat.# - catalogue number; DMSZ - Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures; 
ECACC - European Collection of Cell Cultures; ATCC - American Type Culture Collection; AMEM - Minimum Essential 
Medium Alpha; DMEM - Dulbecco’s Modified Eagle’s Medium; RPMI - Roswell Park Memorial Institute medium; FBS – 
Foetal bovine serum; TEER - Trans-epithelial resistance. NEAA – Non-essential aminoacids. 
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To improve the intrinsic limitations of Caco-2 cells (presented in Section 1.4.5) 
several strategies have been employed to increase or decrease the expression of 
various proteins. Using chemical agents such as 1-alpha,25-dihydroxyvitamin-D3, the 
CYP3A4 expression levels were increased (Schmiedlin-Ren et al. 2001). Using BNPP, an 
inhibitor of CESs, a model for permeability evaluation without active CESs was 
achieved (Ohura et al. 2010). Genetic manipulation of Caco-2 cells has also been 
attempted, not only for the up-regulation of genes, but also for their knockdown, 
such as the case of Caco-2 transduction with small hairpin RNA (shRNA) targeting P-gp 
(Li et al. 2011). 
1.6 Thesis goals 
The main goals of the work developed and presented in this thesis were to enlarge 
the fundamental knowledge on hCES2 and to improve the Caco-2 cell model by 
increasing the levels of this enzyme, which is crucial in the metabolism of ester 
containing drugs and prodrugs.  
To achieve the proposed goals, a step-wise approach was followed, where a 
journey from analytical chemistry to protein manufacturing and cell line development 
culminates in the opening of several new hypothesis and challenges for this research 
field, discussed in greater detail in the last section.  
The first challenge in this journey, described in Section 2, was the difficulty of 
studying the activity of hCES2 in biological samples. The existing techniques allowing 
the differentiation and quantification of the activity of hCES2 were highly time- and 
sample-consuming. Our first goal was to develop a tool enabling to differentiate and 
quantify hCES2 activity in different biological samples rapidly and with low sample 
consumption, for a proper study of this enzyme. 
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The second challenge faced was the unavailability of a purified hCES2 from 
human cells. Although an hCES2 form was available from mouse myeloma cells, our 
goal was to further investigate the properties of hCES2 produced and purified from a 
human origin. To achieve this goal, a pioneering strategy, described in Section 3, was 
followed using human embryonic kidney (HEK-293T) cells.  
The combined knowledge acquired through the work developed allowed 
tackling the third challenge: the improvement of the most widely used intestinal 
permeability model, the Caco-2 cell line. Although used by both academia and 
industry and accepted by pharmaceutical regulatory authorities, this cell model has 
weaknesses. Our third goal, detailed on Section 4, was to overcome one of these 
constraints, the low expression of hCES2 in comparison with human enterocytes. 
Overall, the work reported herein impacts different research fields ranging 
from fundamental to applied biology and biotechnology as well as analytical 
chemistry, specifically contributing to the fields of xenobiotic metabolising enzymes 
and relevant preclinical in vitro models. 
1.7 References 
Alam MA, Al-Jenoobi FI, Al-Mohizea AM (2012) Everted gut sac model as a tool in pharmaceutical 
research: limitations and applications. J Pharm Pharmacol 64: 326-336.  
Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. Molecular Biology of the Cell. 4
th
 edition. New 
York: Garland Science; 2002. Carrier Proteins and Active Membrane Transport. Available from: 
http://www.ncbi.nlm.nih.gov/books/NBK26896/  
Aldridge WN (1993) The esterases: perspectives and problems. Chem Biol Interact 87: 5-13.  
Akashi T, Aoki T, Ayabe S (2005) Molecular and biochemical characterization of 2-hydroxisoflavanone 
dehydratase. Involvement of carboxylesterase-like proteins in leguminous isoflavone 
biosynthesis. Plan Physiol 137: 882-891. 
Altschul SF, Madden TL, Schäffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ (1997) Gapped BLAST and PSI-
BLAST: a new generation of protein database search programs. Nucleic Acids Res 25: 3389-3402. 
Section 1 
 36
Ammann RA, Tissing WJ, Phillips B (2012) Rationalizing the approach to children with fever in 
neutropenia. Curr Opin Infect Dis 25: 258-265.  
Anderle P, Rakhmanova V, Woodford K, Zerangue N, Sadée W (2003) Messenger RNA expression of 
transporter and ion channel genes in undifferentiated and differentiated Caco-2 cells compared 
to human intestines. Pharm Res 20: 3-15. 
Angkawidjaja C, Koga Y, Takano K, Kanaya S (2012) Structure and stability of a thermostable 
carboxylesterase from the thermoacidophilic archaeon Sulfolobus tokodaii. FEBS J 279: 3071-
3084. 
Ashida H, .Ogawa M, Kim M, Mimuro H, Sasakawa C (2011) Bacteria and host interactions in the gut 
epithelial barrier. Nat Chem Biol 8: 36-45.  
Balimane PV, Chong S (2005) Cell culture-based models for intestinal permeability. A critique. Drug 
Discov Today 10: 335-343. 
Balimane PV, Han YH, Chong S (2006) Current industrial practices of assessing permeability and P-
glycoprotein interaction. AAPS J 8: E1-E13.  
Béaslas O, Torreilles F, Casellas P, Simon D, Fabre G, Lacasa M, Delers F, Chambaz J, Rousser M, Carrière 
V (2008) Transcriptome response of enterocytes to dietary lipids: impact on cell architecture, 
signalling, and metabolism genes. Am J Physiol Gastrointest Liver Physiol 295: G942-G952.  
Beaulieu JF, Ménard D (2012) Isolation, characterization, and culture of normal human intestinal crypt 
and villus cells. Methods Mol Biol 806: 157-173.  
Bédrine-Ferran H, Le Meur N, Gicquel I, Le Cunff M, Soriano N, Guisle I, Mottier S, Monnier A, Teusan R, 
Fergelot P, Le Gall JY, Léger J, Mosser J (2004) Transcriptome variations in human Caco-2 cells: a 
model for enterocyte differentiation and its link to iron absorption. Genomics 83: 772-789.  
Bencharit S, Morton CL, Xue Y, Potter PM, Redinbo MR (2003) Structural basis of heroin and cocaine 
metabolism by a promiscuous human drug-processing enzyme. Nat Struct Biol 10: 349–356. 
Bonnefille P, Sezgin-Bayindir Z, Belkhelfa H, Arellano C, Gandia P, Woodley J, Houin G (2011) The use of 
isolated enterocytes to study Phase I intestinal drug metabolism: validation with rat and pig 
intestine. Fundam Clin Pharmacol 25: 104-114.  
Brockhausen I, Romero PA, Herscovics A (1991) Glycosyltransferase changes upon differentiation of 
Caco-2 human colonic adenocarcinoma cells. Cancer Res 51: 3136-3142. 
Bruyneel EA, Debray H, De Mets M, Mareel MM, Montreuil J (1990) Altered glycosylation in Madin-Darby 
canine kidney (MDCK) cells after transformation by murine sarcoma virus. Clin Exp Metastasis 8: 
241-253. 
Buckley ST, Fischer SM, Fricker G, Brandl M (2012) In vitro models to evaluate the permeability of poorly 
soluble drug entities: challenges and perspectives. Eur J Pharm Sci 45: 235-250.  
Castilho LR, Moraes AM; Augusto EFP, Butler M. Animal Cell-Technology: From Biopharmaceuticals to 
Gene Therapy. 1
st
 edition. Taylor & Francis Group; 2008. 
Introduction 
 37
Cheng KC, Li C, Uss AS (2008) Prediction of oral drug absorption in humans – from cultured cell lines and 
experimental animals. Expert Opin Drug Metab Toxicol 4: 581-590. 
Christensen J, El-Gebali S, Natoli M, Sengstag T, Delorenzi M, Bentz S, Bouzourene H, Rumbo M, Felsani 
A, Siissalo S, Hirvonen J, Vila MR, Saletti P, Aguet M, Anderle P (2012) Defining new criteria for 
selection of cell-based intestinal models using publicly available databases. BMC Genomics 13: 
274.  
Christians U, Schmitz V, Haschke M (2005) Functional interactions between P-glycoprotein and CYP3A in 
drug metabolism. Expert Opin Drug Metab Toxicol 4: 641-654.  
Chopra DP, Dombkowski AA, Stemmer PM, Parker GC (2010) Intestinal epithelial cells in vitro. Stem Cells 
Dev 19: 131-142.  
Chougule P, Herlenius G, Hernandez NM, Patil PB, Xu B, Sumitran-Holgersson S (2012) Isolation and 
characterization of human primary enterocytes from small intestine using a novel method. Scand 
J Gastroenterol doi: 10.3109/00365521.2012.708940.  
Church DM, Goodstadt L, Hillier LW, Zody MC, Goldstein S, She X, Bult CJ, Agarwala R, Cherry JL, DiCuccio 
M, Hlavina W, Kapustin Y, Meric P, Maglott D, Birtle Z, Marques AC, Graves T, Zhou S, Teague B, 
Potamousis K, Churas C, Place M, Herschleb J, Runnheim R, Forrest D, Amos-Landgraf J, Schwartz 
DC, Cheng Z, Lindblad-Toh K, Eichler EE, Ponting CP; Mouse Genome Sequencing Consortium 
(2009) Lineage-specific biology revealed by a finished genome assembly of the mouse. PLoS Biol 
7: e1000112. 
Claudianos C, Ranson H, Johnson RM, Biswas S, Schuler MA, Berenbaum MR, Feyereisen R, Oakeshott JG 
(2006) A deficit of detoxification enzymes: pesticide sensitivity and environmental response in 
the honeybee. Insect Mol Biol 15: 615-636. 
Crespi CL, Penman BW, Hu M (1996) Development of Caco-2 cells expressing high levels of cDNA-derived 
cytochrome P4503A4. Pharm Res 13: 1635-1641. 
Crow JA, Borazjani A, Potter PM, Ross MK (2007) Hydrolysis of pyrethroids by human and rat tissues: 
examination of intestinal, liver and serum carboxylesterases. Toxicol Appl Pharmacol 221: 1-12. 
de Jong FA, Scott-Horton TJ, Kroetz DL, McLeod HL, Friberg LE, Mathijssen RH, Verweij J, Marsh S, 
Sparreboom A (2007) Irinotecan-induced diarrhea; functional significance of the polymorphic 
ABCC2 transporter protein. Clin Pharmacol Ther 81: 42-49.  
Des Rieux A, Fievez V, Théate I, Mast J, Préat V, Schneider YJ (2007) An improved in vitro model of human 
intestinal follicle-associated epithelium to study nanoparticle transport by M cells. Eur J Pharm 
Sci 30: 380-391.  
Dickson M, Gagnon JP (2004) Key factors in the rising cost of new drug discovery and development. Nat 
Rev Drug Discov 3: 417-429. 
DiMasi JA, Hansen RW, Grabowski HG (2003) The price of innovation: new estimates of drug 
development costs. J Health Econ 22: 151-185. 
Directive 2010/63/EU, OJ L 276, p. 33 to 79 of 20.10.2010  
Section 1 
 38
Directive number 63 of 2010, Official Journal of 20 October 2010, L 276, pages 33 to 79. 
Dubreuil JD (2012) The whole Shebang: the gastrointestinal tract, Escherichia coli enterotoxins and 
secretion. Curr Issues Mol Biol 14: 71-82.  
Durand N, Chertemps T, Maïbèche-Coisne M (2012) Antennal carboxylesterases in a moth, structural and 
functional diversity. Commun Integr Biol 5: 284-286.  
Elamin E, Jonkers D, Juuti-Uusitalo K, can Ijzendoorn S, Troost F, Duimel H, Broers J, Verheyen F, Dekker J, 
Masclee A (2012) Effects of ethanol and acetaldehyde on tight junction integrity. In vitro study in 
a three dimensional intestinal epithelial cell culture model. PLoS One 7: e35008.  
Engle MJ, Goetz GS, Alpers DH (1998) Caco-2 cells express a combination of colonocyte and enterocyte 
phenotypes J Cell Physiol 174: 362-369. 
European Medicines Agency. Guideline on the Investigation of Drug Interactions. 
EMA/CHMP/EWP/125211/2010 (European Medicines Agency, London, UK, 2012). 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/05/WC50
0090112.pdf (2012). 
Fagerholm U (2007) Prediction of human pharmacokinetics – gastrointestinal absorption. J Pharm 
Pharmacol 59: 905-916.  
Ferruzza S, Rossi C, Scarino ML, Sambuy Y (2012) A protocol for differentiation of human intestinal Caco-
2 cells in asymmetric serum-containing medium. Toxicol In Vitro doi: 10-1016/j.tiv.2012.01.008. 
Fleet JC (2007) Using genomics to understand intestinal biology. J Physiol Biochem 63: 83-96.  
Fogh J, Fogh JM, Orfeo T (1977) One hundred and twenty-seven cultured human tumor cell lines 
producing tumors in nude mice. J Natl Cancer Inst 59: 221-226. 
Food and Drug Administration. FDA Guidance for industry, waiver of in vivo bioavailability and 
bioequivalence studies for immediate-release solid oral dosage forms based on a 
biopharmaceutics classification system. (Food and Drug Administration, Baltimore, MD, 2000). 
http://www.fda.gov/cder/guidance/3618fnl.htm (2012).  
Fukami T, Yokoi T (2012) The Emerging Role of Human Esterases. Drug Metab Pharmacokinet doi: 
10.2133/dmpk.DMPK-12-RV-042. 
Furihata T, Hosokawa M, Nakata F, Satoh T, Chiba K (2003) Purification, molecular cloning, and functional 
expression of inducible liver acylcarnitine hydrolase in C57BL/6 mouse, belonging to the 
carboxylesterase multigene family. Arch Biochem Biophys 416: 101-109. 
Geerts T, Vander Heyden T (2011) In silico predictions of ADME-Tox properties: drug absorption. Comb 
Chem High Throughput Screen 14: 339-361.  
Gibbs RA, Weinstock GM, Metzker ML, Muzny DM, Sodergren EJ, Scherer S, Scott G, Steffen D, Worley 
KC, Burch PE, Okwuonu G, Hines S, Lewis L, DeRamo C, Delgado O, Dugan-Rocha S, Miner G, 
Morgan M, Hawes A, Gill R, Celera, Holt RA, Adams MD, Amanatides PG, Baden-Tillson H, 
Barnstead M, Chin S, Evans CA, Ferriera S, Fosler C, Glodek A, Gu Z, Jennings D, Kraft CL, Nguyen 
Introduction 
 39
T, Pfannkoch CM, Sitter C, Sutton GG, Venter JC, Woodage T, Smith D, Lee HM, Gustafson E, Cahill 
P, Kana A, Doucette-Stamm L, Weinstock K, Fechtel K, Weiss RB, Dunn DM, Green ED, Blakesley 
RW, Bouffard GG, De Jong PJ, Osoegawa K, Zhu B, Marra M, Schein J, Bosdet I, Fjell C, Jones S, 
Krzywinski M, Mathewson C, Siddiqui A, Wye N, McPherson J, Zhao S, Fraser CM, Shetty J, 
Shatsman S, Geer K, Chen Y, Abramzon S, Nierman WC, Havlak PH, Chen R, Durbin KJ, Egan A, Ren 
Y, Song XZ, Li B, Liu Y, Qin X, Cawley S, Worley KC, Cooney AJ, D'Souza LM, Martin K, Wu JQ, 
Gonzalez-Garay ML, Jackson AR, Kalafus KJ, McLeod MP, Milosavljevic A, Virk D, Volkov A, 
Wheeler DA, Zhang Z, Bailey JA, Eichler EE, Tuzun E, Birney E, Mongin E, Ureta-Vidal A, Woodwark 
C, Zdobnov E, Bork P, Suyama M, Torrents D, Alexandersson M, Trask BJ, Young JM, Huang H, 
Wang H, Xing H, Daniels S, Gietzen D, Schmidt J, Stevens K, Vitt U, Wingrove J, Camara F, Mar 
Albà M, Abril JF, Guigo R, Smit A, Dubchak I, Rubin EM, Couronne O, Poliakov A, Hübner N, 
Ganten D, Goesele C, Hummel O, Kreitler T, Lee YA, Monti J, Schulz H, Zimdahl H, Himmelbauer H, 
Lehrach H, Jacob HJ, Bromberg S, Gullings-Handley J, Jensen-Seaman MI, Kwitek AE, Lazar J, 
Pasko D, Tonellato PJ, Twigger S, Ponting CP, Duarte JM, Rice S, Goodstadt L, Beatson SA, Emes 
RD, Winter EE, Webber C, Brandt P, Nyakatura G, Adetobi M, Chiaromonte F, Elnitski L, Eswara P, 
Hardison RC, Hou M, Kolbe D, Makova K, Miller W, Nekrutenko A, Riemer C, Schwartz S, Taylor J, 
Yang S, Zhang Y, Lindpaintner K, Andrews TD, Caccamo M, Clamp M, Clarke L, Curwen V, Durbin 
R, Eyras E, Searle SM, Cooper GM, Batzoglou S, Brudno M, Sidow A, Stone EA, Venter JC, Payseur 
BA, Bourque G, López-Otín C, Puente XS, Chakrabarti K, Chatterji S, Dewey C, Pachter L, Bray N, 
Yap VB, Caspi A, Tesler G, Pevzner PA, Haussler D, Roskin KM, Baertsch R, Clawson H, Furey TS, 
Hinrichs AS, Karolchik D, Kent WJ, Rosenbloom KR, Trumbower H, Weirauch M, Cooper DN, 
Stenson PD, Ma B, Brent M, Arumugam M, Shteynberg D, Copley RR, Taylor MS, Riethman H, 
Mudunuri U, Peterson J, Guyer M, Felsenfeld A, Old S, Mockrin S, Collins F; Rat Genome 
Sequencing Project Consortium (2004) Genome sequence of the Brown Norway rat yields insights 
into mammalian evolution. Nature 428: 493-521. 
Gumbiner BM (1996) Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Cell 
84: 345-357.  
Hakamata W, Machida A, Oku T, Nishio T (2011) Design and synthesis of an ER-specific fluorescent probe 
based on carboxylesterase activity with quinone methide cleavage process. Bioorg Med Chem 
Lett 21: 3206-3209. 
Harrison AP, Erlwanger KH, Elbrønd VS, Andersen NK, Unmack MA (2004) Gastrointestinal-tract model 
and techniques for use in safety pharmacology. J Pharmacol Toxicol Methods 49: 187-199.  
Hatfield MJ, Tsurkan L, Hyatt JL, Yu X, Edwards CC, Hicks LD, Wadkins RM, Potter PM (2010) Biochemical 
and molecular analysis of carboxylesterase-mediated hydrolysis of cocaine and heroin. Br J 
Pharmacol 160: 1916-1928. 
Hatfield MJ, Tsurkan L, Garrett M, Shaver TM, Hyatt JL, Edwards CC, Hicks LD, Potter PM (2011) Organ-
specific carboxylesterase profiling identifies the small intestine and kidney as major contributors 
of activation of the anticancer prodrug CPT-11. Biochem Pharmacol 81: 24-31.  
Hayeshi R, Hilgendorf C, Artursson P, Augustijns P, Brodin B, Dehertogh P, Fisher K, Fossati L, Hovenkamp 
E, Korjamo T, Masungi C, Maubon N, Mols R, Müllertz A, Mönkkönen J, O’Driscoll C, Oppers-
Tiemissen HM, Ragnarsson EG, Rooseboom M, Ungell AL (2008) Comparison of drug transporter 
gene expression and functionality in Caco-2 cells from 10 different laboratories. Eur J Pharm Sci 
35: 383-396. 
Section 1 
 40
Heikkinen AT, Baneyx G, Caruso A, Parrot N (2012) Application of PBPK modelling to predict human 
intestinal metabolism of CYP3A substrates – An evaluation and case study using GastroPlus™. Eur 
J Pharm Sci 47: 375-386.  
Hidalgo IJ, Raub TJ, Borchardt RT (1989) Characterization of the human colon carcinoma cell line (Caco-2) 
as a model system for intestinal permeability. Gastroenterology 96: 736-749.  
Holmes RS, Chan J, Cox LA, Murphy WJ, VandeBerg JL (2008) Opossum carboxylesterases: sequences, 
phylogeny and evidence for CES gene duplication events predating the marsupial-eutherian 
common ancestor. BMC Evol Biol 8: 54.  
Holmes RS, Glenn JP, VandeBerg JL, Cox LA (2009) Baboon carboxylesterases 1 and 2: sequences, 
structures and phylogenetic relationships with human and other primate carboxylesterases. J 
Med Primatol 38: 27-38.  
Holmes RS, Wright MW, Laulederkind SJ, Cox LA, Hosokawa M, Imai T, Ishibashi S, Lehner R, Miyazaki M, 
Perkins EJ, Potter PM, Redinbo MR, Robert J, Satoh T, Yamashita T, Yan B, Yokoi T, Zechner R, 
Maltais LJ (2010) Recommended nomenclature for five mammalian carboxylesterase gene 
families: human, mouse, and rat genes and proteins. Mamm Genome 21: 427-441. 
Hotelier T, Renault L, Cousin X, Negre V, Marchot P, Chatonnet A (2004) ESTHER, the database of the 
alpha/beta-hydrolase fold superfamily of proteins. Nucleic Acid Res 32: D145-147. 
Hubatsch I, Ragnarsson EG, Artursson P (2007) Determination of drug permeability and prediction of 
drug absorption in Caco-2 monolayers. Nat Protoc 2: 2111-2119. 
Hull RN, Cherry WR, Weaver GW (1976) The origin and characteristics of a pig kidney cell strain, LLC-PK. 
In Vitro 12: 670-677. 
Humerickhouse R, Lohrbach K, Li L, Bosron WF, Dolan ME (2000) Characterization of CPT-11 hydrolysis by 
human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res 60: 1189-1192.  
Huynh L, Masereeuw R, Friedberg T, Ingelman-Sundberg M, Manivet P (2009) In silico platform for 
xenobiotics ADME-T pharmacological properties modelling and prediction. Part I: Beyond the 
reduction of animal model use. Drug Discov Today 14: 401-405. 
Innocenti F, Kroetz DL, Schuetz E, Dolan ME, Ramírez J, Relling M, Chen P, Das S, Rosner GL, Ratain MJ 
(2009) Comprehensive pharmacogenetic analysis of irinotecan neutropenia and 
pharmacokinetics. J Clin Oncol 27: 2604-2614.  
Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR (1999) MDCK (Madin-Darby 
canine kidney) cells: A tool for membrane permeability screening. J Pharm Sci 88: 28-33. 
Jacob A, Pratuangdejkul J, Buffet S, Launay JM, Manivet P (2009) In silico platform for xenobiotics ADME-
T pharmacological properties modelling and prediction. Part II: The body in a Hilbertian space. 
Drug Discov Today 14: 406-412.  
Jeon JH, Kim SJ, Lee HS, Cha SS, Lee JH, Yoon SH, Koo BS, Lee CM, Choi SH, Lee SH, Kang SG, Lee JH (2011) 
Novel metagenome-derived carboxylesterase that hydrolyzes β-lactam antibiotics. Appl Environm 
Microbiol 77: 7830-7836. 
Introduction 
 41
Karpova MB, Schoumans J, Ernberg I, Henter JI, Nordenskjöld M, Fadeel B (2005) Raji revisited. 
Cytogenetics of the original Burkitt’s lymphoma cell line. Leukemia 19: 159-161.  
Kernéis S, Bogdanova A, Kraehenbuhl JP, Pringault E (1997) Conversion by Peyer’s patch lymphocytes of 
human enterocytes into M cells that transport bacteria. Science 277: 949-952. 
Kim EB, Fang X, Fushan AA, Huang Z, Lobanov AV, Han L, Marino SM, Sun X, Turanov AA, Yang P, Yim SH, 
Zhao X, Kasaikina MV, Stoletzki N, Peng C, Polak P, Xiong Z, Kiezun A, Zhu Y, Chen Y, Kryukov GV, 
Zhang Q, Peshkin L, Yang L, Bronson RT, Buffenstein R, Wang B, Han C, Li Q, Chen L, Zhao W, 
Sunyaev SR, Park TJ, Zhang G, Wang J, Gladyshev VN (2011) Genome sequencing reveals insights 
into physiology and longevity of the naked mole rat. Nature 479: 223-227. 
Kubo T, Kim SR, Sai K, Saito Y, Nakajima T, Matsumoto K, Saito H, Shirao K, Yamamoto N, Minami H, 
Ohtsu A, Yoshida T, Saijo N, Ohno Y, Ozawa S, Sawada J (2005) Functional characterization of 
three naturally occurring single nucleotide polymorphisms in the CES2 gene encoding 
carboxylesterase 2 (HCE-2). Drug Metab Dispos 33: 1482-1487. 
Kweekel D, Guchelaar HJ, Gelderblom H (2008) Clinical and pharmacogenetic factors associated with 
irinotecan toxicity. Cancer Treat Rev 34: 656-669.  
Lagas JS, Damen CW, can Waterschoot RA, Iusuf D, Beijnen JH, Schinkel AH (2012) P-gp, Mrp2, Cyp3a, 
and carboxylesterase affect the oral availability and metabolism of vinorelbine. Mol Pharmacol 
doi: 10.1124/mol.111.077099.    
Lee IJ, Hom K, Baj G, Shapiro M (2009) NMR metabolomics analysis of Caco-2 cell differentiation. J 
Proteome Res 8: 4104-4108. 
Lennernäs H (1998) Human intestinal permeability. J Pharm Sci 87: 403-410.  
Li B, Sedlacek M, manoharan I, Boopathy R, Duysen EG, Masson P, Lockridge O (2005) 
Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present 
in human plasma. Biochem Pharmacol 70: 1673-1684.  
Li J, Volpe DA, Wang Y, Zhang W, Bode C, Owen A, Idalgo IJ (2011) Use of transporter knockdown Caco-2 
cells to investigate the in vitro efflux of statin drugs. Drug Metab Dispos 39: 1196-1202.  
Li R, Fan W, Tian G, Zhu H, He L, Cai J, Huang Q, Cai Q, Li B, Bai Y, Zhang Z, Zhang Y, Wang W, Li J, Wei F, Li 
H, Jian M, Li J, Zhang Z, Nielsen R, Li D, Gu W, Yang Z, Xuan Z, Ryder OA, Leung FC, Zhou Y, Cao J, 
Sun X, Fu Y, Fang X, Guo X, Wang B, Hou R, Shen F, Mu B, Ni P, Lin R, Qian W, Wang G, Yu C, Nie 
W, Wang J, Wu Z, Liang H, Min J, Wu Q, Cheng S, Ruan J, Wang M, Shi Z, Wen M, Liu B, Ren X, 
Zheng H, Dong D, Cook K, Shan G, Zhang H, Kosiol C, Xie X, Lu Z, Zheng H, Li Y, Steiner CC, Lam TT, 
Lin S, Zhang Q, Li G, Tian J, Gong T, Liu H, Zhang D, Fang L, Ye C, Zhang J, Hu W, Xu A, Ren Y, Zhang 
G, Bruford MW, Li Q, Ma L, Guo Y, An N, Hu Y, Zheng Y, Shi Y, Li Z, Liu Q, Chen Y, Zhao J, Qu N, 
Zhao S, Tian F, Wang X, Wang H, Xu L, Liu X, Vinar T, Wang Y, Lam TW, Yiu SM, Liu S, Zhang H, Li D, 
Huang Y, Wang X, Yang G, Jiang Z, Wang J, Qin N, Li L, Li J, Bolund L, Kristiansen K, Wong GK, 
Olson M, Zhang X, Li S, Yang H, Wang J, Wang J (2010) The sequence and de novo assembly of the 
giant panda genome. Nature 463: 311-317. 
Liederer BM, Borchardt RT (2006) Enzymes involved in the bioconversion of ester-based prodrugs. J 
Pharm Sci 95: 1177-1195. 
Section 1 
 42
Lin JH, Chiba M, Baillie TA (1999) Is the role of the small intestine in first-pass metabolism 
overemphasized? Pharmacol Rev 51: 135-158.  
Lindblad-Toh K, Wade CM, Mikkelsen TS, Karlsson EK, Jaffe DB, Kamal M, Clamp M, Chang JL, Kulbokas EJ 
3rd, Zody MC, Mauceli E, Xie X, Breen M, Wayne RK, Ostrander EA, Ponting CP, Galibert F, Smith 
DR, DeJong PJ, Kirkness E, Alvarez P, Biagi T, Brockman W, Butler J, Chin CW, Cook A, Cuff J, Daly 
MJ, DeCaprio D, Gnerre S, Grabherr M, Kellis M, Kleber M, Bardeleben C, Goodstadt L, Heger A, 
Hitte C, Kim L, Koepfli KP, Parker HG, Pollinger JP, Searle SM, Sutter NB, Thomas R, Webber C, 
Baldwin J, Abebe A, Abouelleil A, Aftuck L, Ait-Zahra M, Aldredge T, Allen N, An P, Anderson S, 
Antoine C, Arachchi H, Aslam A, Ayotte L, Bachantsang P, Barry A, Bayul T, Benamara M, Berlin A, 
Bessette D, Blitshteyn B, Bloom T, Blye J, Boguslavskiy L, Bonnet C, Boukhgalter B, Brown A, Cahill 
P, Calixte N, Camarata J, Cheshatsang Y, Chu J, Citroen M, Collymore A, Cooke P, Dawoe T, Daza 
R, Decktor K, DeGray S, Dhargay N, Dooley K, Dooley K, Dorje P, Dorjee K, Dorris L, Duffey N, 
Dupes A, Egbiremolen O, Elong R, Falk J, Farina A, Faro S, Ferguson D, Ferreira P, Fisher S, 
FitzGerald M, Foley K, Foley C, Franke A, Friedrich D, Gage D, Garber M, Gearin G, Giannoukos G, 
Goode T, Goyette A, Graham J, Grandbois E, Gyaltsen K, Hafez N, Hagopian D, Hagos B, Hall J, 
Healy C, Hegarty R, Honan T, Horn A, Houde N, Hughes L, Hunnicutt L, Husby M, Jester B, Jones C, 
Kamat A, Kanga B, Kells C, Khazanovich D, Kieu AC, Kisner P, Kumar M, Lance K, Landers T, Lara M, 
Lee W, Leger JP, Lennon N, Leuper L, LeVine S, Liu J, Liu X, Lokyitsang Y, Lokyitsang T, Lui A, 
Macdonald J, Major J, Marabella R, Maru K, Matthews C, McDonough S, Mehta T, Meldrim J, 
Melnikov A, Meneus L, Mihalev A, Mihova T, Miller K, Mittelman R, Mlenga V, Mulrain L, Munson 
G, Navidi A, Naylor J, Nguyen T, Nguyen N, Nguyen C, Nguyen T, Nicol R, Norbu N, Norbu C, 
Novod N, Nyima T, Olandt P, O'Neill B, O'Neill K, Osman S, Oyono L, Patti C, Perrin D, Phunkhang 
P, Pierre F, Priest M, Rachupka A, Raghuraman S, Rameau R, Ray V, Raymond C, Rege F, Rise C, 
Rogers J, Rogov P, Sahalie J, Settipalli S, Sharpe T, Shea T, Sheehan M, Sherpa N, Shi J, Shih D, 
Sloan J, Smith C, Sparrow T, Stalker J, Stange-Thomann N, Stavropoulos S, Stone C, Stone S, Sykes 
S, Tchuinga P, Tenzing P, Tesfaye S, Thoulutsang D, Thoulutsang Y, Topham K, Topping I, Tsamla T, 
Vassiliev H, Venkataraman V, Vo A, Wangchuk T, Wangdi T, Weiand M, Wilkinson J, Wilson A, 
Yadav S, Yang S, Yang X, Young G, Yu Q, Zainoun J, Zembek L, Zimmer A, Lander ES (2005) 
Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature 
438: 803-819.  
Linnankoski J, Mäkelä J, Pamgren J, Mauriala T, Vedin C, Ungell AL, Lazorova L, Artursson P, Urtti A, 
Yliperttula M (2010) Paracellular porosity and pore size of the human intestinal epithelium in 
tissue and cell culture models. J Pharm Sci 99: 2166-2175.  
Marsh S, Hoskins JM (2010) Irinotecan pharmacogenomics. Pharmacogenomics 11: 1003-1010.  
Marsh S, Xiao M, Yu J, Ahluwalia R, Minton M, Freimuth RR, Kwok PY, McLeod HL (2004) 
Pharmacogenomic assessment of carboxylesterases 1 and 2. Genomics 84: 661-668. 
Melcher R, Koehler S, Steinlein C, Schmid M, Mueller CR, Luehrs H, Menzel T, Scheppach W, Moerk H, 
Scheurlen M, Koehrle J, Al-Taie O (2002) Spectral karyotype analysis of colon cancer cell lines of 
the tumor suppressor and mutator pathway. Cytogenet Genome Res 98: 22-28.  
Morgan EW, Yan B, Greenway D, Parkinson A (1994) Regulation of two rat liver microsomal 
carboxylesterase isozymes: species differences, tissue distribution, and the effects of age, sex and 
xenobiotic treatment of rats. Arch Biochem Biophys 315: 513-526.  
Introduction 
 43
Mural RJ, Adams MD, Myers EW, Smith HO, Miklos GL, Wides R, Halpern A, Li PW, Sutton GG, Nadeau J, 
Salzberg SL, Holt RA, Kodira CD, Lu F, Chen L, Deng Z, Evangelista CC, Gan W, Heiman TJ, Li J, Li Z, 
Merkulov GV, Milshina NV, Naik AK, Qi R, Shue BC, Wang A, Wang J, Wang X, Yan X, Ye J, Yooseph 
S, Zhao Q, Zheng L, Zhu SC, Biddick K, Bolanos R, Delcher AL, Dew IM, Fasulo D, Flanigan MJ, 
Huson DH, Kravitz SA, Miller JR, Mobarry CM, Reinert K, Remington KA, Zhang Q, Zheng XH, 
Nusskern DR, Lai Z, Lei Y, Zhong W, Yao A, Guan P, Ji RR, Gu Z, Wang ZY, Zhong F, Xiao C, Chiang 
CC, Yandell M, Wortman JR, Amanatides PG, Hladun SL, Pratts EC, Johnson JE, Dodson KL, 
Woodford KJ, Evans CA, Gropman B, Rusch DB, Venter E, Wang M, Smith TJ, Houck JT, Tompkins 
DE, Haynes C, Jacob D, Chin SH, Allen DR, Dahlke CE, Sanders R, Li K, Liu X, Levitsky AA, Majoros 
WH, Chen Q, Xia AC, Lopez JR, Donnelly MT, Newman MH, Glodek A, Kraft CL, Nodell M, Ali F, An 
HJ, Baldwin-Pitts D, Beeson KY, Cai S, Carnes M, Carver A, Caulk PM, Center A, Chen YH, Cheng 
ML, Coyne MD, Crowder M, Danaher S, Davenport LB, Desilets R, Dietz SM, Doup L, Dullaghan P, 
Ferriera S, Fosler CR, Gire HC, Gluecksmann A, Gocayne JD, Gray J, Hart B, Haynes J, Hoover J, 
Howland T, Ibegwam C, Jalali M, Johns D, Kline L, Ma DS, MacCawley S, Magoon A, Mann F, May 
D, McIntosh TC, Mehta S, Moy L, Moy MC, Murphy BJ, Murphy SD, Nelson KA, Nuri Z, Parker KA, 
Prudhomme AC, Puri VN, Qureshi H, Raley JC, Reardon MS, Regier MA, Rogers YH, Romblad DL, 
Schutz J, Scott JL, Scott R, Sitter CD, Smallwood M, Sprague AC, Stewart E, Strong RV, Suh E, 
Sylvester K, Thomas R, Tint NN, Tsonis C, Wang G, Wang G, Williams MS, Williams SM, Windsor 
SM, Wolfe K, Wu MM, Zaveri J, Chaturvedi K, Gabrielian AE, Ke Z, Sun J, Subramanian G, Venter 
JC, Pfannkoch CM, Barnstead M, Stephenson LD (2002) A comparison of whole-genome shotgun-
derived mouse chromosome 16 and the human genome. Science 296: 1661-1771. 
Natoli M, Leoni BD, D’Agnano I, D’Onofrio M, Brandi R, Arisi I, Zucco F, Felsani A (2011) Cell growing 
density affects the structural and functional properties of Caco-2 differentiated monolayer. J Cell 
Physiol 226: 1531-1543.  
Natoli M, Leoni BD, D’Agnano I, Zucco F, Felsani A (2012) Good Caco-2 cell culture practices. Toxicol In 
Vitro doi: 10.1016/j.tiv.2012.03.009. 
Nicoletti C (2000) Unsolved mysteries of intestinal M cells. Gut 47: 735-739.  
Nishimura M, Naito S (2006) Tissue-specific mRNA expression profiles of human phase I metabolizing 
enzymes except for cytochrome P450 and phase II metabolizing enzymes. Drug Metab 
Pharmacokinet 21: 357-374.  
Ohura K, Sakamoto H, Ninomiya S, Imai T (2010) Development of a novel system for estimating human 
intestinal absorption using Caco-2 cells in the absence of esterase activity. Drug Metab Dispos 38: 
323-331.  
Ozols J (1989) Isolation, properties, and the complete amino acid sequence of a second form of 60-kDa 
glycoprotein esterase. Orientation of the 60-kDa proteins in the microsomal membrane. J Biol 
Chem 264: 12533-12545. 
Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL (2010) How to 
improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discov 9: 
203-214. 
Perreault N, Beaulieu JF (1998) Primary cultures of fully differentiated and pure intestinal epithelial cells. 
Exp Cell Res 245: 34-42.  
Section 1 
 44
Pindel EV, Kedishvili NY, Abraham TL, Brzezinski MR, Zhang J, Dean RA, Bosron WF (1997) Purification and 
cloning of a broad substrate specificity human liver carboxylesterase that catalyzes the hydrolysis 
of cocaine and heroin. J Biol Chem 272: 14769-14775. 
Pinto M, Robine-Leon S, Appay MD, Kedinger M, Triadou N, Dussaulx E, Lacroix B, Simon-Assmann P, 
Haffen K, Fogh J, Zweibaum A (1983) Enterocyte-like differentiation and polarization of the 
human colon carcinoma cell line Caco-2 in culture. Biol Cell 47: 323-330.  
Prieto P, Hoffmann S, Tirelli V, Tancredi F, González I, Bermejo M, De Angelis I (2010) An exploratory 
study of two Caco-2 cell models for oral absorption: a report on their within-laboratory and 
between-laboratory variability, and their predictive capacity. Altern Lab Anim 38: 367-386.  
Prieto P, Kinsner-Ovaskainen A, Stanzel S, Albella B, Artursson P, Campillo N, Cecchelli R, Cerrato L, Díaz L, 
Di Consiglio E, Guerra A, Gombau L, Herrera G, Honegger P, Landry C, O’Connor JE, Páez JA, 
Quintas G, Svensson R, Turco L, Zurich MG, Zurbano MJ, Kopp-Schneider A (2012) The value of 
selected in vitro and in silico methods to predict acute oral toxicity in a regulatory context: 
Results from the European Project ACuteTox. Toxicol In Vitro doi.org/10.1016/j.tiv.2012.07.013 
Pulvertaft RJV (1964) Cytology of Burkitt’s tumour (African lymphoma) Lancet 283: 238-240.  
Ramond MJ, Martinot-Peignoux M, Erlinger S (1985) Dome formation in the huma colon carcinoma cell 
line Caco-2 in culture. Influence of oubain and permeable supports. Biol Cell 54: 89-92. 
Randall KJ, Turton J, Foster JR (2011) Explant culture of gastrointestinal tissue: a review of methods and 
application. Cell Biol Toxicol 27: 267-284.  
Redinbo MR, Potter PM (2005) Mammalian carboxylesterases: from drug targets to protein therapeutics. 
Drug Discov Today 10: 313-325.  
Rejón JD, Zienkiewicz A, Rodríguez-García MI, Castro AJ (2012) Profiling and functional classification of 
esterases in olive (Olea europaea) pollen during germination. Ann Bot doi: 10.1093/aob/mcs174.  
Renault L, Nègre V, Hotelier T, Cousin X, Marchot P, Chatonnet A (2005) New friendly tools for users of 
ESTHER, the database of the alpha/beta-hydrolase fold superfamily of proteins. Chem Biol 
Interact 157-158: 339-343. 
Rizk P, Barker N (2012) Gut stem cells in tissue renewal and disease: methods, markers, and myths. Wiley 
Interdiscip Rev Syst Biol Med 4: 475-496.  
Rodolosse A, Barbat A, Chantret I, Lacasa M, Brot-Laroche E, Zweibaum A, Rousset M (1998) Selecting 
agent hygromycin B alters expression of glucose-regulated genes in transfected Caco-2 cells. Am J 
Physiol 274: G931-G938. 
Romero-Calvo I, Mascaraque C, Zarzuelo A, Suárez MD, martínez-Augustin O, de Medina FS (2011) 
Intestinal inflammation and the enterocyte transportome. Biochem Soc Trans 39: 1096-1101.  
Ross MK, Borazjani A, Wang R, Crow JA, Xie S (2012) Examination of the carboxylesterase phenotype in 
human liver. Arch Biochem Biophys 522: 44-56.  
Introduction 
 45
Ross MK, Crow JA (2007) Human carboxylesterases and their role in xenobiotic and endobiotic 
metabolism. J Biochem Mol Toxicol 21: 187-196.  
Rossi C, Guantario B, Ferruzza S, Guguen-Guillouzo C, Sambuy Y, Scarino ML, Bellovino D (2012) Co-
cultures of enterocytes and hepatocytes for retinoid transport and metabolism. Toxicol In Vitro 
doi: 10.106/j.tiv.2012.04.013. 
Roth WJ, Lindley DJ, Carl SM, Knipp GT (2012) The effects of intralaboratory modifications to media 
composition and cell source on the expression of pharmaceutically relevant transporters and 
metabolizing genes in the Caco-2 cell line. J Pharm Sci 101: 3962-3978.  
Rousset M (1986) The human colon carcinoma cell lines HT-239 and Caco-2: two in vitro models for the 
study of intestinal differentiation. Biochimie 68: 1035-1040. 
Sambuy Y, De Angelis I, Ranaldi G, Scarino ML, Stammati A, Zucco F (2005) The Caco-2 cell line as a model 
of the intestinal barrier: influence of cell and culture-related factors on Caco-2 cell functional 
characteristics. Cell Biol Toxicol 21: 1-26. 
Santos A, Zanetta S, Cresteil T, Deroussent A, Pein F, Raymond E, Vernillet L, Risse ML, Boige V, Gouyette 
A, Vassal G (2000) Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin 
Cancer Res 6: 2012-2020.  
Sato Y, Miyashita A, Iwatsubo T, Usui T (2012) Simultaneous absolute protein quantification of 
carboxylesterase 1 and 2 in human liver tissue fractions using liquid chromatography-tandem 
mass spectrometry. Drug Metab Dispos 40: 1389-1396.  
Satoh T, Hosokawa M (1998) The mammalian carboxylesterases: from molecules to functions. Annu Rev 
Pharmacol Toxicol 38: 257–288. 
Satoh T, Hosokawa M (2006) Structure, function and regulation of carboxylesterases. Chem Biol Interact 
162: 195-211. 
Sanghani SP, Quinney SK, Fredenburg TB, Sun Z, Davis WI, Murry DJ, Cummings OW, Seitz DE, Bosron WF 
(2003) Carboxylesterases expressed in human colon tumor tissue and their role in CPT-11 
hydrolysis. Clin Cancer Res 9: 4983-4991. 
Sarmento B, Andrade F, da Silva SB, Rodrigues F, das Neves J, Ferreira D (2012) Cell-based in vitro models 
for predicting drug permeability. Expert Opin Drug Metab Toxicol 8: 607-621.  
Schiel MA, Green SL, Davis WI, Sanghani PC, Bosron WF, Sanghani SP (2007) Expression and 
characterization of a human carboxylesterase 2 splice variant. J Pharmacol Exp Ther 323: 94-101. 
Schiffelers MJ, Blaauboer BJ, Hendriksen CF, Bakker WE (2012) Regulatory acceptance and use of 3R 
models: a multilevel perspective. ALTEX 29: 287-300. 
Schmiedlin-Ren P, Thummel KE, Fisher JM, Paine MF, Watkins PB (2001) Induction of CYP3A4 by 1 
alpha,25-dihydroxyvitamin D3 is human cell line-specific and is unlikely to involve pregnane X 
receptor. Drug Metab Dispos 29: 1446-1453.  
Section 1 
 46
Schroeder K, Bremm KD, Alépée N, Bessems JG, Blaauboer B, Boehn SN, Burek C, Coecke S, Gombau L, 
Hewitt NJ, Heylings J, Huwyler J, Jaeger M, Jagelavicius M, Jarrett N, Ketelslegers H, Kocina I, 
Koester J, Kreysa J, Note R, Poth A, Radtke M, Rogiers V, Scheel J, Schulz T, Steikellner H, Toeroek 
M, Winkler P, Diembeck W (2011) Report from the EPAA workshop: in vitro ADME in safety 
testing used by EPAA industry sectors. Toxicol In Vitro 25: 589-604. 
Scripture CD, Figg WD (2006) Drug interactions in cancer therapy. Nat Rev Cancer 6: 546-558.  
Shen DD, Kunze KL, Thummel KE (1997) Enzyme-catalyzed processes of first-pass hepatic and intestinal 
drug extraction. Adv Drug Deliv Rev 27: 99-127.  
Siissalo S, Laitinen L, Koljonen M, Vellonen KS, Kortejärvi H, Urtti A, Hirvonen J, Kaukonen AM (2007) 
Effect of cell differentiation and passage number on the expression of efflux proteins in wild type 
and vinblastine-induced Caco-2 cell lines. Eur J Pharm Biopharm 67: 548-554. 
Simon-Assmann P, Turck N, Sidhoum-Jenny M, Gradwohl G, Kedinger M (2007) In vitro models of 
intestinal epithelial cell differentiation. Cell Biol Toxicol 23: 241-256. 
Sone T, Isobe M, Takabatake E, Wang CY (1994) Cloning and sequence analysis of a hamster liver cDNA 
encoding a novel putative carboxylesterase. Biochim Biophys Acta 1207: 138-142. 
Stegmann A, Hansen M, Wang Y, Larsen JB, Lund LR, Ritié L, Nicholson JK, Quistorff B, Simon-Assmann P, 
Troelsen JT, Olsen J (2006) Metabolome, transcriptome, and bioinformatics cis-element analyses 
point to HNF-4 as a central regulator of gene expression during enterocyte differentiation. Physiol 
Genomics 27: 141-155.  
Tabata T, Katoh M, Tokudome S, Nakajima M, Yokoi T (2004) Identification of the cytosolic 
carboxylesterase catalyzing the 5’-deoxy-5-fluorocytidine formation from capecitabine in human 
liver. Drug Metab Dispos 10: 1103-1110. 
Tang M, Mukundan M, Yang J, Charpentier N, LeCluyse EL, Bkack C, Yang D, Shi D, Yan B (2006) 
Antiplatelet agents aspirin and clopidogrel are hydrolysed by distinct carboxylesterases, and 
clopidogrel is transesterificated in the presence of ethyl alcohol. J Pharmacol Exp Ther 319: 1467-
1476.  
Tartar A, Wheeler MM, Zhou X, Coy MR, Boucias DG, Scharf ME (2009) Parallel metatranscriptome 
analyses of host and symbiont gene expression in the gut of the termite Reticulitermes flavipes. 
Biotechnol Biofuels 2: 35. 
Tavelin S, Milovic V, Oklind G, Olsson S, Artursson P (1999) A conditionally immortalized epithelial cell 
line for studies of intestinal drug transport. J Pharmacol Exp Ther 290: 1212-1221. 
Theil FP, Guentert TW, Haddad S, Poulin P (2003) Utility of physiologically based pharmacokinetic models 
to drug development and rational drug discovery candidate selection. Toxicol Lett 138: 29-49. 
Thelen K, Dressman JB (2009) Cytochrome P450-mediated metabolism in the human gut wall. Pharm 
Pharmacol 61: 541-558. 
Introduction 
 47
Thorn CF, Carrillo MW, Ramirez J, Gong L, Marsh S, Schuetz EG, Dolan ME, Innocenti F, Relling MV, 
McLeod HL, Ratain MJ (2003) Irinotecan pathway. PharmGKB: available online 
http://www.pharmgkb.org/pathway/PA2001#PGG.  
Tsurkan LG, Hatfield MJ, Edwards CC, Hyatt JL, Potter PM (2012) Inhibition of human carboxylesterases 
hCE1 and hiCE by cholinesterase inhibitors. Chem Biol Interact doi: 10.1016/j.cbi.2012.10.018  
Uchino J, Takayama K, Harada A, Sone T, harada T, Curiel DT, Kuroki M, Nakanishi Y (2008) Tumor 
targeting carboxylesterase fused with anti-CEA scFv improve the anticancer effect with a less 
toxic dose of irinotecan. Cancer Gene Ther 15: 94-100. 
Ungell AL (2004) Caco-2 replace or refine? Drug Discov Today Technol 4: 423-430. 
van de Waterbeemd H, Gifford E (2003) ADMET in silico modelling: towards prediction paradise? Nat Rev 
Drug Discov 2: 192-204. 
van Waterschoot RA, Schinkel AH (2011) A critical analysis of the interplay between cytochrome P450 3A 
and P-glycoprotein: recent insights from knockout and transgenic mice. Pharmacol Rev 63: 390-
410. 
Vereecke L, Beyaert R, van Loo G (2011) Enterocyte death and intestinal barrier maintenance in 
homeostasis and disease. Trends Mol Med 17: 584-593.  
Volpe DA (2010) Application of method suitability for drug permeability classification. AAPS J 12: 670-
678.  
Wade CM, Giulotto E, Sigurdsson S, Zoli M, Gnerre S, Imsland F, Lear TL, Adelson DL, Bailey E, Bellone RR, 
Blöcker H, Distl O, Edgar RC, Garber M, Leeb T, Mauceli E, MacLeod JN, Penedo MC, Raison JM, 
Sharpe T, Vogel J, Andersson L, Antczak DF, Biagi T, Binns MM, Chowdhary BP, Coleman SJ, Della 
Valle G, Fryc S, Guérin G, Hasegawa T, Hill EW, Jurka J, Kiialainen A, Lindgren G, Liu J, Magnani E, 
Mickelson JR, Murray J, Nergadze SG, Onofrio R, Pedroni S, Piras MF, Raudsepp T, Rocchi M, Røed 
KH, Ryder OA, Searle S, Skow L, Swinburne JE, Syvänen AC, Tozaki T, Valberg SJ, Vaudin M, White 
JR, Zody MC; Broad Institute Genome Sequencing Platform; Broad Institute Whole Genome 
Assembly Team, Lander ES, Lindblad-Toh K (2009) Genome sequence, comparative analysis, and 
population genetics of the domestic horse. Science 326: 865-867. 
Wang J, Williams ET, Bourgea J, Wong YN, Patten CJ (2011) Characterization of recombinant human 
carboxylesterases: fluorescein diacetate as a probe substrate for human carboxylesterase 2. Drug 
Metab Dispos 39: 1329-1333. 
Wells DJ (2011) Animal welfare and the 3Rs in European biomedical research. Ann N Y Acad Sci 1245: 14-
16.  
Wheelock CE, Miller JL, Miller MJ, Phillips BM, Huntley SA, Gee SJ, Tjeerdema RS, Hammock BD (2006) 
Use of carboxylesterase activity to remove pyrethroid-associated toxicity to Ceriodaphnia dubia 
and Hyalella Azteca in toxicity identification evaluations. Environ Toxicol Chem 25: 973-984. 
Williams ET, Wang H, Wrighton SA, Qian YW, Perkins EJ (2010) Genomic analysis of the 
carboxylesterases: identification and classification of novel forms. Mol Phylogenet Evol 57: 23-34. 
Section 1 
 48
Williams ET, Bacon JA, Bender DM, Lowinger JJ, Guo WK, Ehsani ME, Wang X, Wang H, Qian YW, 
Ruterbories KJ, Wrighton SA, Perkins EJ (2011) Characterization of the expression and activity of 
carboxylesterases 1 and 2 from the beagle dog, cynomolgus monkey, and human. Drug Metab 
Dispos 39: 2305-2313. 
Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, Ball SE (2004) Drug-
drug interations for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for 
tipically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 32: 1201-1208. 
Wu L, Martin TD, Carrington M, KewalRamani VN (2004b) Raji B cells, misidentified as THP-1 cells, 
stimulate DC-SIGN-mediated HIV transmission. Virology 318: 17-23.  
Wu MH, Chen P, Remo BF, Cook EH Jr, Das S, Dolan ME (2003) Characterization of multiple promoters in 
the human carboxylesterase 2 gene. Pharmacogenetics 7: 425-435.  
Wu MH, Chen P, Wu X, Liu W, Strom S, Das S, Cook EH Jr, Rosner GL, Dolan ME (2004) Determination and 
analysis of single nucleotide polymorphisms and haplotype structure of the human 
carboxylesterase 2 gene. Pharmacogenetics 14: 595-605. 
Xu X, Nagarajan H, Lewis NE, Pan S, Cai Z, Liu X, Chen W, Xie M, Wang W, Hammond S, Andersen MR, 
Neff N, Passarelli B, Koh W, Fan HC, Wang J, Gui Y, Lee KH, Betenbaugh MJ, Quake SR, Famili I, 
Palsson BO, Wang J (2011) The genomic sequence of the Chinese hamster ovary (CHO)-K1 cell 
line. Nat Biotechnol 29: 735-741. 
Yang J, Shi D, Yang D, Song X, Yan B (2007) Interleukin-6 alters the cellular responsiveness to clopidogrel, 
irinotecan, and oseltamivir by suppressing the expression of carboxylesterases HCE1 and HCE2. 
Mol Pharmacol 72: 686-694.  
Yano H, Kayukawa S, Iida S, Nakagawa C, Oguri T, Sanda T, Ding J, Mori F, Ito A, Ri M, Inagaki A, Kusumoto 
S, Ishida T, Komatsu H, Inagaki H, Suzuki A, Ueda R (2008) Overexpression of carboxylesterase-2 
results in enhanced efficacy of topoisomerase I inhibitor, irinotecan (CPT-11), for multiple 
myeloma. Cancer Sci 99: 2309-2314. 
Yoon KJ, Hyatt JL, Morton CL, Lee RE, Potter PM, Danks MK (2004) Characterization of inhibitors of 
specific carboxylesterases: development of carboxylesterase inhibitors for translational 
application. Mol Cancer Ther. 3: 903-909. 
Zucco F, Batto AF, Bises G, Chambaz J, Chiusolo A, Consalvo R, Cross H, Dal Negro G, de Angelis I, Fabre G, 
Guillou F, Hoffman S, Laplanche L, Morel E, Pinçon-Raymond M, Prieto P, Turco L, Ranaldi G, 
Rousset M, Sambuy Y, Scarino ML, Torreilles F, Stammati A (2005) An inter-laboratory study to 
evaluate the effects of medium composition on the differentiation and barrier function of Caco-2 
cell lines. Alter Lab Anim 33: 603-618. 
 
SECTION 2 
Analytical methodology development 
 for CES2 activity evaluation 
 
 
Adapted from: 
Lamego J, Coroadinha AS, Simplício AL. (2011) Detection and quantification of 
carboxylesterase 2 activity by capillary electrophoresis. Anal Chem 83: 881-887. 
 
and 
 
Simplício AL, Coroadinha AS, Gilmer JF, Lamego J. A methodology for detection and 
quantification of esterase activity. Capillary Electrophoresis of Biomolecules: Methods 
and Protocols; in press. 
 
This work has been partially presented, at the 2
nd
 National Meeting on Medicinal 
Chemistry, held on the 28
th
 of November of 2010 in Coimbra, Portugal.  
Section 2 
 50
Abstract 
Carboxylesterases (CESs) are important enzymes for xenobiotic metabolism and are 
receiving increased attention in the context of cancer therapies. Quantification of 
individual CES activity is important since protein levels do not always correlate to 
activity and significant inter-organ, inter-individual, and interspecies variations exist.  
The purpose of this study was to develop an analytical method to quantify the relative 
activities of CESs in biological samples. Taking advantage of loperamide, a selective 
carboxylesterase 2 (CES2) inhibitor, and bis-p-nitrophenyl phosphate (BNPP), an 
irreversible CESs inhibitor, a capillary electrophoresis (CE) method that enables 
detecting and distinguishing CES2 activity from other CESs in complex biological 
samples is proposed for the first time. The capillary electrophoresis method proved to 
be fast, simple, repeatable, and applicable to the measurement of the specific activity 
of CESs. The method was successfully applied to the evaluation of human cells 
overexpressing human CES2 (hCES2) and to several mammalian sera, using extremely 
small amounts of samples in comparison with traditional spectrophotometric 
methods. The same rationale can be applied to establish methods for determining the 
activity of other esterases, using the appropriate specific inhibitors or substrates. 
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2.1 Introduction 
Mammalian carboxylesterases are α,β-hydrolase folded proteins involved in the 
efficient hydrolysis of xenobiotics and endogenous ester- or amide-containing 
compounds (Satoh and Hosokawa 1998; Satoh and Hosokawa 2006; Xie et al. 2002). 
The classification of these enzymes is difficult due to the large number of isoenzymes, 
complex tissue distribution, and overlapping substrate recognition (Satoh and 
Hosokawa 2006; Liederer and Borchardt 2006). The most recent classification of 
mammalian CESs categorises these enzymes into five subfamilies, from CES1 to CES5, 
according to their sequence homology (Satoh and Hosokawa 1998; Williams et al. 
2010). Also, CES nomenclature was recently revisited, as explained in Section 1 
(Holmes et al. 2010). 
Carboxylesterases merit close attention because of their important functions 
in the detoxification of narcotics and other drugs, metabolism of pyrethroids, and 
prodrug activation (Hicks et al. 2009; Holmes et al. 2009). Several studies have been 
conducted to compare the enzymatic activities of the different CESs in mammals, due 
to the implications that these differences may have for (pre)clinical results (Xie et al. 
2002; Li et al. 2005; Jewell et al. 2007a; Williams et al. 2011). 
More recently, these enzymes have gained additional attention in the cancer 
treatment area. It has been discovered, for example, that the levels of some 
isoenzymes are different in certain tumours: human carboxylesterase 1 (hCES1) 
protein levels have been found to be increased in patients suffering from 
hepatocellular carcinoma (Na et al. 2009). Moreover, a correlation was established 
between hCES2 expression in solid tumours and the activation of the anticancer 
prodrug Irinotecan (CPT-11), and this has led to the investigation into 
enzyme/prodrug strategies with the goal to target expressed hCESs to tumours prior 
to the treatment with the prodrug (Xu G et al. 2002; Hatfield et al. 2008). Human 
carboxylesterase 2, the major human intestinal CES, thus attracts considerable 
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attention. It has been suggested that, prior to the treatment of human lung cancer 
cells with CPT-11, it is crucial to check if the cells express this enzyme (Satoh and 
Hosokawa 2006). 
Considering the current trends, it becomes evident that fast, reliable, 
economical, and easy to perform analytical methods, enabling the evaluation of CES2 
activity, will be needed for routine application in the near future. There are currently 
several ways to assess hCES2 expression levels and activities (Ross and Borazjani 
2007), such as simple spectrophotometric (Crow et al. 2007), native in-gel hydrolysis 
(Ross and Crow 2007), Western blot (Kubo et al. 2005), real-time polymerase chain 
reaction (RT-PCR; Jewell et al. 2007a), and Northern blot assays (Zhu et al. 2000). A 
simple spectrophotometric assay enables one to quantify total CESs activity, but does 
not identify the relative activity of each specific CES in a complex biological sample or 
enzyme mixture since the majority of cases results in overlapping absorbance when 
inhibitors are used. A native in-gel hydrolysis assay allows one to distinguish the 
activities of the different CESs in complex biological samples, but only estimates on 
protein quantity are possible. With Western blot assays it is possible to detect specific 
proteins using appropriate antibodies, but only estimates concerning enzymatic 
activity or protein quantity are possible. RT-PCR and Northern blot assays enable one 
to quantify and detect, respectively the analysis of mRNA expression profiles; again, 
no information concerning enzyme activity is obtained (Ross and Borazjani 2007). As 
reported before, the protein levels of CESs do not always correlate with their activity 
levels (Ross and Crow 2007). As CESs are promiscuous enzymes with overlapping 
substrate recognition, it becomes difficult to attribute a specific activity to one 
isoenzyme in complex protein samples such as cellular extracts, serum, or other 
biological samples (Ross and Crow 2007; Adam et al. 2003). Accordingly, the classical 
substrate used for CES activity, p-nitrophenyl acetate (p-NPA), is also hydrolysed by 
cholinesterases, thus constituting an example of the substrate recognition of these 
enzymes. This overlapping substrate recognition often leads to contradictions in the 
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literature (Satoh and Hosokawa 2006); in 2005, it was clearly demonstrated that 
human healthy plasma does not contain CES activity (Li et al. 2005). 
In this work, a new analytical methodology is provided for the CES field, which 
involves the use of several substrates and inhibitors enabling the identification and 
quantification of CES2 activity in complex biological samples. Capillary electrophoresis 
was chosen as the separation technique since simple spectrophotometric assessment 
is precluded due to overlapping absorbance between some substrates and inhibitors. 
Capillary electrophoresis is a powerful separation technique that has established itself 
as an alternative to chromatographic techniques (Elbashir et al. 2010). Capillary 
electrophoresis advantages rely on the reduced electrolyte and sample needs, the low 
cost of the capillaries, in comparison with the high-performance liquid 
chromatography (HPLC) columns, faster method development, and versatility (Fleury-
Souverain et al. 2009). Nonetheless, HPLC can still be used with the proposed 
methodology. The method was successfully applied to the quantification of CES2 
activity in transfected cell extracts and animal sera, and the same rationale can be 
quickly extended to the study of other enzymes and/or substrates in other biological 
samples. 
2.2 Materials and Methods 
2.2.1 Enzymes and reagents 
Carboxylesterase 1 enzyme (esterase from porcine liver) was acquired from Sigma 
(Buchs, Switzerland); butyrylcholinesterase (BuChE) from equine serum and 
acetylcholinesterase (AcChE) from electric eel were also from Sigma (St. Louis, U.S.A.). 
Recombinant hCES2 was from R&D Systems, Inc. (Minneapolis, U.S.A.). 
All reagents were analytical grade or higher. 4-Methylumbelliferyl acetate (4-
MUBA) (≥98%), 4-methylumbelliferone (4-MUB) (≥98%), p-NPA (>99%), procaine 
hydrochloride (>97%), p-aminobenzoic acid (p-ABA) (>99%), Trizma hydrochloride 
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(>99%), and Trizma base (>99.9%) were from Sigma (St. Louis, U.S.A.). S-
Butyrylthiocholine (BuTCh) iodide (≥99%) and acetylthiocholine (AcTCh) iodide (≥99%) 
were also from Sigma (Buchs, Switzerland). Loperamide hydrochloride (analytical 
grade) was from Fluka (Seelze, Germany), whereas bis-p-nitrophenyl phosphate 
(BNPP) (>99%) and potassium chloride (≥99.5%) were from Aldrich (Steinheim, 
Germany). Potassium dihydrogen phosphate (≥99%), disodium tetraborate (≥99.5%), 
and ethanol (99.5%) were all from Panreac (Barcelona, Spain); dimethyl sulfoxide 
(DMSO) (95%) was from Lab-Scan (Dublin, Ireland), and sodium dihydrogen 
phosphate (>99%) was from Merck (Darmstadt, Germany). 
2.2.2 Instrumentation 
CE detection was performed using a Beckman Coulter (Palo Alto, U.S.A.) P/ACE MDQ 
capillary electrophoresis system equipped with a diode array detector. A fused silica 
capillary (Agilent; Santa Clara, U.S.A.) with 75 μm i.d., and 42 cm total length (32 cm 
to detector) was used. 
The capillary was housed in a standard cartridge and maintained at 25 
o
C 
during all experiments. The sample tray was kept at 15 
o
C to minimize solution 
deterioration. Injections were conducted hydrodynamically, at 0.2 psi for 10 s, with 
cathodic migration. Separations were performed at constant current (+70.0 μA). UV 
absorption was measured at 230 (thiocholines), 254 (p-ABA), 280 (procaine), 350 (4-
MUB) and 400 nm (p-nitrophenol (p-NP)). 
Each new capillary was pretreated with sodium hydroxide 0.1 mM, rinsed 
with Milli-Q water, and conditioned with background electrolyte solution (BES), 30 
mM borate-phosphate buffer (30 mM disodium tetraborate, 30 mM sodium 
dihydrogen phosphate; pH 8.0; Tang et al. 2007), at a pressure of 5.0 psi for 20 min 
each, for a total of 60 min. This procedure was repeated at the end of each day. The 
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capillary was conditioned between all runs, by a short sequence (30 s each) of this 
procedure. 
Data acquisition, storage, and analysis were performed using P/ACE MDQ 
version 7.0. All the injected solutions used were diluted in equal proportion (50% v/v) 
of ethanol as the samples to be analysed. 
2.2.3 Preparation of human cell extracts  
Human embryonic kidney cells (HEK-293T; ATCC CRL-11268) were transfected as 
described before (Xie et al. 2002), following some modifications. In brief, cells were 
plated at 5x10
4
 cell.cm
-2
 and transfected, on the following day, at 60-80% of cell 
density with polycation polyethylenimine (PEI; Polysciences; Eppelheim, Germany) 
using 16 μg/mL of pDEST26-CES2 plasmid vector (vector map in Appendice) in a 1:3 
ratio of plasmid DNA and PEI. pDEST26-CES2 plasmid vector was acquired from 
imaGENES (Berlin, Germany) with hCES2 (geneID 8824) cloned into pDEST26 plasmid 
(Invitrogen; Carlsbad, U.S.A.). 
Cells were harvested 48 h after transfection and chemically lysed with M-PER 
mammalian extraction reagent (Pierce Biotechnology; Rockford, U.S.A.). The 
supernatant, obtained by centrifugation at 10,000g for 10 min at 4 
o
C, was stored at   
-20 
o
C without the addition of protease inhibitors. Total protein concentration was 
determined using bicinchoninic acid (BCA) protein assay kit (Pierce Biotechnology), 
according to the manufacturer’s instructions. 
2.2.4 Serum preparation 
Human, domestic cat, bovine, domestic dog, and equine sera, from one individual 
each, were collected without the addition of anticoagulants (Li et al. 2005; 
Christensen and Stalker 1991). Samples were stored at 4 
o
C for 24 h and centrifuged 
afterward at 3,000 rpm for 15 min. Each sample was aliquoted and stored at -20 
o
C 
until analysis. 
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2.2.5 Enzymatic assays and inhibition studies 
The enzymatic activity reactions were performed in a final volume of 150 μL, under 
substrate saturation conditions (0.5 mM of 4-MUBA). The addition of each reaction 
component was performed in ice, and unless otherwise stated, reactions were 
undertaken at 37 
o
C for 8 min, accounting enzyme reaction linearity. Purified and/or 
recombinant enzymes, cells extracts, and serum were diluted in 50 mM Tris-HCl 
buffer (pH 7.4).  
 Stock solutions of the substrates were prepared in ethanol, and stock 
solutions of the inhibitors were prepared in DMSO. The organic solvent percentage in 
the final reaction volume never exceeded 5% (v/v). A mixture of 90 mM KH2PO4 and 
40 mM KCl (pH 7.3) was used as the reaction buffer (Pindel et al. 1997). 
The inhibition studies were performed by pre-incubation with loperamide 
(0.25 mM) or BNPP (0.5 mM) at 37 
o
C for 15 or 10 min, respectively. The enzymatic 
reactions were stopped by the addition of an equal volume of ethanol and 
centrifuged at 10,000g for 10 min before analysis. 
All samples were injected in triplicate, and average results are presented 
throughout the text. Intermediate precision was determined by pooled standard 
deviation, based on replicate independent assays preformed in three different days in 
two different concentrations and in the presence and absence of inhibitor. Mean t 
tests were performed for evaluation of the statistical significant differences (p = 0.01) 
between samples, considering intermediate precision. 
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2.3 Results and Discussion 
2.3.1 Capillary electrophoresis method development 
There are several methods for the determination of CES activities described in the 
literature, ranging from spectrophotometric (Hatfield et al. 2008) to HPLC (Ross and 
Borazjani 2007) and native in-gel hydrolysis assays (Ross and Borazjani 2007); 
nonetheless, CESs activities appear not to be previously analysed by CE. 
There are substrates known to be selective for each CES. As an example, 
temocapril is hydrolysed by hCES1 but not by hCES2 (Jewell et al. 2007a); in contrast, 
procaine has been shown to be hydrolysed by hCES2 but not by hCES1 (Takai et al. 
1997). Several efforts have been made to identify specific inhibitors that enable 
separation of the activities of different CESs (Ross et al. 2006; Crow et al. 2010; 
Wadkins et al. 2005), and there is also an effort to develop new assays that enable the 
evaluation of inhibitors (Wang et al. 2011). An analytical method was developed for 
the selective measurement of CES2 activity in any biological sample. The goal was to 
have a simple, fast, and reliable analytical tool that would enable evaluation of 
different biological samples. For method development, 4-MUBA was used as a 
substrate, because of its higher stability than the classical CES substrate p-NPA. 4-
MUBA is a general CES substrate, and is routinely used in native in-gel hydrolysis 
assays (Ross and Borazjani 2007; Crow et al. 2007; Ross et al. 2006), and we have 
found that cholinesterases do not hydrolyse 4-MUBA (data not shown). 
To our knowledge, 4-MUBA and its hydrolysis product, 4-MUB, have not been 
previously analysed using CE, and therefore we proceeded to develop a method 
optimised for this substrate. When borate-phosphate buffer at pH 8.0 is used, in the 
CE method, 4-MUB presents an absorbance maximum at 350 nm and has a migration 
time of about 4.0 min (Figure 2.1). 4-MUBA was not detected. Equipment response 
was linear for 4-MUB at least in the range of 23.4 μM to 1.5 mM (R
2
 = 0.999). 
Arbitrary absorbance units were converted to concentration using commercially 
Analytical methodology development for CES2 activity evaluation 
 59
available 4-MUB, as standard. The theoretical limit of detection (13.7 μM) was 
calculated based on the residual standard deviation of the calibration curve and a 
signal-to-noise ratio of 3.3. The limit of quantification (23.4 μM) was chosen from the 
lowest calibration point where the coefficient of variation of repeatability (CVr) was 
still under 10% (n=3). CVr was obtained in the indicated range, 23.4 μM to 1.5 mM 4-
MUB, specifically at 1.5 mM and 750, 375, 187.5, 93.8, 46.9, and 23.4 μM. If higher 
sensitivity is needed, 4-MUB has the advantage of being fluorescent, and thus, using 
the appropriate detectors, detection and quantification limits can be further 
improved.  
Besides being specific for CESs and since 4-MUBA is not a cholinesterase 
substrate at the concentrations used, this methodology was found to be compatible 
with other esterase substrates such as p-NPA, procaine, BuTCh and AcTCh, and their 
corresponding products p-NP, p-ABA, and thiocholine (TCh), respectively (Figure 2.1). 
Therefore, the extension of this method to the detection and quantification of the 
activity of other enzymes may be easily performed. Nonetheless, care should be taken 
as, for instance, procaine was already shown to be hydrolysed by BuChE (Yuan et al. 
2007). 
2.3.2 Evaluation of esterase enzymatic activities by CE 
Carboxylesterases, AcChEs, and BuChEs are classified as type-B esterases 
(Aldridge 1953). As previously stated, these enzymes not only show overlapping 
substrate recognition such as CES2 and BuChE both hydrolysing CPT-11, but they also 
co-localise in several tissues, such as plasma, intestine, and kidney of several 
mammals (Liederer and Borchardt 2006). The method was further developed for the 
ability to discriminate CES2 activity from these other enzymatic activities. Commercial 
CESs (CES1 and hCES2 recombinant enzyme) and cholinesterases (BuChE and AcChE) 
were tested toward the hydrolysis of 4-MUBA (Figures 2.2, 2.3a, and data not shown).  
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Figure 2.1 a) Electropherograms of substrates, products, and inhibitors detected by CE. 0.25 mM 4-
MUB, 0.5 mM p-NP, 0.1 mM p-ABA, 0.1 mM procaine, 0.5 mM BuTCh, 0.5 mM AcTCh, and 0.25 mM BNPP 
in a silica capillary 75 µm x 42 cm, 25 
o
C, using hydrodynamic injections (0.2 psi for 10 sec). Separation 
was at +70.0 µA with cathodic migration. b) Maximum absorption wavelengths and migration times. 
N.d. Not detected. (*) BNPP is also detected at 350 nm.  
Compound Wavelength (nm) Migration time (min) 
4-MUBA N.d. 
4-MUB 350 4.0 
BNPP 280* 4.8 
Loperamide N.d. 
p-NPA N.d. 
p-NP 400 6.0 
Procaine 280 2.2 
p-ABA 254 6.8 
AcTCh 230 2.0 
BuTCh 230 2.0 
TCh 230 2.5 
A 
B 
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For testing 4-MUBA hydrolysis by commercial cholinesterases, 50 ng of each 
enzyme were incubated in the same conditions as used for CESs. Additionally, 
cholinesterases were also tested using 0.5 and 1 mM of BuTCh and AcTCh substrates 
(Figure 2.3b and 2.4). Only CESs were able to hydrolyse the substrate as no significant 
difference was detected between the spontaneous hydrolysis of 4-MUBA and the 
hydrolytic activity of the cholinesterases (data not shown).  
To distinguish specific hCES2 activity from the activity of the other CESs we 
propose the use of the hCES2 selective inhibitor loperamide (Jewell et al. 2007b). 
Although BuChE and AcChE did not hydrolyse 4-MUBA, some biological samples may 
contain other enzymes that could metabolise this substrate. For this reason, we 
evaluated BNPP, an irreversible inhibitor specific for CESs (Tanino et al. 2008; Eng et 
al. 2010). 
Figure 2.2 Commercial CES activity toward 4-MUBA in the presence and absence of inhibitors. 12.5 ng 
of CES1 or 50 ng of hCES2 enzymes were incubated with 0.5 mM 4-MUBA in a total reaction volume of 
150 μL. Mixtures of the two enzymes included mix 12.5 / 50 (12.5 ng of CES1 and 50 ng of hCES2) and mix 
12.5 / 25 ng (12.5 ng of CES1 and 25 ng of hCES2). Pre-incubation with 0.25 mM loperamide or 0.5 mM 
BNPP was performed when appropriate. The spontaneous hydrolysis of 4-MUBA is also shown. Each 
result represents the average of three injections, and error bars represent the standard deviation. A * 
represents a statistical significant difference (p = 0.01) between the enzymatic activities in the presence 
(grey or dashed bars) and in the absence (black bars) of the inhibitor, based on standard deviation of 
intermediate precision. The amount of 4-MUB (μM) formed in each sample is mentioned on the top of 
each bar. 
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Figure 2.3 Electropherograms of incubation mixtures. a) 12.5 ng of CES1 and 50 ng of hCES2 enzyme 
reactions were detected by CE at 350 nm. 4-MUBA (0.25 mM) spontaneous hydrolysis was also detected 
at the same wavelength. b) 50 ng of BuChE and 50 ng of AcChE enzyme reactions using BuTCh (0.5 mM) 
and AcTCh (0.5 mM), respectively, were detected by CE at 230 nm. The substrates (0.5 mM) spontaneous 
hydrolysis was also detected at the same wavelength. 
Taking advantage of these two cheap and commercially available inhibitors, 
the relative activity of CES2 can be determined in any biological sample. BNPP also 
absorbs at 350 nm, and therefore classical spectrophotometric enzymatic assays 
cannot be used. As different biological samples may contain different amounts of 
esterases or hCES2, we decided to use high amounts of each inhibitor to ensure that 
A 
B 
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maximum inhibition is achieved. Lower amounts of inhibitors can be used as 
demonstrated below (Figure 2.5).  
 
 
 
 
 
 
 
 
 
 
Figure 2.4 BuChE and AcChE activities. 50 ng of each enzyme were incubated with 1 mM BuTCh or AcTCh, 
respectively, in a total reaction volume of 150 µL. Pre-incubation with 0.25 mM of loperamide was 
performed when appropriate. Each result represents the average of three injections and the error bars 
represent the standard deviation. A * represents a statistical significant difference (p = 0.01) between the 
enzymatic activities in the presence (grey bars) and in the absence (black bars) of the inhibitor, based on 
standard deviation of intermediate precision. 
In the developed CE method the BNPP absorption spectrum shows a 
maximum at 280 nm. Despite the fact that it is also detected at 350 nm, the migration 
time of this inhibitor (4.8 min) does not overlap with that of 4-MUB (4.0 min; Figure 
2.1); thus, 4-MUB can be quantified by CE in the presence of BNPP. Using BuChE, 
AcChE, and their respective substrates BuTCh and AcTCh (Tecles and Cerón 2001), we 
could observe that loperamide does inhibit both enzymes (Figure 2.4).  
Using the described CE method, we could also detect thiocholine (the 
hydrolysis product of both substrates) at 230 nm as well as both substrates at the 
same wavelength. Substrates and thiocholine migration times do not overlap, being 
completely distinguishable (2.0 min for both substrates and 2.5 min for thiocholine, in 
average; Figure 2.3b). 
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Figure 2.5 Commercial CESs activities towards 4-MUBA in the presence and absence of 50 µM of 
loperamide. 25 ng of CES1 and 25 ng hCES2 enzymes were incubated with 0.5 mM of 4-MUBA in a total 
reaction volume of 150 µL. Pre-incubation with 50 µM of loperamide was performed when appropriate. 
The spontaneous hydrolysis of 4-MUBA is also shown. Each result represents the average of three 
injections and error bars represent the standard deviation. A * represents a statistical significant 
difference (p = 0.01) between the enzymatic activities in the presence (grey bars) and in the absence 
(black bars) of the inhibitor, based on standard deviation of intermediate precision. 
According to available published data (Pindel et al. 1997; Nishi et al. 2006), 
hCES2 shows a higher catalytic efficiency, defined as kcat/(kdif*(KM + [S])) (Ceccarelli et 
al. 2008), toward 4-MUBA than hCES1, but our data is suggesting the opposite. This 
may simply be due to species differences, to differences in assay conditions, or to 
differences in enzymes sources. In the described catalytic efficiency formula, besides 
the enzymatic kinetic parameters, KM (Michaelis-Menten constant) and kcat (rate 
constant), kdif (rate for a diffusion-controlled process, approximately 10
9
 M
-1
.s
-1
) and 
[S] (substrate concentration) are considered. This has been presented as a more 
correct way of evaluating the performance of different enzymes acting on the same 
substrate, than the simple kcat/KM specificity constant (Ceccarelli et al. 2008).  
As expected, loperamide completely inhibited the activity of hCES2 but not 
commercial CES1 (Figure 2.2). On the other hand, the activities of both CESs were 
completely inhibited by BNPP. We were not expecting to observe CES1 inhibition in 
the presence of loperamide (Jewell et al. 2007b), but Figure 2.2 disproved this 
expectation. The IC50 and Ki values for these enzymes were previously reported 
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(Quinney et al. 2005; Williams et al. 2011), showing a dramatic difference between 
the sensitivity of the enzymes toward loperamide inhibition. In fact, the Ki for hCES2 is 
practically 1,000 times lower in comparison to the one for hCES1. Thus, this 
unexpected inhibition verified in CES1 enzyme can be easily overcome by reducing 
loperamide concentration. We further confirmed this by testing the same 
concentration of each enzyme with a lower concentration of loperamide, 50 μM. We 
observed that no significant inhibition is detected in CES1, whereas hCES2 is 
completely inhibited (Figure 2.5). 
In order to demonstrate the ability of the method to distinguish between 
hCES2 and CES1, we mixed the two enzymes (50 or 25 ng of hCES2 with 12.5 ng of 
CES1) and performed the same set of assays, ensuring substrate saturation conditions 
(Figure 2.2). As expected, the incubation of BNPP with both mixtures completely 
inhibited enzymatic activity. The incubation of each mixture with loperamide caused a 
decrease in the relative percentage of activity to the same levels, in both mixtures. 
Although the protein levels of CESs do not always correlate with their activity 
levels (Ross and Crow 2007), the proposed methodology enables revealing the 
relative activities of the enzymes, through the use of the different inhibitors. Other 
techniques, such as Western blots, estimate the amount of an enzyme in a biological 
sample but do not provide any information concerning their activity. On the other 
hand, native in-gel hydrolysis assays permit the detection of enzyme activities, but no 
direct protein quantification is possible. 
This methodology also offers the possibility to determine specific enzyme 
activities. For this, one has to follow classical enzymatic study rules like ensuring that 
the assays are performed in the linear range of the enzymatic reaction and the 
substrate is not at a limiting concentration. In fact, we have quickly determined the 
linear range of enzymatic reaction for CES1 enzyme (data not shown). In this way, 
there is no need to appeal to other methodologies usually used, such as 
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spectrophotometric methods, to determine these parameters. The intermediate 
precision of the method was determined (CVi = 12.8%) for two different CES1 
concentrations (25 and 12.5 ng) in the presence and in the absence of one of the 
inhibitors (loperamide) on three different days. 
Using the same rationale, the different types of assays that can be performed 
are unlimited. It is worth noting that the inhibition of BuChE and AcChE by loperamide 
does not interfere with the detection and/or quantification of hCES2 activity in 
biological samples as we also saw that BuChE and AcChE do not hydrolyse 4-MUBA. 
2.3.3 Carboxylesterase 2 activity determination in complex biological samples 
To demonstrate its potential, this methodology was applied to several different 
biological samples, with different complexities. Human carboxylesterase 2 activity was 
analysed in extracts from human cells that were transfected with hCES2 to evaluate 
the specific activity of the enzyme. Since HEK-293T human cell line only has basal 
expression of esterases (Xie et al. 2002), the original cells have also been analysed as 
a control. The linear range of the reaction was assayed and the specific activity of 
hCES2 was determined both in the overexpressing as well as in the original cells 
(Figure 2.6).  
Total protein in each sample was determined, and all the assays were 
performed using the same total protein amount. This methodology enabled the use of 
extremely low amounts of protein, from 3 to 6 μg (Figure 2.6), whereas in classical 
spectrophotometric assays, the minimum protein amount used in similar assays is 20 
μg (Xie et al. 2002), and in native in-gel hydrolysis assays, it reaches 30 μg of total 
protein amount of tissue extracts (Ross and Crow 2007). We are thus able to use 
almost 7 times less protein compared to the other methods. 
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Figure 2.6 Human carboxylesterase 2 specific activity in HEK-293T transfected cells. HEK-293T cells 
transfected with hCES2 and non-transfected cells extracts were incubated with 0.5 mM 4-MUBA in a total 
reaction volume of 150 μL. An amount of 6 μg of total protein was used in each experiment. Pre-
incubation with 0.25 mM loperamide or 0.5 mM BNPP was performed when appropriate. The 
spontaneous hydrolysis of 4-MUBA is also shown. Each result represents the average of three injections, 
and error bars represent the standard deviation. A * represents a statistical significant difference (p = 
0.01) between the enzymatic activities in the presence (grey or dashed bars) and in the absence (black 
bars) of the inhibitor, based on standard deviation of intermediate precision. 
By evaluating the obtained data, it was possible to conclude the specific 
activity of hCES2 was increased 15-fold in the transfected cells. In addition, as 
reported, basal expression of esterases is detected in this cell line. Comparing the 
specific activities obtained in the presence of loperamide and in the absence of the 
inhibitor for the transfected cell line it can be concluded that hCES2 activity accounts 
for 93% of the total specific activity of these transfected cells. 
The methodology was further applied in the evaluation of a more complex 
matrix in terms of enzyme activity. Different mammalian sera, which are known to 
contain different types and amounts of esterases (Satoh and Hosokawa 1998; 
Liederer and Borchardt 2006; Tecles and Cerón 2001) were chosen. The serum from 
one individual of human, bovine, equine, domestic dog, domestic cat, and rat species 
were thus tested. Using 10% (v/v) of serum of each mammal consistent results were 
obtained for the CESs relative activities (Figure 2.7) to the ones described in the 
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literature (Li et al. 2005). In fact, we did not observe any CES activity in human or 
bovine sera and the highest levels of CESs activities were found in rat, equine, and cat 
sera. 
 
 
 
 
 
 
 
 
Figure 2.7 Mammalian sera activities toward 4-MUBA in the presence and absence of inhibitors. An 
amount of 10% (v/v) of serum from one individual of each mammalian species was incubated with 0.5 
mM 4-MUBA in a total reaction volume of 150 μL. Pre-incubation with 0.25 mM loperamide or 0.5 mM 
BNPP was performed when appropriate. The spontaneous hydrolysis of 4-MUBA is also shown. Each 
result represents the average of three injections, and error bars represent the standard deviation. A * 
represents a statistical significant difference (p = 0.01) between the enzymatic activities in the presence 
(grey or dashed bars) and in the absence (black bars) of the inhibitor, based on standard deviation of 
intermediate precision. 
In human serum, for example, we can detect esterase activity that is not 
inhibited by loperamide or BNPP as no significant statistical difference (p = 0.01) is 
observed between the enzymatic activities obtained in the presence and absence of 
inhibitors. It is known that human plasma contains four types of esterases, namely, 
BuChE, AcChE (present in negligible amounts only), paraoxonase, and albumin (Li et 
al. 2005). We thus hypothesise that the esterase activity detected in human serum is 
due to one or several of the enzymes that can possibly hydrolyse 4-MUBA but that are 
not CESs. In fact, albumin is known to hydrolyse this substrate (Crow et al. 2007). 
Nonetheless, the method proves unaffected by basal activity due to esterases other 
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than CESs, with inhibition by BNPP and by loperamide being valuable indicators of 
CESs and CES2 activity, respectively.  
Assuming loperamide inhibits CES2-like enzymes from mammalian species as 
well as it inhibits hCES2, we determined the specific activities of CES2 and total CESs 
in the different mammals in the linear range of the enzymatic reaction of each serum 
(Table 2.1). Carboxylesterase 2 activity was detected and quantified in equine, rat, 
and cat sera. In fact, in equine serum it is apparently the only CES present.  
The highest CES2 activity is observed in rat serum; on the contrary, dog serum 
shows no significant CES2 activity. Once again, our results are consistent with the 
trends reported in the literature (Li et al. 2005). One should note, however, that our 
purpose is to demonstrate that we achieve quantifiable and consistent values of 
specific CES2 activities with our proposed methodology. A deeper evaluation of the 
CESs present in each mammalian serum would require a higher number of individuals 
per species. 
Table 2.1 Specific activity of CES2 enzymes in mammalian sera a 
 nmol 4-MUB . min
-1
 . serum % 
-1
 
Species total serum  CES2 other CESs 
Equine 0.25 ± 0.01 0.13 ± 0.01 N.D. 
Dog 0.10 ± 0.01 N.d. 0.05 ± 0.01 
Rat 1.07 ± 0.10 0.82 ± 0.07 0.16 ± 0.03 
Cat 0.62 ± 0.07 0.40 ± 0.04 0.06 ± 0.02 
Bovine 0.60 ± 0.13  N.d. N.d. 
Human 0.60 ± 0.05 N.d. N.d. 
a 
Specific activities were determined using 0.5 mM 4-MUBA as described before. Amounts of 10% (v/v) of 
equine, dog, human, and bovine serum, 1% (v/v) rat serum, and 2.5% (v/v) cat serum were used, to cope 
with the linear range of the enzymatic reactions. Pre-incubation with 0.25 mM loperamide or 0.5 mM 
BNPP was performed when appropriate. The spontaneous hydrolysis of 4-MUBA was accounted. Each 
result represents the average of three injections (± standard deviation). N.d.: not detected. 
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To quantify esterase activity and to distinguish CES2 activity from other CESs, 
we propose the following steps depicted in Figure 2.8. Starting with an unknown 
sample, an appropriate dilution must be determined in order to detect or to quantify 
the specific activity of CES2. This can be achieved with 4-MUBA or another substrate 
hydrolysed by CES2. The ability of an unknown sample to hydrolyse 4-MUBA indicates 
that it contains esterases able to hydrolyse this substrate; if no activity is detected, 
the presence of CES2 activity can be excluded and the analysis terminated. 
Confirmation of activity exclusively due to carboxylesterases is performed in the 
presence of BNPP, which inhibits these enzymes. If no activity is detected in this step, 
no CESs are present, and thus analysis will be ended. The analysis of the enzymatic 
activity in the presence of loperamide enables one to discriminate and quantify the 
activity of CES2. Loperamide inhibits CES2 but not other CESs, and therefore CESs 
activities other than CES2 can be determined by the difference between the 
inhibitions observed using BNPP and loperamide. 
Figure 2.8 Flow diagram for CES2 activity identification and determination. 
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2.4 Conclusions 
Capillary electrophoresis was used for quantification of CESs activities. The 
methodology proved fast, repeatable, and requires up to 7 times less sample, than 
classical spectrophotometric methods. Moreover, this approach proved to be 
applicable even when substrates and products absorb at the same wavelength. 
The proposed methodology should be applicable to a wide variety of samples 
with esterase activity. For example, the analysis and determination of CES1 exclusive 
activity would only imply the replacement of loperamide by a specific inhibitor of this 
enzyme such as the partially noncompetitive inhibitor 27- hydroxycholesterol (Tanino 
et al. 2008). For the analysis of the activities of other esterases, appropriate 
substrates and inhibitors should be used. 
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Abstract 
Human carboxylesterase 2 (hCES2), the main carboxylesterase expressed in human 
intestine, is an increasingly important enzyme in anti-cancer combined therapies for 
the treatment of different pathologies like colon adenocarcinoma and malignant 
glioma. The production of human recombinant CES2, in human embryonic kidney cells 
(HEK-293T cells) using serum-free media, is herein described. Carboxylesterase 2 
secretion to the media was achieved by the simple addition of an in-frame C-terminal 
10× histidine tag (CES2-10xHis) without the need for additional N-terminal signal 
sequences or the mutation or deletion of the C-terminal HTEL motif responsible for 
retaining the protein in the lumen of endoplasmic reticulum. This secretion allowed a 
four-fold increase in hCES2 production. The characterisation of human recombinant 
CES2 showed this protein exists in additional active and inactive forms than the 
described 60 kDa monomer. 
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3.1 Introduction 
Carboxylesterase 2 (CES2) is one of the most abundant carboxylesterases (CESs) in 
humans (Crow et al. 2007; Satoh and Hosokawa 2006; Schwer et al. 1997). 
Mammalian CESs are a subset of esterases (Liederer and Borchardt 2006) able to 
hydrolyse ester containing drugs and prodrugs as well as pesticides such as 
pyrethroids (Hicks et al. 2009; Holmes et al. 2009). These enzymes are present in 
diverse tissues such as the liver, testis, small intestine, kidney, and lung, intra or 
extracellularly depending on the species (Holmes et al. 2009; Satoh and Hosokawa 
2006).  
Human CESs are not found in the plasma (Li et al. 2005). They are located 
intracellularly due to the existence of a C-terminal retention sequence composed of 
four conserved amino acid residues: HTEL, QEDL, and HIEL for hCES2, 
carboxylesterase 3 (hCES3) and carboxylesterase 1 (hCES1), respectively. This motif 
enables the retention of CESs in the lumen of the endoplasmic reticulum (ER; Holmes 
et al. 2010; Satoh and Hosokawa 2006). In humans, hCES2 is found at highest levels in 
the liver and intestine (Schwer et al. 1997; Crow et al. 2007). It is described as being a 
very unstable 60 kDa monomeric enzyme (Ross and Borazjani 2007; Pindel et al. 
1997). 
Carboxylesterase 2 is receiving increased attention due to its potential role in 
anti-cancer therapies for the treatment of different pathologies such as colon 
carcinoma (Oosterhoff et al. 2002) and malignant glioma (Tyminski et al. 2005). Also, 
it has been recommended to monitor hCES2 expression levels before the treatment 
of human lung cancer with specific drugs, such as Irinotecan (CPT-11; Satoh and 
Hosokawa 2006). Carboxylesterase 2 has also been used in combined enzyme–drug 
therapies, where tumour specific activation (Oosterhoff et al. 2002) enables drug 
dosage reduction and consequently the decrease of its severe adverse side effects 
(Uchino et al. 2008). 
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To date, only one human CES crystallographic structure is available. The 
human carboxylesterase 1 structure, known since 2003, showed that this enzyme is 
found as active trimers composed of approximately 60 kDa monomers, but the 
enzyme was also shown to exist as hexamers. In fact, through crystallographic and 
atomic force microscopy (AFM) studies, hCES1 was shown to exist in trimer–hexamer 
equilibrium. This equilibrium can be shifted towards the trimer or the hexamer 
depending on the substrate present (Bencharit et al. 2003). Moreover, hCES1 was also 
shown to be active as dimers (Takai et al. 1997). Not as much is known about hCES2, 
which, before the present work had only been demonstrated to be active in its 
monomeric form (Vistoli et al. 2010). A better knowledge of hCES2 and other hCESs 
structural features will be crucial for the understanding of their properties as well as 
the well-described similarities and differences in their behaviour towards different 
substrates and inhibitors (Bencharit et al. 2003; Fleming et al. 2005). 
The recombinant expression of different CESs, from rodents to humans, has 
been reported in the literature, using yeast (Morton and Potter 2000; Lange et al. 
2001), insect (Morton and Potter 2000; Sun et al. 2004; Schiel et al. 2007;Wadkins et 
al. 2005), and mammalian cells (Morton and Potter 2000; Uchino et al. 2008; Xie et al. 
2002). Moreover, different purification strategies have been applied (Morton and 
Potter 2000; Sun et al. 2004), with the most rapid and versatile being immobilized 
metal affinity chromatography (IMAC; Williams et al. 2008; Bornhorst and Falke 2003; 
Waugh 2005). Recombinant protein production using mammalian cells is becoming 
increasingly frequent, as they are able to perform post-translational modifications, 
unlike what occurs in prokaryotes. The usage of transient gene expression systems is 
a valuable tool for decreasing the manufacture time. The choice of the mammalian 
cell line is a key feature in this process. Presently, the most used mammalian cell lines 
for large scale gene expression of recombinant proteins are Chinese hamster ovary 
(CHO) and human embryonic kidney (HEK-293) cells (Pham et al. 2006). This work 
describes and characterises the manufacturing of human recombinant CES2 using 
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suspension adapted HEK-293T cells. Carboxylesterase 2 is shown to be secreted by 
the addition of an in-frame C-terminally localised 10× histidine tag, without the need 
of additional N-terminal signal sequences or the modification or deletion of the ER 
retention sequence. Moreover, the purification of human recombinant CES2 and its 
further characterisation through biochemical techniques unravelled new fundamental 
features, the presence of oligomeric active and inactive forms. 
3.2 Materials and Methods 
3.2.1 Materials 
Carboxylesterase 1 enzyme (esterase from porcine liver) was from Sigma (Buchs, 
Switzerland). Endoglycosydase H (Endo H) enzyme was from Roche (Mannheim, 
Germany). N-glycosidase F (PNGase F) was from Prozyme (Hayward, U.S.A.). 
Ribonuclease B (RNase B) was from Sigma (Schnelldorf, Germany). 
4-Methylumbelliferyl acetate (4-MUBA) (≥98%), 4- methylumbelliferone (4-
MUB) (≥98%), Trizma hydrochloride (>99%), Trizma base (>99.9%), Tris-buffered 
saline (p.a.) and imidazole (≥99.5%) were from Sigma (St. Louis, U.S.A.). Potassium 
chloride (≥99.5%), brefeldin A (99.9%) and bis-p-nitrophenyl phosphate (BNPP) 
(>99%) were from Aldrich (Steinheim, Germany). Sodium acetate (≥99.0%) and 
loperamide hydrochloride (p.a.) were from Fluka (Seelze, Germany). Potassium 
dihydrogen phosphate (≥99%), disodium tetraborate (≥99.5%) and ethanol (99.5%) 
were from Panreac (Barcelona, Spain). Sodium chloride (≥99.5%), disodium hydrogen 
phosphate (≥99.5%), sodium dihydrogen phosphate (>99%), methanol (≥99.9%), 
albumin fraction V (≥98.0%), nickel sulphate (extra pure), Tween 20 (for synthesis) 
and skim milk (for microbiology) were from Merck (Darmstadt, Germany). Dimethyl 
sulphoxide (95%) was from Lab-Scan (Dublin, Ireland). Stock solutions of substrates, 
products and inhibitors were prepared in ethanol. Milli-Q water (Direct-Q 3 UV 
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ultrapure water purification system from Millipore; Billerica, U.S.A.) was used for the 
preparation of all working and buffer solutions. 
3.2.2 Cells and media 
Human embryonic kidney cells (HEK-293T; ATCC CRL-11268) were maintained in 
suspension cultures using 125-mL Erlenmeyer flasks (Corning; Amsterdam, The 
Netherlands), with 20 mL of FreeStyle 293 Expression Medium (serum free, animal 
origin free, chemically defined) from Gibco (Grand Island, U.S.A.), at 37 °C in a 
humidified atmosphere containing 8% (v/v) CO2 in air, using orbital agitation (130 
rpm). Cells were routinely sub cultured twice a week, using an inoculum of 0.5×106 
cell.mL-1. Cell concentration and viability were determined with a Fuchs–Rosenthal 
counting chamber (Marienfeld; Lauda-Königshofen, Germany) using trypan blue 
(Gibco; Carlsbad, U.S.A.) staining. 
3.2.3 Plasmids 
For the generation of pCI-neo-CES2 and pCI-neo-CES2-10xHis mammalian expression 
vectors, human CES2 gene (geneID 8824) and human recombinant CES2 gene 
synthetically synthesized with a C-terminal 10xHis tag (GeneArt; Regensburg, 
Germany) were cloned, respectively, in pCI-neo plasmid (Promega; Madison, U.S.A.) 
using SalI and NotI restriction endonucleases (New England Biolabs; Ipswich, U.S.A.). 
For the formation of a full transcript containing the C-terminal histidine tag, the stop 
codon of CES2 gene was deleted. Both constructs were fully sequenced to verify the 
integrity of CES2 gene. Production and purification of both expression vectors were 
performed and evaluated according to standard molecular biology techniques. 
3.2.4 Human recombinant CES2-10xHis protein production 
For the establishment of the best transfection conditions, HEK-293T cells were 
transiently transfected with pCI-neo-CES2 or pCI-neo-CES2-10xHis plasmids in 500 mL 
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Erlenmeyer flasks, containing 90 mL of FreeStyle 293 Expression Medium. Briefly, cells 
were seeded at 1×106 cell.mL-1 and allowed to grow for 3 to 6 h. Chemical transient 
transfection was performed with polycation polyethylenimine (PEI; Polysciences; 
Eppelheim, Germany). Different plasmid DNA concentrations were tested: 2, 5, 10 
and 20 μg.mL-1. Plasmid DNA and PEI were used in a 1:3 ratio and prepared in 10% of 
the total volume of used media. Cell growth and viability was followed throughout a 
time period of 96 h. Ten-millilitre samples were taken at 24, 48, 72, and 96 h post-
transfection (hpt). Cells were harvested by centrifugation at 200g, for 10 min and 
lysed with 200 μL of M-PER mammalian extraction reagent (Pierce Biotechnology; 
Rockford, U.S.A.) and further clarified at 10,000g for 10 min at 4 °C. Both cell extracts 
and supernatant media were stored at −20 °C, without the addition of protease 
inhibitors. Each transfection experiment was independently repeated at least twice. 
For the establishment of the best purification conditions, HEK-293T cells were 
cultured in 500 mL Erlenmeyer flasks, with 90 mL of FreeStyle 293 Expression Medium 
and transiently transfected as described above, using 5 μg.mL-1 of pCI-neo-CES2-
10xHis plasmid. At least three 500 mL Erlenmeyer flasks were used per experiment. 
Cell growth and viability were followed throughout 96 h. Cells were harvested 96 hpt, 
by centrifugation at 200g, for 10 min. The culture media, containing the soluble 
human recombinant CES2-10xHis protein, was analysed and stored at −20 °C until the 
beginning of the purification process. 
For larger scale production, a 5 L working volume bioreactor (BIOSTAT DCU-3, 
Sartorius Stedim Biotech; Aubagne, France) was inoculated at 0.5×106 cell.mL-1 of 
HEK-293T cells. Transient transfection was performed as described above, using 5 
μg.mL-1 of pCI-neo-CES2-10xHis plasmid. The bioreactor was operated in batch mode, 
equipped with two 6-D Rushton impellers. The pO2 was set at 40% of air saturation 
and sequentially controlled varying the agitation rate (60 to 210 rpm) and the oxygen 
partial pressure in the gas inlet (0–100%). pH was controlled at 7.2 using CO2 and 1 M 
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sodium bicarbonate addition. Culture gassing was performed using a ring sparger at a 
constant gassing rate of 0.01 vvm. The temperature was kept at 37 °C by water 
recirculation in the vessel jacket. Data acquisition and process control were 
performed using MFCS/Win (Multi Fermenter Control Supervisory for Windows) 
control and data acquisition software (SCADA, Sartorius Stedim Biotech). 
3.2.5 Impairment of the protein secretion pathway with brefeldin A 
Inhibition of the protein secretion pathway was performed with brefeldin A antibiotic, 
as described before (Potter et al. 1998), with some modifications. HEK-293T cells 
were transiently transfected with 5 µg.mL-1 of pCI-neo-CES2-10xHis or pCI-neo-CES2 
expression vectors, as described above. At 24, 48, 72 and 96 hpt, two samples (of 10 
mL) from each transfection were centrifuged at 200g for 10 min. Cells were 
resuspended in FreeStyle 293 Expression medium with or without 10 µg.mL-1 of 
brefeldin A. Cells were incubated according to the same conditions described above 
for 4 h. Immediately after the incubation period, cell extracts and supernatant were 
processed as described above and CES activity was evaluated by spectrophotometry. 
3.2.6 Purification of human recombinant CES2-10xHis protein 
Purification of human recombinant CES2 was performed by affinity chromatography 
in an ÄKTA explorer 10S system (GE Healthcare; Little Chalfont, UK), using a 5-mL 
HiTrap Chelating High Performance column (GE Healthcare), loaded with 100 mM of 
nickel sulphate and equilibrated with 20 mM sodium phosphate buffer, pH 7.4, 
containing 20 mM imidazole and 500 mM sodium chloride. 
Two hundred millilitres of cell supernatant, obtained as described above and 
further clarified by centrifugation at 10,000g, for 10 min at 4 °C, were diluted in an 
equal volume of 20 mM sodium phosphate buffer, pH 7.4, containing 20 mM 
imidazole and 500 mM sodium chloride, and loaded onto the column. A washing step 
was performed with the same buffer until stabilisation of the baseline at 280 nm. 
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Elution of the His-tagged bound proteins was performed with a two-step imidazole 
gradient, from 10 to 500 mM. The first lower step was performed from 10 until 250 
mM of imidazole in ten column volumes. The following step, until 500 mM of 
imidazole, was performed with five column volumes. A flow rate of 5 mL.min-1 was 
used.  
Buffer exchange and protein concentration were performed with 20 mM 
sodium acetate buffer (pH 5, containing 600 mM sodium chloride) to all eluted 
fractions using Vivaflow cassettes (Sartorius Stedim Biotech; Goettingen, Germany) 
with a membrane cut-off of 30 kDa. After imidazole removal, all samples were 
sterilized by filtration, using Acrodisc 0.2-μm low protein binding syringe filter (Pall 
Life Sciences; Ann Arbor, U.S.A.). After the addition of 20% (v/v) glycerol, all samples 
were aliquoted and stored at −80 °C. All fractions were analysed by SDS-PAGE and 
Western blot as described below. 
3.2.7 Glycosylation analysis 
Purified CES2-10xHis (100 ng) was incubated with 2.5 mU of Endo H or 1 mU of 
PNGase F overnight (ON) at 37 °C,, according to the manufacturer’s instructions. 
Negative controls, without deglycosylation enzymes, were performed. RNAse B was 
used as positive control of both enzymatic deglycosylations. The reaction products 
were precipitated with four volumes of ice-cold ethanol and analysed by Western blot 
as detailed below. 
3.2.8 SDS- and native PAGE 
Total protein concentration was determined using bicinchoninic acid protein assay 
(Pierce Biotechnology), according to the manufacturer’s instructions. For the cell 
culture supernatant, total protein concentration was not determined due to the 
interference of the medium components in the protein quantification methods. When 
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needed, samples were concentrated using Microcons (Millipore) with a 10 kDa cut-
off.  
Unless otherwise stated, for SDS-PAGE electrophoresis, the same total protein 
amount (50 μg) was loaded onto NuPAGE 4–12% (w/v) bis-tris acrylamide gels 
(Invitrogen). All samples were denatured and reduced for 10 min at 70 °C, according 
to the manufacturer’s instructions. Electrophoresis was performed in XCell SureLock 
mini-cell system (Invitrogen) using MOPS SDS running buffer (Invitrogen), according to 
the manufacturer’s instructions. Proteins were stained with Instant Blue (Expedeon; 
Harston, U.K.) or with SilverXpress staining kit (Invitrogen), according to each 
manufacturer’s instructions. 
Electrophoresis under native conditions was performed using native 4–16% 
(w/v) bis-tris acrylamide gels (Invitrogen), according to the manufacturer’s 
instructions, at 4 °C. In-gel activity assay with the substrate 4-MUBA was performed 
as described before (Ross et al. 2006; Ross and Borazjani 2007) with some 
modifications. In brief, the gel was washed in Milli-Q water for 10 min and incubated 
with 0.01% (w/v) of 4-MUBA in sodium phosphate buffer (pH 7.0) for 20 min with 
gentle agitation. The gel was visualized under UV transillumination, and the resulting 
fluorescence was acquired with ChemiDoc (Bio-Rad; Hercules, U.S.A.) and quantified 
with ImageJ open source software (NIH; Bethesda, U.S.A.). 
3.2.9 Western blot analysis 
Western blots were performed using denaturing, non-denaturing and native 
conditions. For denaturing conditions, SDS-PAGE electrophoresis was performed as 
described above. For non-denaturing conditions, SDS-PAGE electrophoresis was 
performed as described above with the exception that the samples were not reduced 
or denatured. For native conditions, native PAGE electrophoresis was performed as 
described above. The gels were transferred to nitrocellulose (GE Healthcare) or to 
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PVDF (Millipore) membranes and blocked ON with 5% (w/v) milk in 0.05% (v/v) 
Tween, Tris-buffered saline solution. Semi-dry transfer was performed using 
Amersham Hoefer TE 70 transfer unit (GE Healthcare) according to the 
manufacturer’s instructions. 
The following primary antibodies were used: rabbit anti-CES2 (1:200), from 
Sigma and goat anti-CES2 (1:200), from R&D systems (Minneapolis, U.S.A.). Secondary 
antibodies used were: alkaline phosphatase (AP)-goat anti-rabbit (1:2,000), from 
Sigma; horseradish peroxidase (HRP)-rabbit anti-goat (1:5,000), from Invitrogen and 
HRP-donkey anti-rabbit (1:20,000), from GE Healthcare. Detection was performed 
with NBT/BCIP (Pierce Biotechnology), for AP, or Amersham ECL™ Plus (GE 
Healthcare), for HRP. Image acquisition was performed with ChemiDoc and quantified 
using ImageJ. At least three images, acquired with different exposure times, without 
saturation of the obtained signal were used for quantification. Each experiment was 
repeated at least twice to confirm the verified pattern. 
3.2.10 Spectrophotometric assay for esterase activity 
The enzymatic activity assays were performed using the substrate 4-MUBA in 96-well 
plates. All the components were added on ice to a final reaction volume of 250 μL per 
well. Reactions were undertaken at 37 °C under substrate saturation conditions. 
Unless otherwise stated, for cell extract samples, the same total protein amount (10 
μg) was used in each assay; for all culture supernatant samples, the same volume (50 
μL) was used in each assay. Each sample was diluted in 50 mM Tris–HCl buffer (pH 
7.4). A mixture of 90 mM potassium dihydrogen phosphate and 40 mM potassium 
chloride (pH 7.3) was used as reaction buffer. Stock solutions of the substrate were 
prepared in ethanol. The organic solvent percentage in the final reaction volume 
never exceeded 5% (v/v). 
Production and characterisation of human recombinant CES2  
 87
Measurement of the production of 4-MUB, the hydrolytic product of 4-MUBA, 
was performed at 350 nm (Pindel et al. 1997) on a SpectraMax 340 plate reader 
(Molecular Devices; Sunnyvale, U.S.A.). An extinction coefficient of 12.2 mM−1 .cm−1 
(Pindel et al. 1997) was considered. Non-enzymatic hydrolysis was subtracted for 
each enzymatic reaction. Results of esterase activity are presented as micromoles per 
minute per millilitre of product formed for cell extracts and culture media, or as CES 
specific activity (micromoles per minute per milligram of total protein) for the purified 
fractions. Enzyme kinetic parameters were determined for purified recombinant CES2 
through nonlinear regression using GraphPad Prism (GraphPad Software; La Jolla, 
U.S.A.). Results represent the average and standard deviation of three independent 
assays, which were performed in triplicate. 
3.2.11 Capillary electrophoresis assay for CES activity 
For hCES2 specific activity detection and quantification, a capillary electrophoresis 
(CE) method developed by our group was used (Lamego et al. 2011). In brief, for 
inhibition studies, each sample was pre-incubated with loperamide (25 μM) or BNPP 
(500 μM), for 15 and 10 min, respectively, to selectively inhibit total hCES2 or total 
hCESs activity. The enzymatic reactions were performed as described above. Unless 
otherwise stated, reactions were stopped after 8 min by the addition of equal 
quantity (v/v) of ethanol and centrifuged at 10,000g for 10 min before analysis. 
The enzymatic linear range was assessed using different concentrations of 
each sample. CE separation and detection were performed using a Beckman Coulter 
(Palo Alto, U.S.A.) P/ACE MDQ capillary electrophoresis system equipped with a diode 
array detector. 4-MUB, was detected at 350 nm. Non-enzymatic hydrolysis was 
subtracted for each sample. Arbitrary absorbance units were converted to 
concentration using commercially available 4-MUB, as standard. Results are 
presented as the average and standard deviation of three independent assays. Mean t 
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tests were performed for the evaluation of the statistical significant differences (p = 
0.05) between samples. 
3.3 Results 
3.3.1 Evaluation of human recombinant CES2 expression in HEK-293T cells 
HEK-293T cells were transiently transfected in suspension cultures with 5 μg.mL-1 of 
pCI-neo-CES2-10xHis and pCIneo-CES2 expression vectors in serum-free media and 
allowed to grow for 24 h before harvesting. Both cell culture supernatant and cells 
were collected and processed as described in Materials and Methods. The expression 
profiles of esterases both in cell extracts as well as in the supernatant were evaluated. 
Esterase activity was detected in HEK-293T cell supernatants when using pCI-neo-
CES2-10xHis plasmid but not pCI-neo-CES2 plasmid (Figure 3.1a) as soon as 24 hpt. 
Considering the total activity of each sample, both intra- and extracellularly, it 
became clear that more than 80% of the esterase activity was detected in the 
supernatant of HEK-293T cells transiently transfected with pCI-neo-CES2-10xHis 
expression vector. Moreover, total expression was higher when pCI-neo-CES2-10xHis 
transfection is performed. The presence of the enzyme in the supernatant is not due 
to cell lysis since no significant decrease in cell viability was detected (initial viability 
95±4%; viability 24 hpt 90±9%). 
The activity of human recombinant CES2 in the supernatant of HEK-293T cells 
transfected with each expression vector was determined through capillary 
electrophoresis in the presence of loperamide (a selective inhibitor of hCES2; Williams 
et al. 2011) to confirm the observed increase in esterase activity was due to hCES2 
(Figure 3.1b; Lamego et al. 2011). 
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Figure 3.1 Carboxylesterase 2 expression and activity in HEK-293T transiently transfected cells 24 hpt. 
a) Esterase activity towards 4-MUBA evaluated by spectrophotometry both in cell extracts (intracellular) 
and in cell culture supernatant (extracellular). Activity is shown as the relative percentage to the total 
esterase activity (intra plus extracellular) of HEK-293T pCI-neo-CES2-10xHis sample, the maximum activity 
observed. Error bars represent the standard deviation of three independent assays. b) Evaluation of the 
activity specifically due to hCES2 towards 4-MUBA, in 50 μL cell culture supernatant evaluated by 
capillary electrophoresis. Each result represents the average of three independent assays, and error bars 
represent the standard deviation. A * represents a statistical significant difference (p = 0.05) between the 
enzymatic activities in the absence (black bar) and in the presence of the inhibitors loperamide or BNPP 
(white or dashed bars, respectively). c) Western blot of pCI-neo-CES2-10xHis (CES2-10xHis) or pCI-neo-
CES2 (CES2) transfected and non-transfected (NC, negative control) HEK-293T cell extracts (Intra) and in 
the respective cell culture supernatant (Extra). Fifty micrograms (total protein) of intracellular and 10 μL 
of extracellular samples were analysed, using rabbit anti-CES2 and AP-conjugated anti-rabbit antibodies. 
The 62 (upper) and 49 (lower) kDa bands of the ladder are shown. 
The detection and quantification of the activity of other CESs in the sample 
were performed by subtracting the activity obtained in the presence of loperamide to 
the one obtained in the presence of BNPP (an inhibitor of all CESs). If esterases, other 
than CESs, are present in the sample, their activities will be revealed by the 
maintenance of activity in the presence of BNPP. The results clearly show that, in the 
supernatant of HEK-293T cells transiently transfected with pCI-neo-CES2-10xHis, the 
detected esterase activity, 24 hpt, is mainly due to hCES2. In fact, upon the addition 
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of loperamide or BNPP, there is no statistically significant difference (p = 0.05) 
between the obtained activities, meaning that there are no active CESs in the cell 
culture supernatant other than hCES2. However, the possible existence of other 
proteins with esterase activity in the cell culture supernatant cannot be ruled out, as a 
small activity percentage is detected in the presence of BNPP (Figure 3.1b). 
Carboxylesterase 2 activity accounts for more than 89% of the total enzymatic activity 
detected in the sample. 
The expression of human recombinant CES2 was also confirmed by Western 
blot. As expected, and in accordance with the obtained results for enzyme activities, 
hCES2 in HEK-293T cell extracts transfected with both expression vectors was 
unequivocally detected while no hCES2 was detected in non-transfected control cells 
(Figure 3.1c). Moreover, human recombinant CES2 was detected in the supernatant 
of HEK-293T cells when transfected with pCI-neo-CES2-10xHis but not when 
transfected with pCI-neo-CES2 plasmid, or in the non-transfected control cells. Thus it 
is showed that by masking the ER retention motif in the C-terminus region (through 
the addition of a Histidine tag), hCES2 enzyme is secreted without the need to mutate 
or remove the KDEL retaining motif or add any extra signal peptides at the N-terminal 
region. 
3.3.2 Optimisation of soluble human recombinant CES2 expression 
The expression profile of CES2-10xHis in the supernatant of HEK-293T transiently 
transfected cells was further monitored using different concentrations of plasmid 
DNA (2, 5, 10, and 20 μg.mL-1 of pCI-neo-CES2-10xHis expression vector). The 
evaluation of total enzymatic activity in extracellular culture media throughout time 
(Figure 3.2a) reveals that 2 μg.mL-1 of the vector was an insufficient concentration as 
it gave rise to the lowest detected activities, nearly undetected. On the other hand, 
20 μg.mL-1 of plasmid showed to be too high of a DNA concentration since lower 
enzymatic activities than at 5 and 10 μg.mL-1 were detected. 
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Figure 3.2 Optimisation and evaluation of hCES2 expression in HEK-293T cells transiently transfected 
with different pCI-neo-CES2-10xHis DNA concentrations. a) Esterase activity towards 4-MUBA evaluated 
by spectrophotometry, 24, 48, 72, and 96 hpt with different vector concentrations: 0, 2, 5, 10 and 20 
μg.mL
-1
. Esterase activity is expressed as product formed per time unit (micromoles per minute) in 10 mL 
of cell culture supernatant. Each result represents the average of three independent assays, and error 
bars represent the standard deviation. b) Total cell concentration (cell.mL
-1
) and viability (%) of HEK-293T 
non-transfected and transfected (5 and 10 μg.mL
-1
) cells throughout time. Error bars represent a 10% 
error in cell counting. c) Stability of esterase activity in cell culture medium evaluated by 
spectrophotometry. Twenty-four hpt supernatant was centrifuged at 200g to remove the cells and 
incubated for 48, 72, and 96 h at 37 °C and 130 rpm. Decay in esterase activity is shown as the relative 
percentage to the maximum activity observed at 24 hpt. 
The highest activities were achieved in all assays at 96 hpt with the exception 
of the 10 μg.mL-1 assay where it was achieved at 48 hpt. Thus, transfection with 5 and 
10 μg.mL-1 of plasmid originated the highest activities although at different culture 
times. Total cell concentration and viability were also evaluated for these two best 
DNA conditions (Figure 3.2b). There was no decrease in cell concentration when 
comparing transfected vs. non-transfected cells. At 96 hpt, both in transfected and 
non-transfected cells, there was a decrease in cell viability (Figure 3.2b). This suggests 
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that, at this stage, cell lysis may contribute to the enzymatic activity detected in the 
cell supernatant. Since other hCESs than hCES2 are expressed intracellularly, these 
may also contribute to the overall enzyme activity detected in the extracellular 
culture media. 
To test this hypothesis, hCES2 activity was investigated in the culture media of 
HEK-293T cells transfected with 5 μg.mL-1 of pCI-neo-CES2-10xHis, by capillary 
electrophoresis, as detailed above. Carboxylesterase activity in the absence of 
inhibitors (374.8 ± 23.2 μmol.min−1.mg−1) shows a dramatic decrease in the presence 
of loperamide (5.6 ± 2.4 μmol.min−1.mg−1) and in the presence of BNPP (1.5 ± 0.2 
μmol min−1.mg−1). The results show that, as verified for 24 hpt, the detected hCES 
activity was mainly due to hCES2. In fact, upon the addition of loperamide or BNPP, 
there was no statistical significant difference (p=0.05) between the obtained 
activities, meaning that there are no active hCESs other than hCES2 in the 
supernatant. 
To evaluate the stability of the activity of the enzyme in the cell culture 
supernatant, HEK-293T cells were transiently transfected with 5 μg.mL-1 of pCI-neo-
CES2-10xHis. Cells were removed 24 hpt. The decrease in the enzyme activity in the 
cell culture supernatant was followed spectrophotometrically until 96 hpt. The results 
showed a 20% decrease in hCES activity. The activity decrease was more accentuated 
during the first 24 h after cell removal (Figure 3.2c). Taking these results together, the 
5 μg.mL-1 pCI-neo-CES2-10xHis at 96 hpt was the most appropriate plasmid DNA 
concentration and harvesting time to obtain the highest amount of active human 
recombinant CES2-10xHis in the culture media of HEK-293T transiently transfected 
cells without compromising the enzyme activity and quality. 10 μg.mL-1 DNA at 48 or 
72 hpt would also be suitable, but, since it implied the use of twice the amount of 
expression vector, the 5 μg.mL-1 was preferred. 
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3.3.3 Human recombinant CES2 secretion in HEK-293T cells 
Human recombinant CES2-10xHis produced by transient transfection in HEK-293T 
cells was secreted to the culture media, as shown in the previous sections. This 
secretion to the supernatant was due to the presence of the C-terminal 10xHistidine 
tag as no enzyme activity or expression was detected in the culture media of pCI-neo-
CES2 transiently transfected HEK-293T cells (Figures 3.1a, c). 
It has been previously reported that the expression of mutated human 
alveolar macrophage CES and rabbit liver CESs, missing the HIEL C-terminal motif, in 
COS-7 monkey fibroblasts, originates the secretion of these enzymes through the 
classical ER/Golgi-dependent exocytosis (Potter et al. 1998). To evaluate whether 
human recombinant CES2-10xHis produced by transient transfection of HEK-293T 
cells was secreted from the cells via the same pathway, brefeldin A (an antibiotic that 
inhibits protein secretion through ER/Golgi pathway; Nickel 2010) was used. 
The incubation of pCI-neo-CES2-10xHis transiently transfected HEK-293Tcells 
with brefeldin A inhibited the secretion of the protein as the hCES activity detected in 
the cell culture media significantly dropped (Figure 3.3). This decrease in extracellular 
hCES activity was accompanied by an increase in the detected intracellular hCES 
activity in the brefeldin A treated vs. non-treated cells (data not shown). The basal 
levels of hCES activity detected in the culture media upon the treatment with 
brefeldin A correspond to the activity of other esterases towards 4-MUBA, as verified 
in the previous sections. The incubation of pCI-neo-CES2 transiently transfected HEK-
293T cells with the antibiotic was performed as control. As expected, the incubation 
of these cells with brefeldin A did not produce any alteration in the intracellular or 
extracellular activity of hCES (data not shown). 
The incubation of the two types of transiently transfected HEK-293Tcells with 
brefeldin A did not originate any decrease in cellular viability in comparison to the 
non-incubated cells (data not shown). 
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Figure 3.3 Effect of brefeldin A on extracellular esterase activity of pCI-neo-CES2-10xHis transiently 
transfected HEK-293T cells. Esterase activity towards 4-MUBA evaluated by spectrophotometry, 24, 48, 
72, and 96 hpt with 5 μg.mL
-1
 of the vector with or without a 4-h treatment with 10 μg.mL
-1
 of brefeldin 
A. Esterase activity is expressed as product formed per time unit (in micromoles per minute) in 10 mL of 
supernatant culture media. Each result represents the average of three independent assays, and error 
bars represent the standard deviation. 
These results clearly demonstrate that CES2-10xHis is secreted to the cell 
milieu through the classical secretory pathway. It can thus be assumed that CES2-
10xHis is undergoing its normal processing pathway, entering the ER where it can be 
properly folded and post-translationally modified. 
3.3.4 Characterisation of purified human recombinant CES2-10xHis 
Human recombinant CES2-10xHis enzyme was purified by nickel affinity 
chromatography, as described in Materials and Methods. Two hundred millilitres of 
the supernatant harvested at 96 h after HEK-293T cells transfection with 5 μg.mL-1 of 
pCI-neo-CES2-10xHis were used to purify the recombinant protein. 
A two-step imidazole gradient was used to allow a proper separation of CES2-10xHis 
from the remaining proteins present in the media. Two fractions were recovered from 
the purification process at 65 (fraction 1) and 250 mM (fraction 2) of imidazole. Both 
fractions as well as the flow-through containing the proteins that did not bind to the 
affinity column were processed immediately for buffer exchange in order to remove 
imidazole from the samples. All samples were stored at −80 °C with 20% glycerol in 
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order to preserve protein stability. Protein quantification revealed that eluted fraction 
1 had higher protein content (26.4 μg.mL-1) than fraction 2 (9.3 μg.mL-1). No 
significant hCES activity was detected in the flow-through of the column (data not 
shown), but both eluted fractions showed hCES activity. However, the specific 
enzymatic activity in fraction 2 (22.8 ± 2.1 μmol.min−1 .mg−1) was five times higher 
than in fraction 1 (4.3 ± 0.3 μmol.min−1 .mg−1). These fractions were further analysed 
by SDS-PAGE to evaluate protein purity (Figure 3.4a). Fraction 2 shows a clear and 
defined band corresponding to the previously described approximately 60 kDa hCES2 
weight (Pindel et al. 1997). Moreover, no major contaminants were identified with 
only two extra faint bands visible in the lane. On the contrary, fraction 1 contains 
several additional bands with different weights, besides a faint band of approximately 
60 kDa, which justifies the higher total protein content and the lower hCES activity 
detected in comparison to fraction 2. 
 
Figure 3.4 Characterisation of human recombinant CES2-10xHis purity after purification. a) Silver 
stained SDS-PAGE electrophoresis, for protein purity evaluation. Twenty-one nanograms of total protein 
of fractions 1 and 2 eluted during the affinity chromatography purification process were used. b) Western 
blot of purified CES2-10xHis after digestion with Endo H and PNGase F. CES2-10xHis incubated with Endo 
H or PNGase F buffer (−). Digested CES2-10xHis (+). Positive control—non-digested CES2-10xHis (PC). Goat 
anti-CES2 and HRP-conjugated antibodies were used.  
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To further confirm that the approximately 60 kDa band in fraction 2 
corresponds to hCES2, a Western blot using a commercially available anti-CES2 
antibody was performed (data not shown). The results indicated that human 
recombinant CES2 was present in eluted fraction 2 with a higher purity level. To 
further confirm that no other hCESs were present in this eluted fraction, hCES2 
activity was evaluated by capillary electrophoresis, showing once again that no other 
hCESs were present in this sample (data not shown). Using 4-MUBA as a substrate, KM 
and kcat kinetic parameters, of human recombinant CES2 were determined to be 
2.5×10−1 ± 2.8×10−2 mM and 1.1×103 ± 1.7×102 min−1, respectively. These results, 
especially the KM, are in agreement with the ones reported by Pindel et al. (1997) 
where hCES2 purified from human liver was characterised. As human recombinant 
CES2 activity was assayed in the same way as described by Pindel et al. (1997), these 
data suggest that CES2-10xHis shows similar substrate binding characteristics in 
comparison to native hCES2 and an apparently lower catalytic efficiency that may be 
due to differences in assay conditions or to differences between the two enzymes 
The glycosylation status of the purified protein was also assessed (Figure 3.4b) 
through the digestion with Endo H, a deglycosylation enzyme that hydrolyses N-
glycan chains of the high-mannose type (Tarentino et al. 1978), and PNGase F, a 
deglycosylation enzyme that hydrolyses N-glycan chains of the complex type 
(Tarentino and Plummer 1994, Fig. 4b). Purified CES2-10xHis was shown to be post-
translationally modified as it is sensitive to PNGase F digestion. 
Having CES2-10xHis protein and a commercially available anti-CES2 antibody 
allowed to estimate CES2-10xHis production as well as the purification process yields. 
In this way, we estimated the volumetric yield of HEK-293T cells transiently 
transfected to be 50 mg.L-1 of CES2 human recombinant protein. Considering only the 
CES2-10xHis protein present at a highly pure degree in the eluted fraction 2, we 
estimate a 2% yield in this purification process. The obtained purification yield is in 
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agreement with recently reported yields for the purification of recombinant CES2 
produced in insect cells, although strategies other than IMAC were applied (Hatfield 
et al. 2010). The possible reasons for the low yields of hCES2 throughout the different 
purification strategies will be further discussed in the following sections. CES2-10xHis 
production was scaled up to 5 L using a bioreactor. All the conditions optimised in 
Erlenmeyer flasks were kept. Cell viability and hCES activity were followed kinetically. 
Cell concentration and viability profiles in the bioreactor were comparable to the 
ones obtained in Erlenmeyer flasks. Taken together, these results show that CES2-
10xHis production obtained through transient transfection of suspension adapted 
HEK-293T cells is scalable. 
3.3.5 Human recombinant CES2 oligomerization 
The purified human recombinant CES2-10xHis was further evaluated by an in-gel 
activity assay using native PAGE electrophoresis (Figure 3.5a). To perform this 
experiment, commercially available CES1 was used as a molecular weight indicator 
since it is active towards the substrate used. This esterase is active in the trimeric 
form, but other oligomers are also detected (Figure 3.5a). 
CES2-10xHis shows a lighter active band, which should correspond to the 
monomeric form described, as well as a heavier, less intense form. To our best 
knowledge, this is the first evidence that hCES2 can be active in structural forms other 
than monomers. Native PAGE electrophoresis, followed by Western blot, indicates 
that in 50 ng of CES2-10xHis, different weight oligomers are present (Figure 3.5b). 
Apparently, the lighter oligomers correspond to the active oligomeric form visualized 
in the in-gel activity assay. 
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Figure 3.5 Purified CES2-10xHis activity analysis under native conditions. a) Native PAGE electrophoresis 
followed by in-gel activity staining with 4-MUBA; 0.3 μg of commercial porcine CES1 (CES1 trimers—180 
kDa) and 1.2 μg of human recombinant CES2-10xHis were used. Human carboxylesterase 2 monomers (62 
kDa) and active oligomers are shown. b) Native Western blot of 50 ng of CES2-10xHis. Goat anti-CES2 and 
HRP-conjugated antibodies were used. Carboxylesterase 2 monomers as well as light and heavier 
oligomers are shown. 
However, the heavier oligomers, visible by Western blot, could not be detected in the 
activity assay. Using ten-fold less protein amount, only the monomeric form of hCES2 
was identified (data not shown). SDS-PAGE electrophoresis performed without 
reducing and denaturing the samples shows again two types of hCES2 forms (Figure 
3.6a). These are also detected, to a lesser extent under denaturing conditions (Figure 
3.6b), when SDS-PAGE was performed using denatured and reduced samples, which is 
probably due to incomplete denaturation of the proteins.  
As the oligomeric forms decrease under reducing conditions, the two pairs of 
cysteines involved in putative disulfide bonds (Pindel et al. 1997) should be involved 
in the oligomerization. The same results were obtained with other commercially 
available anti-CES2 antibody, which recognizes a different region of the protein (data 
not shown). 
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Figure 3.6 Purified CES2-10xHis characterisation by Western blot analysis after SDS-PAGE performed 
under non-denaturing (a) and denaturing conditions (b). Fifty nanograms of CES2-10xHis was used. 
Carboxylesterase 2 monomers and oligomers are shown. Goat anti-CES2 and HRP-conjugated antibodies 
were used. 
In all cases, the detection of CES2-10xHis oligomers was hampered at lower 
protein concentrations (5 ng), which may indicate that these forms were less 
abundant compared to the monomeric forms. This may also explain why oligomeric 
active forms of hCES2 were not previously reported. The 10xHis tag present in the C-
terminus region of the purified protein is not responsible for the appearance of hCES2 
oligomers as these forms were also detected in cell extracts overexpressing hCES2 
without the tag (data not shown). 
3.4 Discussion 
Carboxylesterases have been studied for several years, with the majority of these 
studies dedicated to mammalian CESs (Takai et al. 1997; Satoh and Hosokawa 2006). 
It is a very active research field where novel findings continuously emerge. Critical 
examples are the demonstration of CES absence from human sera (Li et al. 2005) and 
cocaine hydrolysis exclusively by CES2 and not by CES1 (Hatfield et al. 2010). 
To further characterise CESs, particularly hCES2, the present work describes a 
production process through which hCES2 can be secreted in overexpressing human 
cells by the addition of an in-frame C-terminal His tag, thus enabling a simple IMAC 
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purification strategy. Recombinant active CES expression, already reported for several 
mammalian CESs, in different in vitro cell types is mainly performed intracellularly 
(Morton and Potter 2000; Xie et al. 2002; Sun et al. 2004; Schiel et al. 2007). The 
secretion of intracellular CESs has been previously described in several cell types and 
organisms (Morton and Potter 2000). In these, secretion was achieved by one or more 
of the following methods: addition of a signal sequence in the N-terminus region of 
the protein (Hermann et al. 2008; Oosterhoff et al. 2002), deletion of the four HTEL C-
terminal amino acid residues (Morton and Potter 2000; Hermann et al. 2008; 
Oosterhoff et al. 2002; Wadkins et al. 2005; Hatfield et al. 2010), and modification of 
this C-terminal peptide (Robbi and Beaufay 1991, 1992). The secretion of histidine-
tagged human CESs, namely hCES1, hCES2, and hCES3, has been previously shown, in 
insect cells (Williams et al. 2008) by deletion of the KDEL retaining motif. 
This work shows that secretion can occur without the deletion or modification 
of these residues, and we hypothesise that the addition of a 10xHis tag to the C-
terminus of hCES2 masks the HTEL motif hampering its binding and retention inside 
the ER. Secretion of CES2-10xHis due to its overexpression and inability of the cell to 
cope with large protein amounts was ruled out, since the transfection of HEK-293T 
cells with a similar expression vector lacking only the 10xHis tag did not lead to the 
secretion of the protein (Figure 3.1a). Additionally, secretion of hCES2 is not due to 
cell lysis since, as soon as 24 hpt hCES2 specific activity can be detected in the 
supernatant of pCI-neo-CES2-10xHis transiently transfected HEK-293T cells but not in 
the one from pCI-neo-CES2 transiently transfected cells (Figure 3.1a, b). Moreover, 
addition of brefeldin A, a potent inhibitor of the classical secretory system (Nickel 
2010), completely abolishes the secretion of CES2-10xHis to the culture media (Figure 
3.3). These results fully support our hypothesis that the deletion of the KDEL retaining 
motif is not necessary to promote the secretion of the protein and the in-frame His 
tag located immediately after this sequence is sufficient to induce its secretion. 
Additionally, one can assume that CES2-10xHis, despite its secretion, was properly 
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folded and post-translationally modified as it was entering the ER. In fact, purified 
CES2-10xHis was shown to be sensitive to PNGase F digestion (Figure 3.4b), meaning 
that the protein was post-translationally modified. Native hCES2 is known to be 
sensitive to Endo H digestion (Pindel et al. 1997). Since purified CES2-10xHis was 
secreted, further glycosylation modifications were expected in the Golgi apparatus 
and explains why the secreted protein bears complex-type glycosylation and not high-
mannose type. This glycosylation pattern has previously been shown in rat 
carboxylesterases (Yan et al. 1995). It was observed that both liver microsomal and 
secreted forms existed, with the intracellular form sensitive to Endo H digestion and 
the secreted form sensitive to PNGase F. Additionally, the kinetic parameters (KM and 
kcat) for the human recombinant CES2 were determined. KM is in agreement with the 
one reported for native human liver CES2 (Pindel et al. 1997) indicating that the 
recombinant enzyme has similar substrate binding behaviour. Purified recombinant 
CES2 shows lower catalytic efficiency which may result from differences in assay 
conditions. Nonetheless, further studies to confirm that the presence of the 10xHis 
tag or that the different glycosylation pattern are not affecting the activity of the 
enzyme should be performed in the future.   
The levels of intracellular esterase activity both in pCI-neo-CES2-10xHis and 
pCI-neo-CES2 transiently transfected cells showed an increase throughout time, from 
24 to 96 hpt (data not shown). However, the ability of HEK-293T cells to secrete CES2-
10xHis led to a dramatic increase in protein productivity since, as soon as 24 hpt, 80% 
of CES activity was detected extracellularly and only 20% was detected inside the cells 
(Figure 3.1a). This four-fold increase was only possible due to the secretion of the 
protein. The production of human recombinant CES2, in a soluble form was boosted 
to higher levels (50 mg.L-1). This is an important aspect since one of the main 
drawbacks of recombinant protein expression in mammalian cells is the low yields 
when compared to other expression systems (Morton and Potter 2000; Junge et al. 
2008; Schmidt 2004; Zhao et al. 2011). The levels of CES2-10xHis activity show a clear 
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increase throughout time as the activity in the extracellular supernatant is more than 
15-fold higher at 96 than at 24 hpt (Figure 3.1b). This result is easily explained by the 
stability results of hCES2: the removal of the cells 24 hpt showed no evident decrease 
in its activity from 48 to 96 hpt (Figure 3.2c). 
To our best knowledge, the secretion process of a hCES, namely hCES2, to a 
serum-free media by simple addition of an in-frame C-terminally localised His tag 
without the deletion of the HTEL motif in human cells was not previously reported or 
characterised. This optimised production strategy enabled not only keeping all the 
characteristics of the protein as no deletion in the gene sequence was performed, but 
also to perform the expression of the protein as close as possible to its native state, 
using a human cell line. The majority of the reported CESs purification processes 
either for the purification of recombinant CESs (Sun et al. 2004) or the purification of 
native CESs (Beaufay et al. 1974; Morgan et al. 1994; Humerickhouse et al. 2000) 
involve several highly time-consuming steps. For CES2-10xHis purification, affinity 
chromatography was chosen. Previous reports of CES purification produced using 
insect cells showed a huge range of protein yields and purities (Sun et al. 2004; 
Wadkins et al. 2005; Morton and Potter 2000). The most recently published results 
for the purification of soluble recombinant CES2 produced in insect cells report a 9% 
yield of active protein (Hatfield et al. 2010). The obtained yield in the purification 
strategy followed in the presented work for the purification of soluble CES2-10xHis 
from HEK-293T cell supernatant is in close agreement with these previously reported 
yields where a multi-step purification strategy was used. However, in the present 
work, by applying an IMAC purification strategy, only one purification step was 
involved. 
The establishment of a process for human recombinant CES2 production from 
human cells enabled further study of this protein. The results presented in this paper 
point to the existence of active hCES2 in forms other than the 60 kDa monomers 
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(Figure 3.5a). Moreover, the data also suggests that hCES2 is able to form heavier 
oligomers. These, however, are only visible by Western blots (Figure 3.5b) and not by 
in-gel activity assays, which may indicate they are inactive. It was previously reported 
that esterases, such as esterase D, can form active dimers of 35 kDa monomers 
(Okada and Wakabayashi 1988); also hCES1 is active as trimers, monomers, and 
dimers with the hexamers being inactive (Takai et al. 1997; Bencharit et al. 2003; 
Crow et al. 2007). The ability of carboxylesterase 2 to form organised structures and 
be active in forms other than monomers is thus not an unusual property and may 
point for a broader CES shared property. In fact, homology modelling prediction of 
hCES2 structure based on hCES1 has highlighted the presence of the Z-site region, 
which modulates hCES1 trimer–hexamer equilibrium, in the C-terminus of hCES2 
(Vistoli et al. 2010). 
The heavier hCES2 oligomers, visible under native PAGE conditions, are more 
abundant under non-denaturing conditions (Figure 3.6a) in comparison to denaturing 
conditions (Figure 3.6b), as expected. In SDS-PAGE electrophoresis performed under 
non-denaturing conditions, the samples were still in contact with destabilising agents 
during electrophoresis. Under truly denaturing conditions, the presence of the 
heavier oligomers may be simply due to incomplete denaturing conditions. Our 
hypothesis is that hCES2 monomers can associate and form more complex hCES2 
structures, depending on the conditions that surround the protein. To further 
characterise the observed oligomers, size exclusion chromatography would be a good 
approach in future studies. 
The possible formation of very large aggregates, or multimers of more than 
500 kDa, was previously mentioned for CESs, but no information concerning those 
aggregates, their structure, or their activities was reported (Morton and Potter 2000). 
In the present work, the existence of larger aggregates could not be confirmed by 
native PAGE and Western blot due to limitations in the protein separation range. 
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However, no hCES2 activity was detected in the flow-through during the protein 
purification process. Our hypothesis is that hCES2 may be forming oligomers and/or 
larger aggregates and thus masking the C-terminal His tag. This aggregation will lead 
to the formation of inactive hCES2, thereby reducing the obtained yields. 
The possibility of forming inactive oligomers may also account for the 
observed decrease in hCES2 activity in the extracellular supernatant upon the removal 
of the cells 24 hpt (Figure 3.2c). The observed 20% decrease from 24 to 48 hpt may be 
due to hCES2 aggregation. The hypothesis that the 10xHis tag could somehow cause 
the formation of the oligomers was ruled out as they are also found in extracts of 
untagged hCES2 overexpressing cells (data not shown). These new reported findings 
challenge the current knowledge about hCES2 and raise several fundamental 
questions about the structure and activity of this important enzyme. The answer to 
puzzling questions such as the existence and relevance of these heavier structures in 
the organism will be crucial and successfully addressed through a multidisciplinary 
approach where the knowledge of CES2 structure will be the key. 
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Abstract 
The evaluation of systemic toxicity by xenobiotics frequently includes metabolic 
studies at the hepatocyte level. Still, ingested xenobiotics find in human intestine the 
first challenge to reach the entire organism. The study of the toxicological effects of 
xenobiotics in vitro must also account for their fate by this first barrier. Namely it is 
important to find if xenobiotics permeate and are metabolised in human enterocytes. 
Human carboxylesterase 2 (hCES2) is the main phase I carboxylesterase (CES) in 
human intestine. However, it is present at low levels in Caco-2 cells, the most widely 
accepted in vitro model for the study of intestinal absorption.  
This work describes the development of a new cell line derived from Caco-2 cells with 
increased hCES2 activity. A population of Caco-2 cells was stably transfected with 
hCES2, showing a more than two-fold increase in the specific hCES2 activity 21 days 
after seeding. Increases in hCES2 mRNA (two-fold) and protein levels (six-fold) were 
also observed, in comparison with Caco-2 cell line. The population was cloned and 
clones with up to six-fold increases in hCES2 activity were obtained. Nonetheless, 
stability studies over twenty passages showed instability of protein and activity levels. 
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4.1 Introduction 
Orally delivered drugs must cross the gastrointestinal wall in order to reach their site 
of action. To improve the intestinal absorption profile, hydrophilic drugs like 
carboxylic acids or alcohols, may be transformed into lipophilic prodrugs by 
esterification. Esters are then bioactivated in the body into their active compounds 
(Erhardt et al. 2010). A remarkable example is the anti-cancer ester prodrug 
Irinotecan (CPT-11) that is converted by carboxylesterase 2 (CES2) into its active 
compound SN-38 (Xu et al. 2002).  
Intestinal permeability studies may be performed in vivo, in vitro, in situ, ex 
vivo and in silico, and their advantages and pitfalls have been extensively reviewed 
(Cheng et al. 2008; Buckley et al. 2012; Volpe 2010; Geerts et al. 2011). Most models 
use animals, animal parts, or animal cells, but it has been demonstrated that the 
differences existing between animals and humans may pose significant constraints to 
the extrapolation of data obtained with these models (Crow et al. 2007; Williams et 
al. 2011). In vitro permeability systems include both non cellular models, such as the 
parallel artificial membrane permeability assay (PAMPA; Reis et al. 2010), and cellular 
models. Several in vitro cellular models exist, enabling the determination of intestinal 
permeability and are reviewed in Simon-Assman et al. 2007. Caco-2, a human colon 
adenocarcinoma isolated cell line (Fogh et al. 1977), spontaneously differentiates in 
culture presenting characteristics of human enterocytes (Pinto et al. 1983). Since its 
characterisation as an intestinal epithelial permeability model (Hidalgo et al. 1989), 
this model has become one of the most used for drug absorption prediction (Buckley 
et al. 2012; Hubatsch et al. 2007), widely applied by industry, and accepted by the 
regulatory authorities. 
Despite its popularity, Caco-2 shows some remarkable differences towards 
human enterocytes such as in the expression levels of certain transporters and the 
absence of CYP3A4 metabolising enzymes (Balimane and Chong 2005; Ungell 2004). 
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Moreover, relative expression levels of carboxylesterases (CESs) in Caco-2 cells were 
shown not to correlate to those found in human enterocytes. RT-PCR analysis of Caco-
2, showed high levels of human carboxylesterase 1 (hCES1) in comparison to the 
lower ones obtained for human carboxylesterase 2 (hCES2; Imai et al. 2005). On the 
contrary, through in-gel activity staining of human intestinal microsomes (HIM), 
almost only hCES2 is detected (Imai et al. 2006). Carboxylesterase 2 is thus the main 
hCES involved in ester metabolism in the human intestine. The fact that its levels are 
low in Caco-2 cells, renders this model inappropriate for the study of ester-containing 
compounds metabolised by hCES2 (Imai and Ohura 2010).  
Several attempts have been made to ameliorate Caco-2 gaps and improve its 
permeability predictions. A wide range of strategies have been applied both for the 
up- and down-regulation of expression. Chemical agents were used in the induction of 
protein expression, such as 1 alpha, 25-dihydroxyvitamin D3 that increases CYP3A4 
expression (Schmiedlin-Ren et al. 2001), and to inhibit protein activity, such as bis-p-
nitrophenyl phosphate (BNPP) that inhibits the activity of human CESs (hCESs; Ohura 
et al. 2010). Genetic manipulation of Caco-2 cells has also been attempted not only 
for the up-regulation of genes but also for their knockdown, such as the case of Caco-
2 transduction with shRNA targeting P-glycoprotein (P-gp; Li et al. 2011). 
The goal of the work herein described was to increase hCES2 activity levels in 
Caco-2 cells in order to develop a model more closely resembling enterocytes in 
terms of the metabolism of ester containing compounds. To our best knowledge, the 
genetic modification of these cells, envisioning the overexpression of hCES2, was not 
previously attempted.  
When working with Caco-2 cells there is always the hurdle of both intra- and 
inter-laboratory variability and efforts have been made to understand and minimize 
these differences (Roth et al. 2012, Natoli et al. 2012; Prieto et al. 2010; Hayeshi et al. 
2008; Coecke et al. 2005). Nonetheless, the effect of seeding inocula on hCES2 
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expression was not previously reported. This work thus starts with a full 
characterisation of hCES2 activity in Caco-2 cells and the effect of both seeding 
inocula and passage number followed by the generation and characterisation of a 
stably transfected cell line with increased levels of hCES2 activity. The evaluation of 
hCES2 expression stability in the newly generated cell line provides an important 
contribution to the field of in vitro cell models refinement by showing a common 
problematic hurdle on Caco-2 cells manipulation that appears to be independent of 
the expressed transgenes, i.e. genes other than hCES2. 
4.2 Materials and Methods 
4.2.1 Materials 
Bovine alkaline phosphatase (ALP), 4-Methylumbelliferyl acetate (4-MUBA) (≥98%), 4-
methylumbelliferone (4-MUB) (≥98%), 4-methylumbelliferyl phosphate (4-MUP), 
Trizma hydrochloride (>99%), Trizma base (>99.9%), Tris-buffered saline (p.a.), 
ethylenediaminetetraacetic acid disodium salt dehydrate (EDTA) (>99.9%), HEPES 
(≥99.5%), sodium hydroxide (≥98%) and Triton X-100 (laboratory grade) were from 
Sigma (St. Louis, U.S.A.). Potassium chloride (≥99.5%) was from Aldrich (Steinheim, 
Germany). Sodium acetate (≥99.0%) and loperamide hydrochloride (p.a.) were from 
Fluka (Seelze, Germany). Potassium dihydrogen phosphate (≥99%) and ethanol 
(99.5%) were from Panreac (Barcelona, Spain). Sodium chloride (≥99.5%), albumin 
fraction V (≥98.0%), and skim milk (for microbiology) were from Merck (Darmstadt, 
Germany). Dimethyl sulphoxide (DMSO; 95%) was from Lab-Scan (Dublin, Ireland). 
Milli-Q water (Direct-Q 3 UV ultrapure water purification system from Millipore; 
Billerica, U.S.A.) was used for the preparation of all solutions.  
4.2.2 Cells and media 
Caco-2 cells (ATCC HTB-37), between passage number 26 to 41, were 
routinely cultured in T-75 flasks (BD Biosciences) using high glucose (4.5 g/L) 
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Dulbecco’s Modified Eagle Medium (DMEM), supplemented with 10% (v/v) fetal 
bovine serum (FBS) and 1% (v/v) non-essential aminoacids (Gibco; Grand Island, 
U.S.A.), at 37 °C in a humidified atmosphere containing 7.5% (v/v) CO2 in air. Once a 
week, before reaching confluence, cells were cultured using Dulbecco’s phosphate-
buffered saline (DPBS) and 0.25% (w/v) Trypsin-EDTA (Gibco). Media replacement was 
performed in alternating days. Cell concentration and viability were determined with 
a Fuchs–Rosenthal counting chamber (Marienfeld; Lauda-Königshofen, Germany) 
using 0.1% (v/v) trypan blue (Gibco) staining. Cell monolayers were prepared, unless 
otherwise stated, by seeding 1.04×10
4
 cell.cm
-2 
in 100 mm  i.d. tissue culture petri 
plates (Becton Dickinson; Franklin Lakes, U.S.A.) or 6-well tissue culture plates (Becton 
Dickinson) for protein and RNA extracts, according to the needed extract amounts. 
For alkaline phosphatase activity determination, 96-well tissue culture plates were 
used. Media change was performed in alternating days for the first week and every 
day for the remaining time in culture until 21 days. 
4.2.3 Plasmids 
Human CES2 gene (geneID 8824) was cloned in pCI-neo plasmid (Promega; Madison, 
U.S.A.) using SalI and NotI restriction endonucleases (New England Biolabs; Ipswich, 
U.S.A.) as previously described (Section 3; please see Appendices for vector map). The 
construct in pCI-neo-CES2 plasmid was fully sequenced to verify the integrity of the 
hCES2 gene. Production and purification of the expression vector was performed and 
evaluated according to standard molecular biology techniques. 
4.2.4 Caco-2 CES2 cell line establishment 
Caco-2 cells were transfected in 6-well tissue culture plates with 20 µg.mL
-1
 pCI-neo-
CES2 plasmid using 60 µg.mL
-1 
polycation polyethylenimine (PEI; Polysciences; 
Eppelheim, Germany) 24 h after seeding at a cell density of 1.04×10
4
 cell.cm
-2
. 
Selection pressure was started 48 h post-transfection (hpt) using 0.95 mg.mL
-1
 of 
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G418 antibiotic (Invitrogen). Medium was changed twice during the first week. One 
week after selection pressure was started, amplification of the selected population 
was performed and a master cell bank of Caco-2 CES2 population was created.  
Cell cloning was performed through the limiting dilution method. Briefly, cells 
were seeded at 1 cell per well in 96-well tissue culture plates using 50% (v/v) 
conditioned media supplemented with 20% (v/v) FBS and 0.48 mg.mL
-1
 of G418 
antibiotic. More than 80 clones were picked from single colony wells. Step-wise 
amplification of each clone was performed, with a gradual increase of available cell 
culture area. 43 clones survived this process and were appropriately stored and 
analysed.  
4.2.5 Real-time qPCR analysis 
Total RNA from Caco-2 cell line and Caco-2 CES2 cell population, at passages 30 and 
39, respectively, were extracted at 7, 14, and 21 days after seeding using RNeasy 
extraction kit (Qiagen; Courtaboeuf, France) according to the manufacturer’s 
instructions. Samples were treated with DNAse. Cells were grown in 6-well tissue 
culture plates as detailed above and three wells were independently extracted for 
each cell type at each time point. RNA concentration and purity was determined using 
NanoDrop 2000c spectrophotometer (Thermo Scientific; Wilmington, U.S.A.).  
Messenger RNA was reverse transcribed to cDNA with Transcriptor High 
Fidelity cDNA synthesis kit (Roche; Mannheim, Germany), using anchored oligo (dT) 
primer and 2 µg of total RNA per reaction, according to the manufacturer’s 
instructions. Real-time PCR analysis was performed using SYBR Green in a LightCycler 
480 System PCR (Roche), according to the manufacturer’s instructions. Previously 
described and tested RT-PCR primers and amplification conditions (Sanghani et al. 
2003) for hCES1, hCES2 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
genes were used. Negative controls were also run in parallel with the cDNA samples 
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to detect contamination problems during PCR analysis and/or DNA contamination 
during RNA extraction. Analysis of relative gene expression of hCES1 and hCES2 
compared to the housekeeping GAPDH gene, previously shown to be invariant from 
undifferentiated to differentiated stages of Caco-2 cells (Bédrine-Ferran et al. 2004), 
was performed according to the 2
-ΔCT
 method (Livak et al. 2001). 
4.2.6 Western blot analysis 
Caco-2 cell extracts were prepared at 7, 14, and 21 days after seeding, as previously 
reported (Lea et al. 2010), with minor modifications. Briefly, cells grown in 6-well 
plates were washed with DPBS and rapidly lysed with 200 µL of a solution containing 
0.25 mM NaCl, 5 mM EDTA, and 1% (v/v) Triton (Korjamo et al. 2006) in 50 mM Tris-
HCl pH 8.0. Cell extracts thus prepared were centrifuged at 10,000g for 10 min at 4 °C 
and were stored at −20 °C. Total protein concentration was determined using 
bicinchoninic acid (BCA) protein assay (Pierce Biotechnology; Rockford, U.S.A.), 
according to the manufacturer’s instructions.  
Unless otherwise stated for SDS-PAGE electrophoresis, the same total protein 
amount (30 μg) was loaded onto NuPAGE 4–12% (w/v) bis-tris acrylamide gels 
(Invitrogen; Carlsbad, U.S.A.). All samples were previously denatured and reduced for 
10 min at 70 °C. Electrophoresis was performed in XCell SureLock mini-cell system 
(Invitrogen) using MOPS SDS running buffer (Invitrogen), according to the 
manufacturer’s instructions. Proteins were transferred from the gels to PVDF 
(Millipore) membranes and blocked overnight (ON) with 5% (w/v) milk in 0.05% (v/v) 
Tween, Tris-buffered saline solution, pH 7.6. Semi-dry transfer was performed using 
Amersham Hoefer TE 70 transfer unit (GE Healthcare; Little Chalfont, U.K.) according 
to the manufacturer’s protocol. 
The following primary antibodies were used: goat anti-hCES2 (1:200) from 
R&D systems (Minneapolis, U.S.A.); rabbit anti-hCES1 (1:250) from Sigma; and mouse 
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anti-β actin (1:500) from Abcam (Cambridge, U.S.A.). Secondary antibodies used 
were: horseradish peroxidase (HRP)-rabbit anti-goat (1:5,000) from Invitrogen; HRP-
donkey anti-rabbit (1:20,000) and HRP-sheep anti-mouse (1:25,000) from GE 
Healthcare. Chemiluminescent detection was performed with ECL Prime (GE 
Healthcare). Image acquisition was performed with ChemiDoc (Bio-Rad; Hercules, 
U.S.A.) and non-saturated images were quantified through densitometry with ImageJ 
open source software (NIH; Bethesda, U.S.A.). Integrated density values were 
normalised per lane with the ones obtained for β-actin. Each result is shown in 
relation to Caco-2 at 21 days, which was used as reference in each gel. Each 
experiment was repeated at least twice to confirm the verified pattern. 
4.2.7 Esterase activity determination  
Caco-2 cell extracts were performed as described above. The enzymatic activity 
assays were performed using the substrate 4-MUBA as previously described (Lamego 
et al. 2012). Briefly, reactions were undertaken in a final reaction volume of 250 μL, at 
37 °C under substrate saturation conditions. Unless otherwise stated, the same total 
protein amount (10 μg) was used in each assay. 90 mM potassium dihydrogen 
phosphate and 40 mM potassium chloride (pH 7.3) were used as reaction buffer. 4-
MUB production was monitored at 350 nm (Pindel et al. 1997) on a SpectraMax 340 
plate reader (Molecular Devices; Sunnyvale, U.S.A.). Results of esterase activity are 
presented as micromoles per minute per milligram of total protein. Mean t tests were 
performed for evaluation of statistically significant differences (p = 0.05) between 
Caco-2 and Caco-2 CES2 samples. 
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4.2.8 Alkaline phosphatase activity determination 
Alkaline phosphatase activity was measured by the activity towards 4-MUP, as 
previously described (Malpique et al. 2007). Briefly, in each time point (7, 14, and 21 
days), cells from 4 independent wells were washed and incubated with 200 µL of a 1:1 
mixture of 1 mM 4-MUP in 20 mM HEPES/NaOH, pH 7.4 and 20 mM HEPES/NaOH, pH 
9.0. Light protected incubations were performed for 1.5 h, 20 min, and 8 min for the 
7
th
, 14
th
, and 21
st
 day, respectively. 75 µL of supernatant was transferred to a 96-well 
black microplate (Greiner Bio-One; Frickenhausen, Germany). 4-MUB production was 
monitored at 535 nm (excitation at 360 nm) on a GloMax Multi detection system 
fluorescence plate reader (Promega). Calibration curves were obtained with ALP in 
the 0.5 to 20 µg.mL
-1
 (0.43 to 17 microUnits) range. Substrate spontaneous hydrolysis 
was accounted. Results are presented as microUnits per viable cell (one unit is 
defined as the activity that hydrolyses one µmol of substrate per minute). 
4.3 Results 
4.3.1 Evaluating hCES2 variability in Caco-2 cells 
Several cell and culture-related factors have been shown to influence Caco-2 
development and characteristics (Sambuy Y et al. 2005; Prieto et al. 2010; Christensen 
et al. 2012). Culture medium has shown to influence the expression of different drug 
transporters and drug metabolising enzymes, including hCES2 (Roth et al. 2012). In 
this study, the researchers found that hCES2 mRNA was slightly up-regulated, without 
statistical significance, when Caco-2 cells were cultured in DMEM (the medium used 
in the present study) in comparison with minimum essential medium alpha (AMEM). 
The initial seeding inoculum of Caco-2 cells has been reported to impact not only cell 
morphology but also the expression of different proteins, including drug transporters 
and drug metabolising enzymes (Volpe 2008; Natoli et al. 2011; Roth et al. 2012). To 
our best knowledge, the effect of cell seeding on hCES2 activity was never evaluated. 
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To study this, Caco-2 cells were cultured at passage 31 with different seeding inocula 
from 1.0x10
4
 to 1.0x10
5
 cell.cm
-2 
(Figure 4.1) and allowed to differentiate for 21 days 
before testing, as described in the Materials and Methods. The results on specific 
esterase activity did not show statistically significant variations (Figure 4.1a). 
However, in the presence of loperamide, a selective CES2 inhibitor (Williams et al. 
2011), variations on hCES2 specific activity were higher, leading to a tendency of 
increased inhibition percentages with higher seeding densities, more evident at 
higher starting seeding inocula (Figure 4.1b) but still with no statistical relevance.  
Passage number has also been indicated as a biological factor influencing 
variability and protein expression profiles in Caco-2 cells (Shah et al. 2006; Siissalo et 
al. 2007). The expression profile of hCES2 (as well as hCES1) was reported to be 
constant between passages 28 and 59 in different laboratories, based on native PAGE 
electrophoresis followed by staining for esterase activity (Imai et al. 2005; Imai 2006), 
but no data was shown. Nonetheless, due to several reports on Caco-2 intra and 
inter-laboratory variability (Press and Di Grandi 2008; Volpe 2008), hCES2 activity was 
herein assessed at different passages (Figure 4.2). This step is mandatory to 
understand the passage range in which it is appropriate to modify these cells, namely, 
to increase hCES2. Two different seeding inocula were used, 1.0x10
4
 and 2.0x10
4
 
cell.cm
-2
. No statistically significant difference was observed when comparing both 
passages under different conditions - in the presence and absence of inhibitor and 
with different starting inocula.  
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Figure 4.1 Seeding inocula effect on esterase activity. a) Caco-2 cells, at different starting seeding 
inocula were tested for esterase specific activity in the absence and presence of loperamide. b) Inhibition 
percentage was calculated through the difference between the activity in the absence and presence of 
the inhibitor, as described before (Lamego et al. 2011). Each result represents the average of three 
independent assays, and error bars represent the standard deviation (a) or the combined standard 
deviation (b).  
 
 
 
 
 
 
 
 
 
 
Figure 4.2 Effect of passage number in esterase activity. Caco-2 cells, in two different passage numbers, 
were tested for esterase specific activity in the absence and presence of loperamide, at two different 
starting seeding inocula. Each result represents the average of three independent assays, and error bars 
represent the standard deviation.  
A B 
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4.3.2 hCES2 transient expression in Caco-2 cells 
To increase hCES2 activity levels, an expression vector was generated using pCI-neo 
plasmid as a backbone. Caco-2 cells were transiently transfected with pCI-neo-CES2, 
using two different seeding inocula, 1.0x10
4
 and 5.0x10
4
 cell.cm
-2
, as described in 
Materials and Methods. Esterase specific activity was evaluated 48 hpt (72 h after 
seeding) in the presence and absence of loperamide (Figure 4.3). Inhibition 
percentage of the transfected samples (Caco-2 CES2), calculated through the 
difference between the activity in the absence and presence of the inhibitor, as 
described before (Lamego et al. 2011), was the same, 28 ± 7%, independently of the 
starting seeding inocula. No inhibition was detected in Caco-2 cells 48 hpt, as 
expected. The increase in esterase specific activity from parental to transiently 
transfected cells is thus shown to be due to the increase in hCES2 activity. 
Figure 4.3 Esterase specific activity in Caco-2 transiently transfected cells. Caco-2 cells, transfected at 
1.0x10
4
 and 5.0x10
4
 cell.cm
-2 
seeding inocula were tested for esterase specific activity in the absence and 
presence of loperamide 48 hpt. Each result represents the average of three independent assays, and error 
bars represent the standard deviation. A * represents a statistically significant difference (p = 0.05) 
between Caco-2 and Caco-2 CES2 samples. 
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4.3.3 Characterisation of Caco-2 CES2 population  
Since pCI-neo-CES2 plasmid bears the neomycin resistance gene, geneticin antibiotic 
(0.95 mg.mL
-1
) was used as selection agent to obtain a Caco-2 CES2 population that 
could be propagated. A kill curve using 0.5 to 2 mg.mL
-1
 of geneticin was performed 
and 0.95 mg.mL
-1
 was chosen as the most effective antibiotic concentration (data not 
shown). Esterase specific activity was determined in parental Caco-2 and selected 
Caco-2 CES2 population at different time points (Figure 4.4). Although no statistically 
significant difference was observed in total esterase specific activity between parental 
Caco-2 and Caco-2 CES2 population (Figure 4.4a), there was a clear difference in 
hCES2 specific activity as reflected by an increase in the inhibition by loperamide 
(Figure 4.4b). A small increase in hCES2 activity, without statistical significance, was 
detected in Caco-2 cell line throughout the differentiation period. However, a 2.5-fold 
increase in inhibition percentage was observed from the first to the second week of 
the differentiation period in Caco-2 CES2 population.  
Figure 4.4 Esterase specific activity in Caco-2 CES2 selected population. Caco-2 (P39) and Caco-2 CES2 
(P37) were seeded at 1.0x10
4
 cell.cm
-2
, in the absence and presence of geneticin, respectively. Esterase 
and hCES2 specific activities were determined at different time points. Each result represents the average 
of three independent assays. a) Esterase specific activity determined in the absence of loperamide. Error 
bars represent the standard deviation of three independent assays. b) hCES2 specific activity showed in 
terms of inhibition percentage, determined in the presence of loperamide. Error bars represent the 
combined standard deviation. A * represents a statistically significant difference (p = 0.05) between Caco-
2 and Caco-2 CES2 samples. 
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Figure 4.5 Carboxylesterase gene and protein expression in Caco-2 and Caco-2 CES2 cells. a, b) hCES2 
and hCES1 relative expression was evaluated in both Caco-2 cell line and Caco-2 CES2 population, 
throughout the differentiation period, by qRT-PCR. GAPDH was used for normalisation. Error bars 
represent the standard deviation. A * represents a statistically significant difference (p = 0.05) between 
Caco-2 and Caco-2 CES2 samples. c, d) Relative protein expression of hCES2 and hCES1 was evaluated in 
both cell types, using Caco-2 21 days as reference sample. Integrated density values were normalised per 
lane towards β-actin. 
Both cell types were also evaluated for protein and gene expression levels 
(Figure 4.5). Human CES1 relative mRNA levels increased over culture time in both 
parental and stably transfected Caco-2 cells and the same increasing pattern was 
shown for protein. Human CES2 relative mRNA levels are always significantly higher in 
Caco-2 CES2 population in comparison to the parental cell line and increase 
throughout the differentiation period. The increase was, nonetheless, more 
pronounced in Caco-2 CES2 population  since the hCES2 relative mRNA levels 
practically doubled from the 7
th
 to the 21
st
 day, whereas in Caco-2 parental cells an 
approximate 60% increase occurred. By evaluating hCES2 protein levels, a similar 
pattern was found. Human CES1 relative mRNA levels were always higher in both 
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Caco-2 and Caco-2 CES2, compared with hCES2. It should be noted the amplified 
region for hCES1 (190 base pairs) and hCES2 (310 base pairs) are different.  
The influence of hCES2 expression was also evaluated in the differentiation 
properties of the transfected population. Alkaline phosphatase activity per viable cell 
was used as a marker of differentiation. No difference was observed at day 21 
between Caco-2 parental cell line and Caco-2 CES2 population (Figure 4.6).  
Figure 4.6 Alkaline phosphatase expression in Caco-2 cell line and Caco-2 CES2 population. ALP activity 
was measured at day 21, as described in Materials and Methods, and normalised with the number of 
viable cells. Error bars represent the standard deviation. 
4.3.4 Caco-2 CES2 cell line establishment and expression stability evaluation 
For the establishment of a Caco-2 CES2 cell line, 84 single-cell clones were selected 
through limiting dilution, as described in Materials and Methods. Only 43 grew well 
enough to be tested. Clones 1 to 14, depicted in Figure 4.7 had higher activity 
compared with parental Caco-2 cells. The stability of hCES2 expression was tested in 
the highest expressing cell lines. Figure 4.8 shows the results for clone 14 in a time 
window of twenty passages, one passage per week. In the first ten passages, passages 
41 to 51, the effect of geneticin antibiotic was tested by culturing the cells in the 
presence and absence of the antibiotic. From passage 51 onwards, no antibiotic was 
used. Clone 14 showed higher hCES2 specific activity levels than the ones found for 
Section 4 
126 
Caco-2 CES2 stably transfected population and this was also reflected in the relative 
protein expression levels. 
 
Figure 4.7 hCES2 specific activity in stably transfected clones. Caco-2 CES2 selected clones were tested at 
day 21, at passage 41, for esterase specific activity in the absence and presence of loperamide and 
inhibition percentage was calculated. Each result represents the average of three independent assays, 
and error bars represent the combined standard deviation. 
However, there is a dramatic decrease in both hCES2 activity and protein 
levels that is independent of the presence of geneticin. In 10 weeks, the cell line 
reverts completely to the levels of hCES2 activity detected for Caco-2 parental cell 
line, not recovering in the following 10 weeks. This same tendency was verified for 
other clones, confirming the detected pattern: 11 clones were tested at passage 
number 51, and 3 at passage number 61. 
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Figure 4.8 hCES2 expression stability evaluation in Caco-2 CES2 cell line. Caco-2 CES2 cell line was 
tested, at day 21, at different passages. Caco-2, P39, and Caco-2 CES2, P37, were used as controls. a) 
Inhibition % calculated through esterase specific activity in the absence and presence of loperamide. Each 
result represents the average of three independent assays, and error bars represent the combined 
standard deviation. b) Relative hCES2 expression, using Caco-2 sample as reference. Integrated density 
values were normalised per lane with β-actin. w/gen – with geneticin; w/o gen – without geneticin.  
4.4 Discussion 
As highlighted before, Caco-2, a cell line derived from a human tumour, was reported 
to bear low levels of hCES2 and high levels of hCES1 expression while evidence 
showed that hCES2 is expressed to a higher extent than hCES1 in normal colon cells 
(Imai et al. 2005). This still unanswered question impelled us to overexpress hCES2 in 
Caco-2 cells and evaluate the stability of the obtained cell line.  
The Caco-2 cell line is well known to be sensitive to variations in culture 
conditions. Seeding density and passage number are some of the factors impacting 
the expression profiles of some transporters such as the mRNA of P-gp (Prieto et al. 
2010; Hayeshi et al. 2008). 
Human carboxylesterase 2 mRNA levels have been previously shown to 
increase throughout the differentiation period of Caco-2 cells (Ohura et al. 2010). In 
this work, we not only confirmed these results but also demonstrated how passage 
number and seeding inocula influence the activity levels of this enzyme in Caco-2 
cells. A tendency for increased hCES2 specific activity, specifically measured in the 
presence of loperamide, with higher seeding inocula was detected. Nonetheless it fell 
A B 
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within the standard deviation of independently performed experiments, pointing to 
the high biological variability affecting this system (Figure 4.1). A tendency towards a 
decrease in hCES2 specific activity at higher passages was detected (Figure 4.2). This 
may provide an indication of the intrinsic instability of this cell line towards hCES2 
expression. Nonetheless, as no statistically significant difference was observed in this 
10 cell-passage interval, it provides an appropriate window of time for manipulating 
Caco-2 cells (Figure 4.2). 
Fitted with a deeper knowledge of the system, the next logical step was to 
genetically modify Caco-2 cells. There are several gene delivery vehicle-DNA 
complexes described in the literature. From these, PEI and lipofectamine are the two 
chemical transfection agents most commonly used (O’ Neill et al. 2011) and have 
been previously applied in Caco-2 cells (Gautrey et al. 2011; Korjamo et al. 2005). PEI, 
being less expensive, was the chosen approach, demonstrated to be suitable for 
hCES2 transient overexpression as the esterase specific activity levels were increased 
48 hpt (Figure 4.3). The increase in hCES2 specific activity was shown to be 
independent of the seeding inocula used. Curiously, the obtained hCES2 activity 48 
hpt was higher than the maximum detected in Caco-2 parental cells after 3 weeks in 
culture (Figures 4.1b and 4.3), suggesting the ability of this cell line to cope with 
increased levels of active hCES2. A stably transfected Caco-2 CES2 population was 
established, with increased hCES2 specific activity (Figure 4.4b). Surprisingly, no 
statistically significant difference was observed in total esterase activity between 
parental Caco-2 and Caco-2 CES2 population (Figure 4.4a). This may be due to 
substrate competition as both hCES1 and hCES2 are known to hydrolyse 4-MUBA. 
Through limiting dilution, it was possible to select a Caco-2 CES2 cell line. 
Caco-2 CES2 population heterogeneity was revealed in the diversity of hCES2 activity 
in the 14 clones depicted in Figure 4.7. As previously reported, protein expression 
levels of hCES1 and hCES2 do not correlate with their enzymatic specific activities 
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(Ross and Crow 2007). In this work additional evidence is provided as there is not a 
proportional correlation between activity (Figure 4.4b), mRNA (Figure 4.5a, b), and 
protein expression (Figure 4.5c, d) of both hCESs. These differences may rely in the 
technical constraints inherent to each analytical technique such as the amplification 
efficiency in qRT-PCR, related, for instance with the size of the amplified region which 
is different for hCES1 and hCES2, or the different antibody binding affinities in 
Western blot. In order to avoid misleading results, the screening of Caco-2 CES2 
expressing clones was based on the assessment of hCES2 specific activity and later 
complemented with protein expression studies.  
To evaluate the feasibility of the usage of this newly generated cell line, with 
increased levels of active hCES2, as a stable and able to be propagated platform for 
drug screening, expression stability tests were performed by culturing the cells for 
increased periods of time. A severe loss of hCES2 activity, reaching basal population 
levels in 10 weeks was shown not to correlate with the presence of the selection 
pressure agent geneticin (Figure 4.8a). This phenotype, verified for several of the 
selected clones, was not reverted in the following ten weeks of culture in the absence 
of the antibiotic. We have further discovered that the decreased hCES2 activity was 
reflected in the levels of protein expression (Figure 4.8b).  
Stable expression of hCES2 was previously reported to be possible through a 
genetic engineering strategy almost identical to the one followed in the present 
study, but using Chinese Hamster Fibroblast cell line (VT79; Imai et al. 2006). This 
evidence suggests that it should be possible to stably express recombinant hCES2 in 
mammalian cells, under the control of the CMV promoter, using chemical transfection 
techniques combined with selection with geneticin selection. However, it was 
previously reported not to be possible to stably increase hCES2 levels in COS-7 
electroporated cells following a similar approach (Wierdl et al. 2008).  
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Expression of proteins was previously shown to be possible in Caco-2 cells. 
Examples are the increase in Glutathione peroxidase 4 (GPx4; Gautrey et al. 2011) and 
the decrease in P-gp levels (Hilgendorf et al. 2004). Using the same genetic 
engineering approach, i.e. the same expression vector backbone, including the same 
promoter, as well as the same type of selection pressure of the one chosen in the 
present study, it was previously reported to be possible to increase the levels of 
membrane dipeptidase (MDP; Pang et al. 2004). However, no data showing the 
stability of the obtained cells throughout time in culture, in any of these cases, was 
shown. 
The problem of Caco-2 modification has been previously highlighted in terms 
of the difficulty of increasing CYP expression (Korjamo et al. 2006). Combining the 
results presented herein with data previously reported, and exemplified in table 4.1, 
there is evidence of an overall problem in stable Caco-2 modification. A possible 
common mechanism through which Caco-2 effectively represses the expression of 
exogenous genes may thus be envisioned. This seems to be independent of the 
transgene, the transfection method and the selection pressure used, as the same 
pattern was previously reported for CYP3A4 and CYP2A6, electroporated and selected 
with hygromycin B (Crespi et al. 1996). 
We have confirmed that this repression does not occur at the enzymatic 
activity level as a decrease in protein expression level was also detected. Since a clear 
response of CES2 mRNA during the differentiation period in Caco-2 CES2 stably 
transfected population occurs we hypothesise that this may be the level of regulation 
of exogenous hCES2 expression, may it be through promoter inhibition or decreased 
mRNA stability. It cannot be excluded, however, that other repression mechanisms 
may also exist. It was previously shown a direct link between transcript inactivation 
and epigenetic modification in stably transfected cell lines gradually loosing transgene 
expression.  
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Table 4.1 Non-differentiated Caco-2 stable transfection  
Gene/ Protein 
Up / 
down 
reg 
Promoter 
type 
Plasmid 
type 
Transfection 
method 
Selecting 
agent 
Expression 
stability  
Reference 
Glutathione 
peroxidase 4 
(GPx4) 
Up  
Viral: 
CMV 
pCDNA3.1 
Chemical: 
Lipofectamine 
2000 
zeocin 
antibiotic 
Clones selected; 
no report 
towards 
expression 
stability 
throughout 
passaging 
Gautry et 
al. 2011 
Membrane 
dipeptidase 
Up  
Viral: 
CMV 
pCIneo 
Physical: 
electroporation 
neomycin 
antibiotic 
Selection 
performed; no 
report towards 
expression 
stability 
Pang et al. 
2004 
P-glycoprotein 
(P-gp) 
Down 
Viral: 
SV40 
pEUK-C1; 
pMAMneo 
Physical: 
electroporation 
G418 
antibiotic 
Clones selected; 
no report 
towards 
expression 
stability 
throughout 
passaging 
Hilgendorf 
et al. 2004 
Human 
pregnane X 
receptor 
(hPXR) 
Up  
Viral: 
CMV 
pCIneo 
Chemical: 
polycation 
polyethylenimine 
(PEI) 
G418 
antibiotic 
Clones selected; 
reported to be 
stable for 15 
passages; results 
are not shown 
Korjamo et 
al. 2005 
Murine 
constitutive 
androstane 
receptor 
(mCAR) 
Up  
Viral: 
CMV 
pCIneo 
Chemical: 
polycation 
polyethylenimine 
(PEI) 
G418 
antibiotic 
Clones selected; 
reported to be 
stable for 12 
passages; results 
are not shown 
Korjamo et 
al. 2005 
P-gp Up  
Viral: 
CMV 
pCIneo 
Chemical: 
polycation 
polyethylenimine 
(PEI) 
G418 
antibiotic 
Clones selected; 
reported to be 
stable for 6 
passages; results 
are not shown 
Korjamo et 
al. 2005 
Caudal-
related 
homeodomain 
protein 2 
(CDX2) 
Up  
Viral: 
CMV 
pTarget 
Chemical: 
Lipofectamine 
2000 
G418 
antibiotic 
Clones selected; 
no report 
towards 
expression 
stability 
throughout 
passaging 
Kusano et 
al. 2012 
CYP3A4, 
CYP3A6 
Up  
Viral: 
CMV 
p220.2 
Physical: 
electroporation 
Hygromycin 
B antibiotic 
CYP3A4 clones 
selected; activity 
reported to 
decrease five-
fold in five 
passages. 
Crespi et 
al. 1996 
P-gp Down 
Human: 
Modified 
U6 
promoter 
Lentiviral 
vectors 
with shRNA 
for P-gp 
(Sigma) 
Transduction: 
Lentivirus 
Puromycin 
antibiotic 
Clones selected 
for 5 passages  
Li et al. 
2011 
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In fact, it was shown that transcript inactivation is followed by promoter DNA 
methylation and histone H3 K9 dimethylation, being the early events of transgene 
silencing the acetylation of histones and their methylation at histone H3 K4 (Mutskov 
and Felsenfeld, 2004). 
Several techniques may help understand and overcome the reasons behind 
the repression of hCES2, in particular, and transfected genes, in general, in Caco-2 
cells. The application of chemical inducers to restore the repressed levels will, for 
instance, influence the expression of other proteins and/or Caco-2 morphology. As 
our goal was to increase hCES2, interfering as little as possible with the parental cell 
environment, it may be concluded that Caco-2 manipulation by transient transfection 
is the fastest and most suitable approach to avoid the intrinsic regulation mechanisms 
of this cell line. Different promoters, both viral and cellular may then be tested. For 
those cases where it is not possible to cope with the variability associated with the 
transient transfection approach, the establishment of a larger and well characterised 
master cell bank may constitute a valid approach, as previously suggested (Crespi et 
al. 1996). In this case, geneticin should be the elected antibiotic, instead of others 
such as hygromycin B. Opposing to what was described to happen with hygromycin B 
(Crespi et al. 1996; Rodolosse et al. 1998), no defects in cell adherence, monolayer 
integrity or cell morphology was detected using geneticin.  
In the future, more innovative approaches in Caco-2 manipulation may 
contribute to overcome its problematic manipulation with the potential to constitute 
a more generalized solution such as the targeted insertion of genes into pre-selected 
highly transcribed regions of the genome. Further improvements to Caco-2 may then 
be envisioned, such as hCES1 down-regulation, to more closely resemble human 
enterocytes.  
A detailed comparison of the newly developed Caco-2 CES2 cell line will be 
needed, being advisable to use 20 passively absorbed drugs, representing a range 
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from low to high intestinal absorption (Volpe et al. 2007), to adequately demonstrate 
its suitability for testing a drug’s permeability and all the other currently performed 
tests using Caco-2 cells.  
4.5 Conclusions 
The work herein presented describes the efforts towards the improvement of 
currently available in vitro tools highly used in research and development through the 
establishment of a new cell line derived from Caco-2 cells with increased hCES2 
activity levels. The new cell line, better reflecting human intestinal metabolism 
towards hCES2 metabolised esters, retains the polarisation and differentiation 
capabilities of the parental cell line, thus having the potential to become, in the future 
and upon complete validation with reference compounds, a useful tool for coupling 
the study of intestinal absorption with intestinal metabolism, especially of ester 
containing drugs and prodrugs. 
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The main goal of the work presented in this thesis was to increase the fundamental 
knowledge on human Carboxylesterase 2 (hCES2) and to improve Caco-2 cells by 
increasing the levels of this enzyme, crucial in the metabolism of ester containing 
drugs and prodrugs. The main contributions to that goal are highlighted in this section 
with a special focus on the future envisioned developments.  
5.1 Setting new analytical approaches 
Currently available tools enabling the assessment of carboxylesterase (CES) 
expression and activities have several limitations, as detailed in Section 2, such as the 
failure to associate protein expression with activity quantification as well as the 
inability to distinguish different CESs and quantify their specific activities. For the 
proper study of CES2 activity in complex biological samples, proper tools had to be 
developed and were described in Section 2. Taking advantage of BNPP, a general and 
irreversible CES inhibitor, and loperamide, a selective CES2 inhibitor, CESs were 
evaluated through capillary electrophoresis for the first time, using a general CES 
substrate, 4-MUBA. First, commercially available enzymes were used, with the 
method later extended to the evaluation of increasingly complex biological samples 
such as human cell extracts and mammalian sera. A workflow where an unknown 
sample may be sequentially tested for its hydrolytic activity towards a general CES 
substrate, such as 4-MUBA, in the absence and presence of these inhibitors was 
proposed. This method, using up to 7-fold less sample than the classical 
spectrophotometric methods, showed to be appropriate when several components of 
the reaction mixture absorb at the same wavelength. 
The future applications of the developed methodology are broad, ranging 
from the possibility of testing different samples to the evaluation of other CESs, or 
even other esterases since the appropriate inhibitors or substrates are used. It may 
also be used with other separation techniques like HPLC. 
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The development of new approaches for the differentiation and 
characterisation of CES activity is of great relevance in this field where much attention 
is being dedicated to the comparison of the specific activities found in different 
mammals, namely those used in preclinical studies by pharmaceutical companies 
(Williams et al. 2011; Bahar et al. 2012). Foreseen is the future development of new 
analytical tools enabling differentiation and characterisation of CES activity in whole-
living cells, where the enzymes are retained in a preserved and more physiological 
cellular environment. In fact specific fluorescent probes have already been developed 
and characterised for their specificity for different CESs (Wang et al. 2011). The 
application of these probes for live imaging was shown to be possible (Hakamata et 
al. 2011) raising the possibility of further applications that may help to understand the 
differences between enzyme activity and protein expression previously reported 
(Ross et al. 2012). 
5.2 Further understanding hCES2 
Having developed the tools allowing its proper study in biological samples, 
human carboxylesterase 2 (hCES2) production was for the first time performed and 
described, in Section 3, in suspension adapted HEK-293T cells. The strategy used 
allowed no need for additional of N-terminal signal sequences or the modification of 
the ER retention sequence to promote hCES2 secretion with the addition of an in 
frame C-terminally localised 10x histidine tag. This, in turn, allowed the purification of 
the protein through affinity chromatography. Although a very satisfactory purity level 
was obtained, the achieved yield was in line with a recent report (Hatfield et al. 2010), 
leaving space for future improvements in the purification process, which the research 
group is already pursuing.  
The manufacturing of hCES2 enabled further comprehension of its behaviour: 
it may present itself as active and inactive oligomers when it was previously reported 
to be exclusively found as 60 kDa monomers (Pindel et al. 1997). We have 
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hypothesised that hCES2 monomers may associate forming structures of higher 
complexity, depending on the environment where the protein is. The further 
characterisation of the observed oligomers may be performed, in the future, through 
size exclusion chromatography; nonetheless, improvement in the purification process 
is needed to increase yields, allowing these types of studies. Whether these oligomers 
exist in the human organism and what is their relevance, are curious still unanswered 
questions.  
The future applications of this produced human recombinant CES2 are 
massive. Due to the high purity levels achieved it will be used in crystallographic 
studies. As, so far, the only human CES structure known is that of carboxylesterase 1 
(hCES1; Bencharit et al. 2003) the determination of hCES2 structure will be an 
important contribution to this field. It may also be used in studies aiming at the 
discovery of new hCES2 inhibitors or in the investigation of the kinetics towards newly 
developed ester containing drugs or prodrugs.  
The novel properties of hCES2 challenge the current knowledge about CESs. 
Several puzzling questions arise concerning the general properties of these proteins 
as well as their evolutionary path.  
May oligomerization be a shared property of CESs? As mentioned before, 
hCES2 ability to form organised structures and being active in forms other than 
monomers may not be an unusual property and suggest a broader CES-shared 
property. For instance, it was previously reported that esterase D can form active 
dimers of 35 kDa monomers (Okada and Wakabayashi 1988) and hCES1 is active as 
trimers, monomers, and dimers with the hexamers being inactive (Takai et al. 1997; 
Bencharit et al. 2003; Crow et al. 2007). In fact, homology modelling prediction of 
hCES2 structure based on hCES1 has highlighted the presence of the Z-site region, 
which modulates hCES1 trimer–hexamer equilibrium, in the C-terminus of hCES2 
(Vistoli et al. 2010). Further studies concerning CES oligomerization are thus 
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envisioned, being important to carefully design and conduct the studies so that the 
most relevant data, from the biological point of view, are obtained. 
What is the importance of glycosylation in protein stability/solubilisation and 
activity? As previously mentioned, native hCES2 is known to be sensitive to Endo H 
digestion (Pindel et al. 1997). Purified and active human recombinant CES2 bears 
complex-type glycosylation and not high-mannose type, thus sensitive to PNGase F, a 
not so surprising characteristic since further glycosylation modifications are expected 
by the Golgi apparatus on secreted proteins. This glycosylation pattern has previously 
been shown in rat carboxylesterases (Yan et al. 1995): it was observed that both liver 
microsomal and secreted forms existed, with the intracellular form sensitive to Endo 
H digestion and the secreted form sensitive to PNGase F. Rat hydrolase S was shown 
to be secreted from rat primary culture of hepatocytes, unlike rat hydrolases A and B 
which are intracellular. The first does not contain the HXEL C-terminus consensus 
sequence, unlike the non-secreted forms, having also more glycosylation sites (Yan et 
al. 1994; Yan et al. 1995). Moreover, the native deglycosylation of hydrolases A and B, 
purified from rat liver microsomes, has shown no effect on enzyme activity, although 
an increased adsorption to glass and plastic was observed for carbohydrate-free 
hydrolase A (Morgan et al. 1994). As previously hypothesised (Morgan et al. 1994) 
these data may point towards a higher relevance of glycosylation for protein stability 
and solubilisation and not as much for enzymatic activity of mature proteins. Other 
investigators have also highlighted the importance to look at the glycosylation sites in 
order to acquire a deeper understanding of the catalytic mechanism of CESs (Satoh 
and Hosokawa 2006).  
Interesting insights were also previously reported from recombinant 
expression of different CESs. Hydrolase C, a rat carboxylesterase very similar to rat 
hydrolase B, was shown to be inactive when expressed in Escherichia coli, a 
prokaryotic organism, but active when expressed in the baculovirus/insect cell 
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(Sporodeptra fugiperda 21 – Sf21) system (Yan et al. 1995b). Curiously, it was 
reported that for full recombinant hCES1 activity, expressed in baculovirus-insect cell 
system, proper glycosylation (especially N-linked glycosylation) was needed (Kroetz et 
al. 1993). These combined data may point towards differences in the glycosylation 
function not only between intra and extracellular forms but also across different CESs. 
The reasoning behind these differences remains unknown.  
To understand if the post-translational modifications encountered in mature 
human secreted CES2 have an impact on protein stability and solubility, an 
experimental approach could be envisioned where the sugar moieties would be 
removed under native conditions and these data would confirm the previous findings 
in rat liver carboxylesterases (Morgan et al. 1994). Moreover, to address the impact 
of post-translational modifications on the maturation of hCES2, site-directed 
mutagenesis should help to understand if glycosylation is needed for the proper 
folding and activity of this enzyme. A similar approach may be used to study the role 
and the impact of the cysteine residues involved in the formation of disulfide bonds. 
What came first: intra or extracellular forms of CESs in mammals? As 
previously reported, humans do not have CESs in the plasma (Li et al. 2005). 
Nonetheless, other mammals, such as rats and mice, have several intra and 
extracellular carboxylesterase forms (Holmes et al. 2010). Is carboxylesterase 
secretion a common ancestral property in mammals that humans lost throughout 
evolution or is it an acquired characteristic that humans did not need to have? Data 
from rat, shown that native hydrolase S was exclusively secreted from the liver, as no 
mRNA was found in other tissues, and differed from the liver microsomal 
carboxylesterase form only in the glycosylation pattern. These previously reported 
results, may point towards the primary existence of carboxylesterases in the 
intracellular form. Supporting this evidence, the intracellular levels of hydrolase S 
were shown to be lower than the ones of hydrolase A and B. Moreover, both forms of 
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hydrolase S, intra and extracellular, were shown to be regulated by inducer and 
suppressor xenobiotics, at the protein and mRNA levels (Yan et al. 1995). 
Nonetheless, these data do not explain why hydrolase S lost the HXEL C-terminus 
motif or why humans do not have CES secretion. 
A non-human organism where human cells were allowed to grow and develop 
would allow gaining new insights towards the possible influence of the environment 
of the organism for the development of the human cells as well as on CES regulation 
and activity. A model organism was already created (Strom et al. 2010) and patented: 
the FRG™ mouse. This commercially available (Yecuris; Portland, U.S.A.) chimeric 
triple knockout (KO) model for fumarylacetoacetate hydrolase, recombinant 
activating gene, and interleukin-2 receptor subunit gamma (Fah
-/-
/Rag2
-/-
/Il2rg
-/-
), 
allows human hepatocytes to grow inside the liver of the animal and almost entirely 
replace native hepatocytes. Rag2 and Il2rg absence renders these mice 
immunodeficient, allowing the prompt acceptance of engrafted human hepatocytes. 
Fah KO leads to chronic liver damage in the mice, which is prevented by 2-(2-nitro-4-
trifluoro-methylbenzoyl)1,3-cyclohexedione (NTBC), keeping them healthy. Upon 
human hepatocyte transplantation, the removal of NTBC application provides the 
selective advantage for the repopulation of the injured mouse liver (Strom et al. 
2010). This model provides an opportunity for evaluating the expression and activity 
of hCES2, as well as other CESs, in human hepatocytes grown in a non-human 
organism in order to understand if changes in the enzymatic profile arise not only in 
comparison to the parental transplanted population but also throughout the 
repopulation stages. This strategy was already applied in the study of other drug 
metabolising enzymes, such as the cytochrome P450 (CYP) family, in various chimeric 
models (Strom et al. 2010). In the Fah
-/-
/Rag2
-/-
/Il2rg
-/-
 model, it was shown that the 
expression levels of different CYP genes as well as their transcriptional inducers, 
pregnane X receptor (PXR) and constitutive androstane receptor (CAR; Lim and Huang 
2008), were similar to the ones found in the donor population (Azuma et al. 2007). To 
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our best knowledge, no data concerning CES expression was reported using this 
strategy.     
This approach would also allow comparing the sera from healthy (control), 
KO, and humanised mice at different stages of repopulation, as mentioned. Through 
CES protein and activity specific detection in the sera, it would be possible to 
investigate whether a decrease in mice CES expression or activity levels occurred 
throughout time. If so, it would point towards a decrease in CES secretion due to the 
decrease in the amount of mice cells in the liver, as would be expected. If not, it might 
mean that mice cells were able to sense the eventual decrease of CES levels in the 
blood and increase secretion of more active enzymes. Another possibility would be 
that the repopulating cells might somehow acquire (or re-acquire) the ability to 
secrete CESs or that they can reprogram themselves or be reprogramed by the 
environment to do so. This would be a tremendous result, providing new insights 
towards mice and human CESs expression and activity regulation, strengthening the 
quest of understanding why human cells do not secrete CESs while other animals do.  
5.3 Improving Caco-2 cells 
Fitted with a deep knowledge about hCES2, Caco-2 cells were successfully genetically 
engineered, obtaining a population with increased hCES2 mRNA, protein expression 
and activity levels, as described in Section 4, without changing crucial Caco-2 
characteristics, such as differentiation and polarisation. Through clonal selection by 
limiting dilution, it was possible to generate a Caco-2 CES2 cell line that may be 
suitable in the future for the coupling of in vitro intestinal transport and metabolism 
evaluation of pharmaceutically relevant compounds. It was previously highlighted 
that the coupling of these two mechanisms would render an ideal in vitro 
permeability model (Balimane and Chong 2005). 
Through stability evaluation of hCES2 expression throughout passaging and 
differentiation, an obvious decay was observed rendering this newly developed cell 
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line unsuitable for drug testing at higher passages. Testing the permeability and 
metabolism of ester containing drugs and prodrugs will be possible through the 
establishment of a large cell bank at a low passaging level, as previously reported 
(Crespi et al. 1996) or, alternatively, through the transient transfection of Caco-2 with 
the hCES2 gene. 
The reasons for the observed expression instability remain unclear. The 
general problem to stably modify Caco-2 cells was mentioned before (Korjamo et al. 
2006). It is apparently not related to the chosen methodology for gene expression as 
the same instability was previously reported following a different strategy in terms of 
the chosen transgene, cell transfection and selection pressure (Crespi et al. 1996). Our 
data also point towards an independency of selection pressure used since the decline 
in hCES2 activity was detected both in the presence and in the absence of the 
antibiotic.  
As there are several reports for the stable transfection of Caco-2 cells, with 
different transgenes, without effectively showing cell line stability at later stages, it 
may be envisioned that a possible common mechanism exists through which the cells 
effectively repress the expression of exogenous genes (Crespi et al. 1996; Hilgendorf 
et al. 2004; Gautrey et al. 2011). In the case of hCES2, our data shows that the 
regulation is not at the activity level since it is accompanied by a decrease in protein 
expression. As mentioned in Section 4, due to a clear response of hCES2 mRNA during 
the differentiation period in Caco-2 CES2 stably transfected population, we 
hypothesise that transcription may be at the level of regulation of exogenous hCES2 
expression. We cannot exclude that repression mechanisms may exist at the DNA 
level.   
To understand the level where regulation of the expression occurs, several 
approaches may be followed in the future. If hCES2 mRNA also reflects the verified 
instability, different efforts may be envisioned to understand if this is due to decay in 
the transcription or the turnover rate of mRNA. Xenobiotic inducers of CES 
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expression, known to act at the transcription level, may help to differentiate between 
these two hypotheses. The usage of these inducers, as a solution towards a more 
stable cell line suitable for drug testing at higher passaging levels, seems 
unreasonable since they would affect the expression of other key enzymes and other 
proteins. Another possibility is the usage of CES specific substrates as a way to induce 
or keep the expression of these enzymes. Similar strategies may be followed to 
further investigate whether epigenetic mechanisms are silencing the transgene at the 
DNA level. If such mechanisms are proven to be regulating the expression of the 
transgene, different approaches towards its stable expression must be pursued. One 
of these may be the targeted integration of CES2 following cassette exchange on a 
previously screened stable chromosomal locus, an approach successfully followed in 
the past in other human cell lines (Schucht et al. 2006; Coroadinha et al. 2006). The 
use of insulators sequences may also be an option if the problem arises from 
transcriptional silencing. Chromatin insulators are regulatory elements known to 
reduce the interaction between integrated expression vectors and the surrounding 
cell genome. These interactions may be a source of expression instability associated 
with the integrated transgenes (Emery 2011; van Bortle and Corces 2012). 
In a time where there are ethical, economic, and regulatory needs for better 
alternatives to animal experimentation, this approach has the potential of becoming 
an invaluable tool. Further metabolic improvements may be envisioned, such as 
hCES1 down-regulation and CYP3A4 up-regulation, leading to the establishment of an 
increasingly better in vitro intestinal permeability tool that may be used for research 
purposes as well as pre-clinical studies contributing to the 3R policy, to Replace, 
Reduce, and/or Refine laboratory animal use when possible (Schiffelers et al. 2012; 
Wells 2011). 
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5.4 Final remarks 
Overall, the work described in this thesis contributed significantly to the 
progress of the current state of the art on xenobiotic metabolism and permeability 
fields. Important advancements were made which contributed to the improvement of 
tools for human carboxylesterases studies: a new capillary electrophoresis method 
enabling the quantification of specific hCES2 activity, using up to 7 times less sample 
than classical spectrophotometric methods, was developed. This methodology, having 
the potential to be extended for the quantification of other hCESs, allows performing 
determinations even when substrate, product, or inhibitors absorb at the same 
wavelength.  
A significant contribution was also made to the current knowledge on 
carboxylesterases, through the production and purification of hCES2 in human cells, 
showing, for the first time, the ability of this enzyme to oligomerize. Moreover, 
through the secretion of the enzyme, not only were the production yields boosted, 
achieving 50 mg.L
-1
, but also allowed to find the addition of a C-terminal Histidine tag 
was enough to potentiate hCES2 secretion. In a time when increased awareness to 
interspecies variation exists, as well as growing attention is being devoted to these 
enzymes in anti-cancer combined therapies, the contributions of better human 
carboxylesterases manufacturing techniques and increased understanding on how 
these enzymes behave are invaluable.  
Additionally, a modified intestinal permeability model, based on the widely 
used Caco-2 cell line, was generated. A population of Caco-2 with two-fold increased 
hCES2 activity was obtained and through this, a cell clone was isolated with a six-fold 
increase in the activity of the protein. The establishment of this cell line constitutes an 
important contribution to the current in vitro tools used to determine the intestinal 
permeability, in an urgent time for the effective application of the 3R policy. 
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A.1 CES2 protein across different species  
The following table is the extended version of Table 1.2, presented in Section 1, containing all 
the hits until hCES1 sequence (one hundred and sixty six hits in total).  
As mentioned in Section 1, a BLAST-P search was performed in ESTHER database against all 
protein sequences available (http://bioweb.ensam.inra.fr/ESTHER/general?what=index), using 
as query, the amino acid (a.a.) sequence of hCES2. All the hits were considered, except those 
classified by the database as belonging to the Carb_B_FragtPseudo group, as these constitute 
incomplete sequences. Moreover, the hits were cross-checked against UniProtKB/Swiss-Prot 
database (http://www.uniprot.org) and only those having an identifiable entry were 
considered (forty eight in total, for Table 1.2; one hundred and fifty two for Table A.1).  
The default parameters of the program, in the mentioned webpage, were used: substitution 
matrix – blocks of amino acid substitution matrix 62 (BLOSUM62); gapped alignment; gap 
penalties: existence – 11; extension – 1. 
As also mentioned in Section 1, the sequence identities towards the used query (ID), as well as 
additional information are provided. These include: protein accession numbers in ESTHER and 
UniProt databases; alternative protein entries (italicized); protein name and function 
information available at UniProt database; gene designation (italicized) when existing; 
GeneBank accession number; level of experimental evidence of protein existence (evp); length 
of the full protein (#AA) as well as the last four amino acids. Moreover, the score (S; in bits) for 
each alignment as well as the expectation value (E-value) are shown. Additional references, 
not mentioned in Section 1, may be found in the end of this section.  
The UniProt evp levels were followed (http://www.uniprot.org/manual/protein_existence). 
The criteria for the five types of evidence for the existence of a protein are herein transcribed:  
Evidence at protein level - experimental evidence for the existence of the protein. Criteria: 
partial or complete Edman sequencing, identification by mass spectrometry, X-ray or NMR 
structure, good quality protein-protein interaction or detection of the protein by antibodies. 
Evidence at transcript level - existence of a protein has not been strictly proven; expression 
data (such as existence of cDNA(s), RT-PCR or Northern blots) indicate the existence of a 
transcript. 
Inferred by homology - existence of a protein is probable because clear orthologs exist in 
closely related species. 
Predicted - entries without evidence at protein, transcript, or homology levels. 
Uncertain - existence of the protein is unsure. 
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Table A.1 CES2 protein across different species  
Organism / UniProt 
name 
UNIPROT  
ID 
% 
# 
AA 
Last 4 
AA 
ESTHER  GeneBank  
S /         
E-
value 
Function 
Homo sapiens (Human – class Mammalia)             
Carboxylesterase 2 
(Cocaine esterase) 
O00748 
(A8K367, 
Q4G0E9) 
100 559 HTEL human-2cxes  Y09616.1 
1136 / 
0.0 
Detoxification of xenobiotics and activation of ester and 
amide prodrugs. High catalytic efficiency for hydrolysis of 
cocaine, 4-MUBA, heroin and 6-monoacetylmorphine. (Pindel 
et al. 1997) 
Carboxylesterase 3 Q6UWW8 46 571 QEDL human-est3 
XM_016735, 
AK097538, 
BC053670, 
AY358609, 
EU595874, 
CH471092, AC009084 
483 /  
1e-136 
Carboxylesterase activity (evp: protein level; Sanghani et al. 
2004) 
Liver carboxylesterase 1 P23141 46 567 HIEL human-cxest 
AB119998, 
AB119996, M65261  
473 /  
1e-133 
Carboxylesterase activity (evp: protein level) 
Pan troglodytes (Chimpanzee – class Mammalia)             
Uncharacterised Protein H2QBA6 97 623 HTEL pantr-h2qba6 AACZ03102754.1 1111 / 
0.0 
Hydrolase activity (evp: predicted) 
Uncharacterised Protein H2RA50 47 571 QEDL pantr-h2ra50 
AACZ03102749, 
AACZ03102750, 
AACZ03102751 
478 /  
1e-135 
Hydrolase activity (evp: predicted) 
Uncharacterised Protein H2R2Y7 46 567 HIAL pantr-h2r2y7 AACZ03103390 483 /  
1e-136 
Hydrolase activity (evp: predicted) 
Gorilla gorilla (Lowland gorilla - class Mammalia)             
Uncharacterised Protein 
G3RPG8 
(G3QYW6, 
G3QYX2) 
95 623 HTEL gorgo-g3qyw6 - 
1087 / 
0.0 
Hydrolase activity (evp: predicted) 
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Pongo abelii (Sumatran orangutan - class Mammalia)           
Uncharacterised Protein H2NR54 93 623 HTEL ponab-h2nr54 - 
1071 / 
0.0 
Hydrolase activity (evp: predicted) 
Carboxylesterase 3 Q5RCL7 49 569 QEDL ponab-est3 CR857194, CR858253 
513 /  
1e-146 
Carboxylesterase activity (evp: transcript level) 
Putative uncharacterised 
protein 
Q5R545 46 566 HIEL ponpy-q5r545 CR861029 
473 /  
1e-134 
Hydrolase activity (evp: transcript level) 
Nomascus leucogenys (Northern white-cheeked gibbon - class Mammalia)       
Uncharacterised Protein G1QVW2 91 606 HTEL nomle-g1qvw2 ADFV01013581.1 
1031 / 
0.0 
Hydrolase activity (evp: predicted) 
Uncharacterised protein 
(CES3) 
G1QVY9 47 571 QEDL nomle-g1qvy9 ADFV01013581 
482 /  
1e-136 
Hydrolase activity (evp: predicted) 
Uncharacterised protein 
(CES1) 
G1QM39 45 567 HIEL nomle-g1qm39 
ADFV01012901, 
ADFV01012902, 
ADFV01012903, 
ADFV01012904, 
ADFV01012905, 
ADFV01012906, 
ADFV01012907 
479 /  
1e-135 
Hydrolase activity (evp: predicted) 
Papio hamadryas (Hamadryas baboon - class Mammalia)           
Ces2 B5TZ26 90 561 HTEL papha-b5tz26 FJ147179.1 
1030 / 
0.0 
Hydrolase activity (evp: transcript level; Holmes et al. 2009) 
Carboxylesterase 1 B5TZ25 46 567 HIEL papha-b5tz25 FJ147178 
475 /  
1e-134 
Hydrolase activity (evp: transcript level; Holmes et al. 2009) 
Macaca mulatta (Rhesus monkey - class Mammalia)           
Uncharacterised Protein F6UNJ2 88 543 HTEL macmu-f6unj2 - 
1004 / 
0.0 
Hydrolase activity (evp: predicted) 
Uncharacterised Protein G7NQ39 88 543 HTEL macmu-g7nq39 CM001272.1 
1003 / 
0.0 
Hydrolase activity (evp: predicted) 
Uncharacterised Protein F7AA58 48 534 HIEL macmu-f7aa58 - 
484 /  
1e-137 
Hydrolase activity (evp: predicted; note: described as 
fragment in UniProt) 
Uncharacterised protein 
(CES5A) 
F7AIM4 47 581 VIFL macmu-f7aim4 - 
478 /  
1e-135 
Hydrolase activity (evp: predicted) 
Uncharacterised Protein 
F7AI42 
(F7AI34) 
46 566 HIEL macmu-f7ai42 - 
478 /  
1e-135 
Hydrolase activity (evp: predicted) 
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Callithrix jacchus (White-tufted-ear marmoset - class Mammalia)         
Uncharacterised Protein 
F6ZPL6 
(F6Z7R7) 
83 620 HTEL calja-f6zpl6 
ACFV01013743.1, 
ACFV01013744.1, 
ACFV01013745.1 
946 / 0.0 Hydrolase activity (evp: predicted) 
Uncharacterised Protein 
F6Y4M2, 
(F6Y501) 
58 530 QEEL calja-f6y4m2 
ACFV01013743, 
ACFV01013744, 
ACFV01013745, 
ACFV01013746, 
ACFV01013747, 
ACFV01013748, 
ACFV01013749 
618 /  
1e-177 
Hydrolase activity (evp: predicted; note: described as 
fragment in UniProt) 
Ailuropoda melanoleuca (Giant panda - class Mammalia)           
Putative uncharacterised 
protein 
D2H9C9 
(G1MFN8) 
77 534 HTEL ailme-d2h9c9 
GL192596.1, 
ACTA01043044.1 
852 / 0.0 Hydrolase activity (evp: predicted; Li et al. 2010) 
Putative uncharacterised 
protein (CES5A) 
D2GTV3 
(G1MDU0) 
49 551 SSAP ailme-d2gtv3 
GL192338, 
ACTA01072786 
493 /  
1e-139 
Hydrolase activity (evp: predicted; Li et al. 2010) 
Uncharacterised protein 
(CES1) 
G1MDR5 46 565 HVEL ailme-g1mdr5 
ACTA01064786, 
ACTA01072786 
482 /  
1e-136  
Hydrolase activity (evp: predicted; Li et al. 2010) 
Equus caballus (Horse - class Mammalia)               
Uncharacterised Protein F7BJ10 77 579 HTEL horse-f7bj10 - 892 / 0.0 Hydrolase activity (evp: predicted; Wade et al. 2009) 
Uncharacterised Protein 
(CES5A) 
F7C7A8 48 513 ETLP horse-f7c7a8 - 
483 /  
1e-136 
Hydrolase activity (evp: predicted; note: described as 
fragment in UniProt; Wade et al. 2009)  
Uncharacterised Protein F6VXP7 46 565 HVEL horse-f6vxp7 - 
485 /  
1e-137 
Hydrolase activity (evp: predicted; Wade et al. 2009) 
Uncharacterised Protein F6ZMG7 46 567 HVEL horse-f6zmg7 - 
484 /  
1e-137 
Hydrolase activity (evp: predicted; Wade et al. 2009) 
Uncharacterised Protein F6UN85 46 565 HVEL horse-f6un85 - 
484 /  
1e-137 
Hydrolase activity (evp: predicted; Wade et al. 2009) 
Loxodonta africana (African bush elephant - class Mammalia)         
Ces2 G3TN98 76 554 HTEL loxaf-g3tn98 - 852 / 0.0 Hydrolase activity (evp: predicted)  
Uncharacterised Protein 
(CES5A) 
G3T3N6 49 575 FFAP loxaf-g3t3n6 - 
487 /  
1e-138 
Hydrolase activity (evp: predicted)  
Uncharacterised Protein G3TEZ9 47 537 EHIE loxaf-g3tez9 - 
496 /  
1e-140 
Hydrolase activity (evp: predicted; note: described as 
fragment in UniProt)  
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Uncharacterised Protein 
G3T504 
(G3TND5) 
47 565 HIEL loxaf-g3t504 - 
493 /  
1e-139 
Hydrolase activity (evp: predicted; note: described as 
fragment in UniProt)  
Uncharacterised Protein G3UGH4 45 566 HIEL loxaf-g3ugh4 - 
475 /  
1e-134 
Hydrolase activity (evp: predicted; note: described as 
fragment in UniProt)  
Uncharacterised Protein 
(CES3) 
G3SP52 44 576 QEEL loxaf-g3sp52 - 
474 /  
1e-134 
Hydrolase activity (evp: predicted; note: described as 
fragment in UniProt)  
Canis lupus familiaris (Dog - class Mammalia)             
Ces2 F1P6W8 74 585 HTEL canfa-f1p6w8 - 855 / 0.0 Hydrolase activity (evp: predicted; Lindblad-Toh et al. 2005) 
Carboxylesterase 5A 
Q6AW47 
(F1PQX8) 
48 575 SSAP canfa-cauxin 
NM_001003969, 
AB186392 
493 /  
1e-139 
Hydrolase activity (evp: transcript level; Lindblad-Toh et al. 
2005) 
Carboxylesterase D1 
F1PQV5 
(replaced by 
Q95N05) 
47 565 HVEL canfa-CESDD1 
AB023629; 
AAEX03001588 
498 /  
1e-141 
Hydrolase activity (evp: transcript level; Lindblad-Toh et al. 
2005) 
Oryctolagus cuniculus (European rabbit - class Mammalia)           
Uncharacterised Protein G1TZV1 74 558 HTEL rabit-g1tzv1 AAGW02053044.1 853 / 0.0 Hydrolase activity (evp: predicted)  
Uncharacterised Protein G1SJQ8 74 621 HTEL rabit-g1sjq8 AAGW02067905.1 852 / 0.0 Hydrolase activity (evp: predicted)  
Uncharacterised protein G1T6X7 74 558 HTEL rabit-g1t6x7 AAGW02053044.1 850 / 0.0 Hydrolase activity (evp: predicted)  
Uncharacterised protein G1TDR0 74 534 HTEL rabit-g1tdr0 AAGW02067906.1 820 / 0.0 Hydrolase activity (evp: predicted)  
Uncharacterised protein G1T7P3 73 532 HTEL rabit-g1t7p3 AAGW02053044.1 825 / 0.0 Hydrolase activity (evp: predicted)  
Uncharacterised protein G1T7Q5 73 561 HTEL rabit-g1t7q5 AAGW02053044.1 813 / 0.0 Hydrolase activity (evp: predicted) 
Uncharacterised protein G1SN51 72 561 HTEL rabit-g1sn51 
AAGW02067906.1 
AGW02067907.1 
832 / 0.0 Hydrolase activity (evp: predicted)  
Uncharacterised protein G1TMC5 72 556 HTEL rabit-g1tmc5 AAGW02053046.1 808 / 0.0 Hydrolase activity (evp: predicted) 
Liver carboxylesterase 2 P14943 72 532 HTEL rabit-2cxes - 798 / 0.0 
Detoxification of xenobiotics and activation of ester and 
amide prodrugs. (evp:protein level; Ozols J 1989) 
Uncharacterised protein G1SF18 72 422 HKEL rabit-g1sf18 AAGW02067904 633 / 0.0 
Hydrolase activity (evp: predicted; note: described as 
fragment in UniProt) 
Uncharacterised protein G1T6L1 71 528 HTEL rabit-g1t6l1 AAGW02053044.1 778 / 0.0 Hydrolase activity (evp: predicted) 
Uncharacterised protein G1T441 71 470 FARN rabit-g1t441 AAGW02053044 681 / 0.0 
Hydrolase activity (evp: predicted; note: described as 
fragment in UniProt) 
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Uncharacterised protein G1T867 70 469 ARNG rabit-g1t867 AAGW02053044 665 / 0.0 
Hydrolase activity (evp: predicted; note: described as 
fragment in UniProt) 
Uncharacterised protein G1SF73 67 552 QTEL rabit-g1sf73 - 739 / 0.0 Hydrolase activity (evp: predicted) 
Uncharacterised protein 
(Ces5A) 
G1SRM0 48 536 LSSL rabit-g1srm0 AAGW02052800 
493 /  
1e-140 
Hydrolase activity (evp: predicted; note: described as 
fragment in UniProt) 
Uncharacterised protein G1SRL5 45 564 HIEL rabit-g1srl5 AAGW02052800 
473 /  
1e-133 
Hydrolase activity (evp: predicted) 
Rattus norvegicus (Brown rat - class Mammalia)           
Ces2h Q32Q55 73 558 HTEL ratno-q32q55 BC107806.1 858 / 0.0 
Carboxylesterase activity (evp: transcript level; Gibbs et al. 
2004) 
LOC679149 protein Q4QR68 70 561 HTEL ratno-q4qr68 BC097486.1 797 / 0.0 Carboxylesterase activity (evp: transcript level) 
Ces2E G3V7J5 70 557 HTEL ratno-phebest 
D50580.1, 
CH474006.1 
792 / 0.0 Hydrolase activity (evp: predicted; Gibbs et al. 2004) 
Ces2c G3V9D8 70 561 HAEL ratno-pbcxe 
AB010635.1, 
CH473986.1 
778 / 0.0 Hydrolase activity (evp: predicted; Gibbs et al. 2004) 
Carboxylesterase (Ces2) O70177 69 561 HAEL ratno-sicxe AB010632 789 / 0.0 Carboxylesterase activity (evp: predicted) 
Ces2g D3ZXQ0 67 560 HKEL ratno-d3zxq0 CH473972.1 759 / 0.0 Carboxylesterase activity (evp: predicted; Gibbs et al. 2004) 
Ces2j D3ZP14 67 556 HAEL ratno-d3zp14 - 726 / 0.0 Hydrolase activity (evp: predicted; Gibbs et al. 2004) 
Carboxylesterase (Protein 
Ces2a) 
Q8K3R0 66 558 HAEL ratno-LOC246252 
NM_144743, 
AY034877 
757 / 0.0 
Carboxylesterase activity (evp: transcript level; Gibbs et al. 
2004) 
Ces2i D3ZE31 66 559 HAEL ratno-d3ze31 - 742 / 0.0 Carboxylesterase activity (evp: predicted; Gibbs et al. 2004) 
Carboxylesterase 1D 
P16303 
(G3V822) 
46 565 HVEL ratno-Ces3 
X65296, AF171640, 
L81144, BC061789, 
X51974, X65296, 
L46791, X51974, 
CH474037 
496 /  
1e-140 
Major lipase in white adipose tissue; carboxylesterase activity 
and  long-chain-fatty-acyl ethyl ester hydrolase activity (evp: 
protein level; Robbi et al. 1990) 
Carboxylesterase 1C P10959 46 549 TEHT ratno-est2 
D30620, D00362, 
BC088251, M20629, 
X78489 
480 /  
1e-135 
Carboxylesterase activity (evp: protein level; Takagi et al. 
1998) 
Carboxylesterase 1E Q63108 46 561 HTEL ratno-3cxes AY387066 
476 /  
1e-134 
Carboxylesterase activity (evp: transcript level) 
Carboxylesterase-like  
Q68G49 
(P80250) 
45 565 HVEL ratno-q68g49 BC078681 
483 /  
1e-136  
Hydrolase activity (evp: predicted; Gerhard et al. 2004). Note: 
P80250 is classified as Palmitoyl-CoA hydrolase (64 a.a.) 
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Cavia porcellus (Guinea pig - class Mammalia)             
Uncharacterised protein 
(CES2) 
H0V5V8 73 568 HTEL cavpo-h0v5v8 - 844 / 0.0 Carboxylesterase activity (evp: predicted) 
Uncharacterised protein 
(CES5A) 
H0V479 48 542 NIVP cavpo-h0v479 - 
479 /  
1e-135 
Hydrolase activity (evp: predicted) 
Uncharacterised protein H0VJ36 46 561 RSRH cavpo-h0vj36 - 
484 /  
1e-137 
Carboxylesterase activity (evp: predicted) 
Uncharacterised protein H0V1B7 45 565 HVEL cavpo-h0v1b7 - 
480 /  
1e-135 
Carboxylesterase activity (evp: predicted) 
Uncharacterised protein 
(Ces1d) 
H0VHN0 
(H0VU94) 
45 565 HTEL cavpo-cxest D67037, AB010634 
476 /  
1e-134  
Hydrolase activity (evp: predicted) 
Bos taurus (Aurochs - class Mammalia)               
Ces2 (intestine, liver) 
Q3T0R6 
(F1MU22) 
72 553 HTEL bovin-q3t0r6 
BC102288.1, 
AAFC03046191.1 
812 / 0.0 Carboxylesterase activity (evp: transcript level) 
Uncharacterised protein 
(CES5A) 
E1BN79 49 576 SFAP bovin-e1bn79 AAFC03022775 
483 /  
1e-136 
Hydrolase activity (evp: predicted; Zimin et al. 2009) 
Carboxylesterase 1 
Q2KJ30, 
(Q0VCI3, 
F1MTP2) 
46 566 HVEL bovin-q2kj30 
BC105548, 
BC120153, 
AAFC03040943, 
AAFC03073989, 
AAFC03119755, 
AAFC03119756 
491 /  
1e-139 
Carboxylesterase activity (evp: transcript level); Note, 
alternative form Q0VCI3 shows a different C-terminus a.a. - 
RHHT) 
Retinyl ester hydrolase type 
1 
Q5MYB8 
(Q3SZM8) 
46 565 HVEL bovin-q5myb8 AY369075, BC102781 
483 /  
1e-137 
Carboxylesterase activity (evp: transcript level; Zimin et al. 
2009) 
Heterocephalus glaber (Naked mole rat - class Mammalia)           
Carboxylesterase 2 G5BZE3 72 553 HAEL hetga-g5bze3 JH172552.1 815 / 0.0 Hydrolase activity (evp: predicted; Kim et al. 2011) 
Carboxylesterase 2 G5BDH8 71 523 LFLL hetga-g5bdh8 JH169662 717 / 0.0 Hydrolase activity (evp: predicted; Kim et al. 2011) 
Carboxylesterase 2 G5BP68 70 570 AAQE hetga-g5bp68 JH171227.1 788 / 0.0 Hydrolase activity (evp: predicted; Kim et al. 2011) 
Carboxylesterase 2 G5BP66 69 562 HAEL hetga-g5bp66 JH171227.1 781 / 0.0 Hydrolase activity (evp: predicted; Kim et al. 2011) 
Carboxylesterase 2 G5BP67 67 527 PDEL hetga-g5bp67 JH171227 704 / 0.0 Hydrolase activity (evp: predicted; Kim et al. 2011) 
Carboxylesterase 2 G5BP65 61 534 HTEL hetga-g5bp65 JH171227 672 / 0.0 Hydrolase activity (evp: predicted; Kim et al. 2011) 
Carboxylesterase 3 G5BSD4 47 553 HMEE hetga-g5bsd4 JH171634 
480 /  
1e-135 
Hydrolase activity (evp: predicted; Kim et al. 2011) 
Carboxylesterase 3 G5AS32 46 566 HIEL hetga-g5as32 JH166723 
486 /  
1e-137  
Hydrolase activity (evp: predicted; Kim et al. 2011) 
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Liver Carboxylesterase 1 G5AMH8 45 582 HTEL hetga-g5amh8 JH165998 
482 /  
1e-136 
Hydrolase activity (evp: predicted; Kim et al. 2011) 
Mus musculus (House mouse - class Mammalia)             
Ces2h F6Z9B9 72 558 HKEL mouse-Ces2h 
AC166833.4, 
XM_488149.1 
850 / 0.0 Carboxylesterase activity (evp: predicted; Church et al. 2009) 
Ces2c Q91WG0 71 561 HREL mouse-Ces2c 
BC015290.1, 
AC166833.4 
812 / 0.0 
Carboxylesterase activity (evp: transcript level; Furihata et al. 
2003) 
Uncharacterised protein 
Ces2d-ps 
D3YWM6 71 558 HREL mouse-Ces2d-ps - 799 / 0.0 Hydrolase activity (evp: predicted; Church et al. 2009) 
Ces2b Q6PDB7 71 556 HTEL mouse-Ces2b BC058815.1 783 / 0.0 
Carboxylesterase activity (evp: transcript level; Mural et al. 
2002) 
Carboxylesterase 5 (Protein 
Ces2e) 
Q8BK48 70 559 HKEL mouse-Ces2e 
XM_134366, 
BC022148 
817 / 0.0 Carboxylesterase activity (evp: transcript level) 
Ces2g E9PV38 68 560 HKEL mouse-Ces2g 
BC027185.1, 
BC024548.1, 
BC026641.1 
779 / 0.0 
Carboxylesterase activity (evp: transcript level; Church et al. 
2009) 
Putative uncharacterised 
protein Ces2a Ces6 
Q3TMR2 
(E9Q3D0) 
67 525 HAEL mouse-Ces2a 
BC024491.1, 
BC024517.1, 
BC025537.1 
756 / 0.0 Carboxylesterase activity (evp: transcript level)  
Ces2f 
Q08ED5 
(Q149K3) 
64 561 IKAV mouse-Ces2f AC166833, BC117743 721 / 0.0 
Carboxylesterase activity (evp: transcript level; Church et al. 
2009) 
Carboxylesterase 5A 
(Ces5a, Ces7) 
Q6AW46 47 575 SAAS mouse-cauxin 
NM_001003951, 
XM_357913, 
AB186393, 
AC124591, 
AC162945, AK007235 
479 /  
1e-135 
Hydrolase activity (evp: transcript level; Miyazaki et al. 2006) 
Carboxylesterase 1D 
(Carboxylesterase 3) 
Q8VCT4 46 565 HVEL mouse-Ces1d 
AF378751, 
AB025028, 
AB023631, 
AK078879, BC019198 
486 /  
1e-137 
Carboxylesterase activity (evp: protein level; Furihata et al. 
2004)  
Carboxylesterase 1E 
Q64176 
(Q3UN14, 
H3BL34) 
45 562 HTEL mouse-Ces1e 
S80191, AK144549, 
AC162949 
483 /  
1e-137 
Carboxylesterase activity (evp: protein level; Ovnic et al. 
1991)  
Cricetulus griseus (Chinese hamster - class Mammalia)            
Carboxylesterase 2 G3IIG3 71 511 HGEL crigr-g3iig3 JH003006.1 783 / 0.0 Hydrolase activity (evp: predicted; Xu et al. 2011) 
Liver carboxylesterase G3IIG1 70 561 HKEL crigr-g3iig1 JH003006.1 815 / 0.0 Hydrolase activity (evp: predicted; Xu et al. 2011) 
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Liver Carboxylesterase G3I767 70 535 HKEL crigr-g3i767.2 JH001411.1 780 / 0.0 Hydrolase activity (evp: predicted; Xu et al. 2011) 
Liver carboxylesterase G3I766 69 561 HQEL crigr-g3i766 JH001411.1 801 / 0.0 Hydrolase activity (evp: predicted; Xu et al. 2011) 
Liver carboxylesterase G3I769 67 545 HAEL crigr-g3i769 JH001411.1 742 / 0.0 Hydrolase activity (evp: predicted; Xu et al. 2011) 
Liver carboxylesterase G3IIG0 64 529 NKNV crigr-g3iig0 JH003006 714 / 0.0 Hydrolase activity (evp: predicted; Xu et al. 2011) 
Liver carboxylesterase G3I770 61 420 HAEL crigr-g3i770 JH001411 
551 /  
1e-157 
Hydrolase activity (evp: predicted; Xu et al. 2011) 
Liver carboxylesterase G3I768 57 449 HTEL crigr-g3i768 JH001411 
546 /  
1e-156 
Hydrolase activity (evp: predicted; Xu et al. 2011) 
Liver carboxylesterase 1 G3I7X9 46 765 HVEL crigr-g3i7x9.2 JH001461 
481 /  
1e-136 
Hydrolase activity (evp: predicted; Xu et al. 2011) 
Mesocricetus auratus (Golden hamster - class Mammalia)           
Carboxylesterase O35533 70 559 HQEL mesau-cxest2 D50577 807 / 0.0 
Carboxylesterase activity (evp: trancript level; Sone et al. 
1994) 
Liver carboxylesterase Q64419 66 561 HSEL mesau-cxest D28566.1 743 / 0.0 
Detoxification of xenobiotics and activation of ester and 
amide prodrugs. (evp: transcript level; Sone et al. 1994) 
Carboxylesterase O35534 46 565 HAEL mesau-cxest3 D50578 
487 /  
1e-138 
Carboxylesterase activity (evp: trancript level; Sone et al. 
1994) 
Otolemur garnettii (Small-eared galago - class Mammalia)           
Uncharacterised protein H0WQ24 62 575 PEEP otoga-h0wq24 
AAQR03153135, 
AAQR03153136, 
AAQR03153137, 
AAQR03153138, 
AAQR03153139 
670 / 0.0 Hydrolase activity (evp: predicted) 
Uncharacterised protein H0X743 46 566 HIEL otoga-h0x743 
AAQR03092733, 
AAQR03092734, 
AAQR03092735, 
AAQR03092736, 
AAQR03092737, 
AAQR03092738 
489 /  
1e-138 
Hydrolase activity (evp: predicted) 
Sarcophilus harrisii (Tasmanian devil - class Mammalia)           
Uncharacterised protein 
G3W1A9 
(G3W1B0) 
58 551 RVEL sarha-g3w1a9 
AEFK01033471, 
AEFK01033472 
645 / 0.0 Hydrolase activity (evp: predicted; Miller et al. 2011) 
Uncharacterised protein G3VZX8 58 551 DQQS sarha-g3vzx8 
AEFK01033470, 
AEFK01033471 
638 / 0.0 Hydrolase activity (evp: predicted; Miller et al. 2011) 
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Uncharacterised protein 
G3VGT0 
(G3VGT1) 
49 568 RSEL sarha-g3vgt0 
AEFK01039751, 
AEFK01039752 
496 /  
1e-140 
Hydrolase activity (evp: predicted; Miller et al. 2011) 
Uncharacterised protein G3VRX2 48 563 HIEL sarha-g3vrx2 AEFK01037694 
521 /  
1e-148  
Hydrolase activity (evp: predicted; Miller et al. 2011) 
Uncharacterised protein G3VRX3 48 567 HIEL sarha-g3vrx3 AEFK01037694 
520 /  
1e-147 
Hydrolase activity (evp: predicted; note: described as 
fragment in UniProt; Miller et al. 2011) 
Uncharacterised protein G3VVI8 48 532 HKRL sarha-g3vvi8 
 AEFK01033463, 
AEFK01033464, 
AEFK01033465, 
AEFK01033466 
489 /  
1e-138 
Hydrolase activity (evp: predicted; note: described as 
fragment in UniProt; Miller et al. 2011) 
Uncharacterised protein G3VIX0 46 565 ITEL sarha-g3vix0 
AEFK01041367, 
AEFK01041368, 
AEFK01041369, 
AEFK01041370 
481 /  
1e-136 
Hydrolase activity (evp: predicted; Miller et al. 2011) 
Monodelphis domestica (Gray short-tailed opossum - class Mammalia)         
Uncharacterised protein 
F7GEP4 
(F7C7S8, 
F7C7R4) 
58 535 RMEL mondo-f7gep4 - 630 / 0.0 
Hydrolase activity (evp: predicted; note: described as 
fragment in UniProt; Mikkelsen et al. 2007) 
Carboxylesterase 2-like 
protein 1 (Uncharacterised 
protein) 
B2BSF5 
(F7C7U9, 
8A4, 882, 
893, 875, 
897, 888, 
870, XF9) 
58 550 DHDY mondo-b2bsf5 EU019537 
625 /  
1e-179 
Hydrolase activity (evp: transcript level; Holmes et al. 2008).  
Note: F7C7U9 to XF9 described as fragments; evp: predicted.  
Uncharacterised protein F7C7T8 56 487 RMEL mondo-f7c7t8 - 
592 /  
1e-169 
Hydrolase activity (evp: predicted; note: described as 
fragment in UniProt; Mikkelsen et al. 2007) 
Carboxylesterase 1 
B2BSZ5 
(F7GJ65, 72, 
F7GJF1, 
GAF2,  
F6TPQ8, K2, 
H0, F6TNT0, 
Q6) 
49 509 NITL mondo-b2bsz5 EU074630 
481 /  
1e-136 
Hydrolase activity (evp: transcript level; note: described as 
fragment in UniProt; Holmes et al. 2008). Note: HIEL appears 
in the alternative fragments, in UniProt  
Uncharacterised protein F7C7P0 47 541 HVEL mondo-f7c7p0 - 
481 /  
1e-136 
Hydrolase activity (evp: predicted; note: described as 
fragment in UniProt; Mikkelsen et al. 2007) 
Uncharacterised protein F7G265 46 539 HVEL mondo-f7g265 - 
484 /  
1e-137 
Hydrolase activity (evp: predicted; note: described as 
fragment in UniProt; Mikkelsen et al. 2007) 
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Uncharacterised protein F7C7R1 46 540 HVEL mondo-f7c7r1 - 
479 /  
1e-135 
Hydrolase activity (evp: predicted; note: described as 
fragment in UniProt; Mikkelsen et al. 2007) 
Uncharacterised protein F7C7P6 46 540 HVEL mondo-f7c7p6 - 
478 /  
1e-135 
Hydrolase activity (evp: predicted; note: described as 
fragment in UniProt; Mikkelsen et al. 2007) 
Uncharacterised protein F6SLK2 45 531 EKPV mondo-f6slk2 - 
475 /  
1e-134 
Hydrolase activity (evp: predicted; note: described as 
fragment in UniProt; Mikkelsen et al. 2007) 
Anolis carolinensis (Green anole - class Reptilia)       
Uncharacterised protein H9GHC5 50 562 HQEL anoca-h9ghc5 - 
541 /  
1e-154 
Hydrolase activity (evp: predicted; note: described as 
fragment in UniProt) 
Uncharacterised protein H9GB75 49 571 HQEL anoca-h9gb75 - 
538 /  
1e-153 
Hydrolase activity (evp: predicted; note: described as 
fragment in UniProt) 
Uncharacterised protein H9G4C9 49 559 HREL anoca-h9g4c9 - 
531 /  
1e-151 
Hydrolase activity (evp: predicted; note: described as 
fragment in UniProt) 
Uncharacterised protein H9GGH4 48 564 HREL anoca-h9ggh4 - 
514 /  
1e-146 
Hydrolase activity (evp: predicted) 
Uncharacterised protein H9GCS3 48 546 DTPR anoca-h9gcs3 - 
501 /  
1e-142 
Hydrolase activity (evp: predicted; note: described as 
fragment in UniProt) 
Xenopus laevis (African clawed frog - class Amphibia)         
LOC443703 protein Q6GM54 50 568 HVEL xenla-q6gm54 BC074230 
526 /  
1e-149 
Hydrolase activity (evp: transcript level; note: described as 
fragment in UniProt) 
Putative uncharacterised 
protein  
Q52L41, 
(Q32N39, 
A1L2G7, 
Q0IH56) 
50 587 HVEL xenla-q52l41 
BC094077, 
BC108855, 
BC129520, BC123305 
521 /  
1e-148 
Hydrolase activity (evp: transcript level; note: described as 
fragment in UniProt) 
Xenopus tropicalis (Western frog - class Amphibia)         
Uncharacterised protein 
F6RDU1 
(F6YVF9) 
51 561 HVEL xentr-LOC394897 
BC064228, 
AAMC01050003, 
AAMC01050004, 
AAMC01050005, 
AAMC01050006, 
AAMC01050007 
526 /  
1e-149 
Hydrolase activity (evp: predicted; note: described as 
fragment in UniProt; Hellsten et al. 2010) 
Uncharacterised protein F6Y4C8 50 575 HVEL xentr-f6y4c8 
AAMC01050011, 
AAMC01050012, 
AAMC01050013, 
AAMC01050014, 
AAMC01050015, 
AAMC01050016, 
AAMC01050017 
525 /  
1e-149  
Hydrolase activity (evp: predicted; note: described as 
fragment in UniProt; Hellsten et al. 2010) 
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Putative uncharacterised 
protein MGC89138 (Ces2) 
Q640T6 
(F6YVB0) 
50 557 RVQL xentr-cxest2 
BC082503, 
AAMC01050001, 
AAMC01050002 
521 /  
1e-148 
Hydrolase activity (evp: transcript level; note: described as 
fragment in UniProt) 
LOC100144981 protein 
(Ces3) 
B0BM77 
(F7DR63) 
50 557 RIEL xentr-b0bm77 
BC158318, 
AAMC01050018, 
AAMC01050019, 
AAMC01050020 
517 /  
1e-147 
Hydrolase activity (evp: transcript level; Hellsten et al. 2010) 
Uncharacterised protein 
(Ces3) 
F6YVE5 48 584 HIEL xentr-f6yve5 
AAMC01136814, 
AAMC01136815 
512 /  
1e-145 
Hydrolase activity (evp: predicted; note: described as 
fragment in UniProt; Hellsten et al. 2010) 
Uncharacterised protein F6V2J6 48 564 RAEL xentr-f6v2j6 AAMC01049999 
494 /  
1e-140 
Hydrolase activity (evp: predicted; note: described as 
fragment in UniProt; Hellsten et al. 2010) 
Taeniopygia guttata (Zebra finch - class Aves)         
Uncharacterised protein H0ZHA8 49 528 HTDL taegu-h0zha8 - 
498 /  
1e-141 
Hydrolase activity (evp: predicted; note: described as 
fragment in UniProt; Warren et al. 2010) 
Ornithorhynchus anatinus (Duck-billed platypus - class Mammalia)       
Uncharacterised protein 
F6S0Q0 
(F7BGV4) 
47 564 RTEL ornan-f6s0q0 - 
506 /  
1e-143 
Hydrolase activity (evp: predicted; note: described as 
fragment in UniProt; Warren et al. 2008) 
Anas platyrhynchos (Mallard – class Aves)       
Fatty acyl-CoA hydrolase 
precursor, medium chain 
(thioesterase B) 
Q04791 47 557 HTDL anapl-thioe L05493 
497 /  
1e-141 
Hydrolase activity; fatty acid biosynthetic process (evp: 
protein level; Hwang et al. 1993) 
Myotis lucifugus (Little brown bat - class Mammalia)         
Uncharacterised protein 
(CES5A) 
G1PJM4 47 576 SFSH myolu-g1pjm4 AAPE02051406 
485 /  
1e-137 
Hydrolase activity (evp: predicted) 
Uncharacterised protein G1Q4P0 47 538 RTHT myolu-g1q4p0 AAPE02051407 
483 /  
1e-137  
Hydrolase activity (evp: predicted; note: described as 
fragment in UniProt) 
Uncharacterised protein G1QAF3 46 566 RIEL myolu-g1qaf3 
AAPE02051406, 
AAPE02051407 
490 /  
1e-139 
Hydrolase activity (evp: predicted; note: described as 
fragment in UniProt) 
Uncharacterised protein 
G1NW29 
(G1PHM4, 
G1Q3Y2) 
46 565 HIEL myolu-g1nw29 AAPE02051407 
488 /  
1e-138 
Hydrolase activity (evp: predicted) 
Sus scrofa (Pig - class mammalia)             
Uncharacterised protein F1RF14 46 565 HAEL sussc-O97582 AF064741, CU694664 
488 /  
1e-138 
Hydrolase activity (evp: predicted). Note: UniProt sequence is 
incomplete; GeneBank sequence was used as reference.  
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Liver carboxylesterase Q29550 46 566 HAEL sussc-cxest 
X63323, EF525540, 
CU694664 
488 /  
1e-138 
Hydrolase activity (evp: protein level; David et al. 1998) 
Alternative pig liver 
esterase 
A9GYW6 46 548 HAEL sussc-a9gyw6 AM774149 
485 /  
1e-137 
Carboxylesterase activity (evp: transcript level; note: 
described as fragment in UniProt; Hermann et al. 2008) 
Felis catus (Domestic cat - class Mammalia)         
Carboxylesterase (CES-K1) Q766D7  46 566 HVEL felca-CESK1 AB114676 
488 /  
1e-138 
Hydrolase activity (evp: transcript level; Miyazaki et al. 2006) 
Carboxylesterase (CES1) Q864S9 46 566 HVEL felca-CES1 AB094147 
483 /  
1e-136 
Hydrolase activity (evp: transcript level; Miyazaki et al. 2006) 
Gallus gallus (Chicken – class Aves)           
Uncharacterised protein 
(CES1) 
E1BYN1 
(F1NYT3) 
48 557 RTDL chick-e1byn1 
AADN02031822, 
AADN02031823, 
AADN02031824, 
AADN02031825 
484 /  
1e-137  
Hydrolase activity (evp: predicted; Hillier et al. 2004 for 
International Chicken Consortium). 
Macaca fascicularis (Long-tailed macaque - class Mammalia)       
Liver carboxylesterase 1 O46421 47 566 HIEL macfa-cxest AB010633 
481 /  
1e-136 
Carboxylesterase activity (evp: trancript level) 
Microtus ochrogaster (Prairie vole - class Mammalia)         
Esterase 1 E0V882 47 547 HTEL micoh-e0v882 DP001217 
479 /  
1e-135  
Hydrolase activity (evp: predicted) 
Esterase 1 E0V887 47 547 HTEL micoh-e0v887 DP001218 
479 /  
1e-135 
Hydrolase activity (evp: predicted) 
Salmo salar (Atlantic salmon - class Actinopterygii)         
Fatty acyl-CoA hydrolase, 
medium chain (SASB) 
C0PUR6 45 556 SQGN salsa-c0pur6 BT072689 
474 /  
1e-134 
Hydrolase activity (evp: transcript level; note: described as 
fragment in UniProt) 
Brachydanio rerio (Zebrafish - class Actinopterygii)         
Novel protein similar to 
vertebrate carboxylesterase 
family (Ces3) 
Q1LUZ9 
(Q5BJI3, 
E7FCK7, 
F1R2A2, 
F1R9X5) 
45 546 LHTA danre-q5bji3 BC091470, BX908765 
474 /  
1e-134 
Hydrolase activity (evp: transcript level) 
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A.2 Maps of plasmid vectors  
Figure A.1 pDEST26-CES2 vector map. Generated with Vector NTI v.6.0. software (Invitrogen). Plasmid 
vector mentioned in Section 2.  
Figure A.2 pCI-neo-CES2 vector map. Generated in Vector NTI v.6.0. software. Plasmid vector mentioned 
in Sections 3 and 4. 
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Figure A.3 pCI-neo-CES2-10xHis vector map. Generated in Vector NTI v.6.0. software. Plasmid vector 
mentioned in Sections 3 and 4. 
Abbreviations: hCES2 – human carboxylesterase gene (geneID 8824); T7 – Escherichia coli bacteriophage 
T7 promoter; SV40 early promoter – eukaryotic simian virus 40 promoter and origin of replication 
enabling episomal replication in cell lines expressing SV-40 large T antigen; polyA – polyadenylation 
signal; Neo(R) – neomycin resistance gene; bla – ampicillin; Amp(R) – ampicillin resistance gene); pUC – 
prokaryotic replication origin (high copy); f1 – phage F1 replication origin (for ssDNA); CMV -  
cytomegalovirus; SalI and NotI restriction endonucleases; 6x or 10x His – tag of 6 or 10 histidines. 
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Thesis Cover: Composite image of a “laughing” Caco-2 clone, growing for 14 days without dividing, and
the flow diagram developed for CES2 specific activity identification and quantification.
“A great pleasure in life is doing what people say you cannot do.”
Walter Bagehot (1826-1877)
